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Abstract 
 Genes are regulated by proteins called transcription factors that bind to DNA in a 
sequence-specific manner and modulate the rate of transcription.  Mutated transcription 
factors often lead to abnormal gene expression, developmental defects, and disease.  This 
thesis describes the design of chemicals called protein-DNA dimerizers that mimic 
natural transcription factor protein-DNA complexes.  In the long-term, it is hoped that 
these dimerizers will be able to engage or even replace mutant transcription factors and 
artificially regulate gene expression in living cells.  Specifically, programmable DNA-
binding pyrrole-imidazole polyamides conjugated to YPWM peptide motifs incorporating 
various linker domains facilitate the binding of a natural transcription factor, 
extradenticle, to DNA.  From a design point of view, it has been explored what the 
minimum size and shape (branched or linear) is that will ultimately be optimal for cell 
uptake with adequate functional potency in the transcriptional apparatus.  Branched 
dimerizers are shown to function with a minimal WM dipeptide protein-binding domain 
in vitro up to 37 °C, and linear dimerizers are shown to function with WMK tripeptides 
up to 20 °C.  Collectively, branched and linear dimerizers can facilitate protein binding to 
DNA from 2 base pair overlap sites to ones that reach 6 base pairs apart.  Polyamide-
WM-fluorescein conjugates are also found to be cell permeable in several cell lines 
including HeLa, MCF-7, and PC3.  These studies provide insight into the importance of 
linker length and composition, binding-site spacing and orientation, and the protein-
binding domain content that are important for the optimization of protein DNA-
dimerizers suitable for biological experiments. 
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Chapter 1
Introduction to Protein-DNA Dimerizers
1.1 Background and Significance
	 Since	 the	sequencing	of	 the	human	genome,	 it	has	been	estimated	 that	humans	
possess	0,000	to	30,000	genes	that	are	expressed	in	a	highly	controlled	manner	by	DNA-
binding	proteins	called	transcription	factors.3,4		The	evolution	of	more	complex	organisms	
is	 thought	 to	 be	 due	 not	 only	 to	 gene	 proliferation,	 but	 also	 increasingly	 sophisticated	
transcriptional	regulation.5		This	is	particularly	evident	from	the	observation	that	prokaryotes	
often	utilize	single	homodimeric	transcription	factors	to	regulate	target	genes,	in	contrast	
to	eukaryotes,	in	which	gene	expression	is	frequently	controlled	in	a	combinatorial	fashion	
by	multiprotein-DNA	complexes.6		Errors	in	regulating	gene	expression	caused	by	mutant	
transcription	factors	often	lead	to	diseases	such	as	cancer	or	birth	defects,	and	therapies	
that counteract these faulty proteins would have a significant impact on human medicine.7	
This	thesis	describes	the	design	of	chemicals	called	protein-DNA	dimerizers	that	mimic	
endogenous	 transcription	 factors	 in	 that	 they	 facilitate	 the	 formation	 of	 protein-DNA	
complexes.		Protein-DNA	dimerizers	are	a	promising	class	of	compounds	that	suggest	we	
may	someday	engage	or	replace	errant	transcription	factors	and	neutralize	their	deleterious	
effects	for	therapeutic	purposes.
1.2 Eukaryotic Gene Transcription
	 The	 protein-coding	 regions	 of	 the	 eukaryotic	 genomes	 are	 transcribed	 by	 RNA	
polymerase	II.	The	polymerase	physically	associates	with	a	number	of	proteins	including	
TFIIA,	TFIIB,	TFIID,	TFIIE,	TFIIF,	and	TFIIH	before	 initiating	 transcription.8	 	TFIID,	
also	called	TATA-binding	protein	 (TBP),	binds	 to	 the	TATA	DNA	sequence	of	 the	core	
promoter	region	adjacent	to	the	start	site	of	genes	(Figure	.).3,4,8		Additional	transcription	
factors	 also	 bind	 close	 to	 the	 core	 promoter	 and	 further	 away	 at	 up-	 and	 downstream	
enhancer regions which influence the rate of transcription.4,8		Large	mutiprotein	complexes	
mediate	the	interactions	between	the	these	transcription	factors	and	the	RNA	polymerase	
II	machinery9 and a unified nomenclature for such mediator proteins has recently been 
3proposed.0	 	Gene	expression	 is	 also	 affected	by	 the	 local	 chromatin	 structure	which	 is	
regulated	by	proteins	such	as	histone-modifying	enzymes.	
1.3 DNA Recognition by Natural Transcription Factors
 Central to the regulation of gene transcription is the sequence specific recognition of 
DNA	by	transcription	factors.		DNA	contains	a	wide	major	groove	and	a	narrow	minor	groove	
that	expose	unique	surfaces	for	interaction	with	these	proteins	(Figure	.).		Transcription	
factors are capable of binding to both the major and minor grooves by making defined 
electrostatic,	hydrogen-bonding,	and	van	der	Waals	contacts	with	the	composite	surface	of	
nitrogenous	bases	and	sugar-phosphate	backbone	of	DNA	(Figure	.3).		Some	proteins,	such	
as	TBP-5 and the zinc-finger Zif268,6	bind	to	DNA	as	monomers,	but	transcription	factors	
often	bind	as	part	of	homo-	and	heterodimeric	complexes.		For	instance,	the	leucine-zipper	
homodimer	of	GCN47	or	the	heterodimer	of	Jun-Fos8	interact	through	their	two	coiled-coil	
domains that position their α-helical DNA-binding domains into the major groove.  These 
protein-DNA	complexes	are	often	reiterated	in	a	combinatorial	fashion	which	enables	the	
integration	 of	 diverse	 cellular	 signals	 to	 regulate	 individual	 genes.	 	This	 combinatorial	
mechanism is exemplified by the interferon-β (IFN-β) enhanceosome	in	which	a	total	of	
Figure 1.1  A schematic	 of	 a	 gene	 promoter.	 	The	RNA	 polymerase	 II	 transcriptional	
complex	 is	 shown	 bound	 at	 the	 gene	 start	 site	 near	 the	 core	 promoter.	 	 Upstream	 and	
downstream	enhancer	elements	are	shown	to	be	much	farther	away	from	the	start	site	of	
the	gene.	 	Enhancers	contain	binding	sites	 for	 transcription	 factors	which	often	 interact	
indirectly	 with	 the	 RNA	 polymerase	 II	 complex	 through	 large	 multiprotein	 mediator	
complexes.
4eight proteins, including ATF-2/c-Jun, IRF-3/IRF-7, and NF-κB, are required to bind to 
a	conserved	stretch	of	55	base	pairs	of	DNA	in	order	to	activate	expression	in	response	
to	viral	infection.9  Recently, an atomic model of the complete IFN-β enhanceosome has 
been	assembled	from	three	separate	x-ray	crystal	structures	(Figure	.4).9
Figure 1.2		The	structure	of	DNA.		On	the	left	a	crystal	structure	of	a	DNA	double	helix	is	
shown	(PDB	code	YSA).		On	the	right,	the	four	nitrogenous	bases	are	shown	as	Watson-
Crick	base	pairs	where	A	complexes	with	T	and	G	with	C.		The	exposed	edges	of	the	base	
pairs	in	the	major	and	minor	grooves	are	indicated	which	are	important	for	the	sequence-
specific recognition of DNA by proteins and small molecules.
5Figure 1.3		Crystal	structures	of	four	transcription	factor-DNA	complexes.		The	top	left	
shows	a	structure	of	TATA-binding	protein	(TBP)	bound	to	the	DNA	minor	groove	as	a	
monomer leading to significant bending and widening of the groove (PDB code  1TGH). 
The top right shows a structure of zinc-finger protein, Zif268, which consists of three 
tandem major-groove recognition domains (PDB code 1ZAA).  The bottom left shows a 
GCN4 leucine-zipper homodimer, which inserts its extended α-helical coiled-coil domains 
into	the	DNA	major	grooves	(PDB	code	YSA).		The	bottom	right	shows	a	c-Jun/c-Fos	
heterodimer,	which	binds	to	DNA	in	a	similar	manner	to	the	GCN4	homodimer	(PDB	code	
FOS).
6Figure 1.4  An atomic model of the IFN-β enhanceosome in which a total of eight transcription 
factors	bind	to	a	highly	conserved	55	base	pair	segment	of	DNA	(PDB	from	supplemental	
of	reference	9).		All	eight	transcription	factors	must	bind	to	the	enhanceosome	to	activate	
IFN-β expression in response to viral infection.
1.4 HOX Transcription Factors
	 Homeobox	(HOX)	proteins	are	a	particular	class	of	transcription	factors	central	to	
this	thesis	that	are	critical	for	the	proper	execution	of	developmental	programs	of	higher	
organisms.0-  HOX genes have been intensely studied in the fruit fly D. melanogaster in	
which they were identified by the abnormal body segment phenotypes caused by mutations 
to	single	genes.0-		For	instance,	a	mutation	to	the	gene	ultrabithorax	(Ubx)	leads	to	the	
development of an additional thorax in place of the fly’s balance-sensing organs called 
halteres.		In	humans,	mutations	to	HOX	proteins	are	implicated	in	several	forms	of	cancer	
and	 limb	 deformation	 diseases.,3-6	 	 Thus,	 HOX	 transcription	 factors	 serve	 as	master	
regulators	of	the	downstream	genes	that	must	be	activated	or	deactivated	at	precise	times	
during	the	course	of	organism	development.		
 In contrast to their specific roles during development, HOX proteins only bind to 
relatively nonspecific 4 to 6 base pair sequences of DNA.7-9	 	By	binding	to	DNA	with	
7Figure 1.5  Crystal	structures	of	three	HOX/TALE/DNA	ternary	complexes.		The	top	shows	
the	 structure	 of	 the	D. Melanogaster developmental	 transcription	 factors	 ultrabithorax	
(Ubx)	and	extradenticle	(Exd)	(PDB	code	B8I).		The	proteins	bind	to	opposite	sides	of	
the DNA duplex primarily in the major groove with their 3 α-helix homeodomains.  The 
conserved	YPWM	peptide	motif	of	Ubx	spans	the	intervening	minor	groove	and	mediates	
a	 direct	 protein-protein	 contact	with	 an	 Exd	 binding	 pocket	 between	 the	 st	 and	 nd α-
helices.		The	middle	structure	shows	the	homologous	human	transcription	factors	HoxB	
and	Pbx	in	which	the	FDWM	peptide	of	HoxB	binds	to	Pbx	in	a	similar	manner	as	
the YPWM of the fruit fly proteins (PDB code 1B72).  A 4th α-helix was discovered in the 
Pbx	structure	that	stabilizes	homeodomain-DNA	binding.	 	The	bottom	structure	shows	
the	human	proteins	HoxA9	and	Pbx	bound	to	DNA	(PDB	code	PUF).		The	divergent	
ANWL	peptide	of	HoxA9	contains	 the	conserved	W	 that	dominates	 the	protein-protein	
interface.		Unique	to	this	structure,	the	linking	amino	acids	between	the	ANWL	peptide	and	
the	homeodomain	are	ordered	and	contact	the	intervening	DNA	minor	groove.
8cofactor	 proteins,	 they	 increase	 their	 composite	 recognition	 site	which	 is	 thought	 to	be	
important	for	their	function	in	developmental	pathways.7		For	instance,	Ubx	binds	the	site	
5′-TTAT-3′ alone, but in complex with extradenticle (Exd) the composite site increases by 
four base pairs to 5′-TGATTTAT-3′.30	 	A	crystal	 structure	of	 the	 ternary	Ubx/Exd/DNA	
complex revealed how both Ubx and Exd’s major groove binding homeodomains interact 
via Ubx’s N-terminal YPWM peptide motif (Figure 1.5).30		In	fact,	all	HOX	proteins	contain	
a conserved homeodomain which adopts a three α-helix bundle that binds to the DNA 
major groove.  The third α-helix, aptly named the recognition helix, makes the majority 
of the specific DNA contacts with the edges of nitrogenous bases.  The YPWM motif of 
Ubx	spans	 the	DNA	minor	groove	between	 the	 two	proteins	and	 inserts	 a	hydrophobic	
tryptophan	into	the	complementary	Exd	binding	pocket.		Additional	crystal	structures	of	
HoxB/Pbx/DNA	and	HoxA9/Pbx/DNA	which	contain	human	homologues	of	Ubx	and	Exd	
have	also	been	reported	in	which	the	conserved	tryptophan	of	the	YPWM	motif	mediates	
the	majority	of	the	protein-protein	contacts.3,3		The	YPWM	motif	is	sometimes	referred	
to as a penta- or hexapeptide since two flanking amino acids are also highly conserved 
yielding	an	overall	consensus	sequence	of	φYPWM(K/R)	where	φ	is	a	hydrophobic	residue	
(Figure	.6).33		Both	Exd	and	Pbx,	sometimes	called	TALE	proteins,	contain	a	three-amino	
acid	loop	extension between the first and second α-helices of their divergent homeodomains 
which line the binding pocket for the YPWM motif.  In fruit flies an Exd mutation leads 
to	the	increase	in	the	number	of	denticles	(i.e.,	extra	denticles)34	and	in	humans	a	t(;9)	
chromosomal	translocation	at	Pbx	and	EA	loci	leads	to	pre-B	cell	leukemia	(i.e.,	pre-B	
cell	transforming	factor).35		
	 The	 t(;9)	 chromosomal	 translocation	 leads	 to	 an	 EA-Pbx	 fusion	 protein	
that	is	observed	in	5%	of	pediatric	and	3%	of	adult	B-cell	acute	lymphoblastic	leukemia	
cases.36	 	 The	 EA-Pbx	 chimeric	 protein	 turns	 Pbx	 into	 a	 constitutive	 transcriptional	
activator	by	fusing	the	activation	domain	of	EA	with	the	DNA-binding	homeodomain	of	
Pbx.37		Like	the	wild-type	Pbx,	EA-Pbx	is	capable	of	cooperatively	binding	to	DNA	
9with	 other	 HOX	 proteins	 to	 the	 motif	
5′-ATCAATCAA-3′.38	 	 Although	 the	
exact	 mechanism	 of	 leukemogenesis	 is	
still	a	matter	of	some	debate,	EA-Pbx	
activates	the	expression	of	a	novel	WNT	
gene,	Wnt6,39	and	a	tyrosine	kinase,	EB-
,40	 which	 are	 believed	 to	 contribute	 to	
oncogenesis.		Recently,	siRNA	inhibition	
of	EA-Pbx	and	subsequent	downstream	
deactivation	of	Wnt6	and	EB-	has	been	
shown	to	increase	apoptosis	in	697	cells	
which	harbor	 the	 t(;9)	 translocation.4	 	
This	 suggests	 that	 interfering	 with	 the	
abnormal	function	of	EA-Pbx	may	be	
a	 possible	 therapeutic	 approach	 for	 this	
type	of	leukemia.			
1.5 Programmable DNA-Binding Small 
Molecules
	 Nature	 produces	 many	 small	
molecules	 which	 bind	 to	 DNA,	 but	 the	
polypyrrole	compounds	netropsin	(1)	and	
distamycin	(2)	are	of	particular	relevance	
to	 the	protein-DNA	dimerizers	designed	
in	this	thesis.		Netropsin	and	distamycin	
bind	to	the	DNA	minor	groove	of	AT-rich	
tracts and make specific H-bonds with 
Figure 1.6  Evolutionary	 conservation	
of the YPWM motifs from fruit flies to 
humans.		Note	that	all	the	motifs	shown	
contain	 W	 and	 M.	 	 W	 is	 absolutely	
conserved	 in	 natural	HOX	 proteins,	 but	
different	 residues	 are	 sometimes	 found	
instead	of	M.		(Sequences	were	compiled	
from	reference	33	except	for	entries	with	
an	asterisk	(*)	which	were	obtained	from	
the	 National	 Center	 for	 Biotechnology	
Information:	www.ncbi.nlm.nih.gov)
0
Figure 1.7  Structures	 illustrating	 DNA	 recognition	 by	 the	 natural	 products	 netropsin	
(1)	and	distamycin	(2).	 	The	dicationic	dipyrrole	netropsin	binds	to	narrow	AT	tracts	of	
the	DNA	minor	groove	as	a	monomer	(PDB	code	6BNA).		The	monocationic	tripyrrole	
distamycin	can	bind	to	AT	tracts	of	the	DNA	minor	groove	as	either	a	monomer	or	a	dimer.	
(PDB	codes	DND	and	378D).
the	edges	of	 the	nitrogenous	bases	(Figure	.7).4-43	 	 It	was	postulated	 in	 the	mid-980s	
that	replacement	of	an	N-methylpyrrole	(Py)	of	distamycin	by	an	N-methylimidazole	(Im)	
would	lead	to	a	compound	that	would	bind	preferentially	to	G	instead	of	A	or	T	by	making	
specific contacts to exocyclic amine of G in the minor groove.44-45		Synthesis	of	such	an	
ImPyPy	distamycin	analogue	in	the	Dervan	group	led	to	the	discovery	that	this	compound	
actually bound preferentially to 5′-WGWCW-3′ instead of the expected 5′-GWW-3′ (where 
W	=	A	or	T).46	 	This	 result	was	 compellingly	 rationalized	 following	 the	 publication	 of	

Figure 1.8  The	chemical	structure	and	schematic	of	a	typical	pyrrole-imidazole	hairpin	
polyamide	(3).		N-methylpyrrole	(Py)	is	represented	by	an	open	circle,	N-methylimidazole	
(Im) by a filled circle, γ-aminobutyic acid (γ) by a half circle, β-alanine (β) by a diamond, 
and	N,N-dimethylaminopropylamine	(Dp)	by	a	half	circle	with	a	plus.		The	ring	pairings	
prefer	binding	to	different	base	pairs:	Im/Py	for	G·C,	Py/Im	for	C·G,	Py/Py	for	A·T	or	T·A.	
The turn residue (i.e., γ) and the C-terminal β, sometimes referred to as the tail, prefer 
binding	over	A·T	or	T·A	base	pairs.
an	NMR	structure	of	a	:	distamycin:DNA	complex,47	which	suggested	Im	could	stack	
across from a Py generating an Im/Py pair that specifically bound to G·C base pairs in the 
context	of	a	noncovalent	ImPyPy	dimer.		
	 In	the	early	990s	it	was	established	that	the	:	distamycin:DNA	complex	could	
be	enforced	by	covalently	attaching	 the	antiparallel	 Im	and	Py	carboxamides	 through	a	
γ-aminobutyric acid linker to generate a hairpin polyamide such as compound 3 (Figure	
.8).48	 	 In	 this	 context,	 a	 set	 of	 pairing	 rules	were	 determined,	 in	which	 an	 Im/Py	 pair	
binds	to	a	G·C,	a	Py/Im	binds	to	a	C·G,	and	Py/Py	binds	to	both	A·T	and	T·A	(i.e.,	W).	
The	W	degeneracy	of	the	Py/Py	pairing	was	broken	with	the	N-methyl-3-hydroxypyrrole	
(Hp)	heterocycle,	in	which	a	Py/Hp	pairing	binds	to	A·T	and	Hp/Py	to	T·A	(Figure	.9).49-
50  For example, the ImImPyPy-γ-ImPyPyPy-β-Dp sequence of compound 3	 has	 been	
programmed to target 5′-WGGWCW-3′.5-5		The	programmable	DNA	binding	properties	
of	polyamides	have	been	thoroughly	studied	by	a	variety	of	physical	techniques,	including	
DNase	and	MPE	footprinting,53	x-ray	crystallography50,54-55	and	multidimensional	NMR,56-
57	 DNA	 microarrays,58 and fluorescence spectroscopy.59-6	 Recently	 a	 7-compound	

Figure 1.9 	A	structure	illustrating	the	DNA	recognition	by	a	synthetic	polyamide.		Similar	
to	the	distamycin	homodimer,	the	polyamide	binds	to	DNA	with	the	stacked	heterocycles	
making	contacts	with	nitrogenous	base	pairs	in	the	minor	groove	(PDB	code	CVX).		On	
the	right,	the	structural	basis	of	the	pairing	rules	is	shown.
polyamide library that can target all sequences of the type 5′-WWGNNNW-3′ has been 
completed.6	 	Polyamides	can	bind	to	DNA	as	it	exists	in	cell	nuclei	on	the	nucleosome	
core	particle63-64 and fluorescently labeled derivatives often localize to the nucleus of living 
cells.65-67	 	Certain	polyamides	have	shown	activity	 in	cell	culture	experiments.	 	Notable	
recent examples inhibit HIF1-α68	and	androgen	receptor69	DNA	interactions	in	the	promoter	
regions	of	target	genes	and	down-regulate	expression.
3
1.6 Synthetic Mimics of HOX Transcription Factors
	 Small-molecule	synthetic	mimics	of	HOX	transcription	factors	have	been	created	
by	combining	the	technology	of	polyamides	with	an	analysis	of	HOX	proteins.70		The	initial	
idea	was	 to	mimic	Ubx	 as	 observed	 in	 the	Ubx/Exd/DNA	 ternary	 complex	 structure.30	
Polyamide-peptide	conjugate	4 was designed to bind the DNA minor groove at 5′-TGGTCA-
3′ and project an FYPWMKG peptide towards Exd bound to the adjacent major groove at 
5′-ATCA-3′ (Figure 1.10).  Electrophoretic mobility shift assays showed that conjugate 4	
enhanced the binding affinity of Exd to DNA by approximately three orders of magnitude 
at the composite site of 5′-TGGTCAATCA-3′ but not mismatch sites.  Subsequently, 
unbiased	DNA	microarray	experiments	demonstrated	that	the	intended	cognate	DNA	site	
enabled	complex	formation	better	than	other	sequences.58		Thus,	this	conjugate	serves	as	a	
protein-DNA	dimerizer	that	mimics	Ubx	and	other	HOX	proteins	by	binding	cooperatively	
to specific DNA sites with the cofactor protein Exd.70		Some	compounds	with	longer	linkers	
have	also	been	shown	to	be	make	temperature	sensitive	protein-DNA	dimerizers.7
1.7 Artificial Transcription Factors
 More	generally,	the	covalent	attachment	of	functional	peptides	to	DNA-binding	small	
molecules has led to the development of compounds called artificial transcription factors.7-
73		An	early	example	of	such	a	compound	utilized	a	triple-helix	forming	oligonucleotide	
(TFO)	conjugated	to	a	VP6	activation	peptide	that	increased	luciferase	gene	expression	
in vitro.74	 	Polyamides	conjugated	to	GCN4	dimerization	and	amphipathic	helix	peptide	
activation	domains	also	lead	to	activation	of	gene	expression	on	a	g-less	cassette	in vitro.75	
The	peptide	domains	have	been	reduced	down	to	as	little	as	8	and	6	amino	acids	and	still	
activate	gene	expression.76		Experiments	using	a	poly-proline	helix	as	a	structurally	rigid	
spacer domain have defined the optimal distance between the polyamide and activation 
peptides.77	 	Only	 in	 the	past	couple	of	years	has	a	non-peptidic	activation	domain	been	
conjugated	to	a	polyamide	and	shown	to	activate	gene	expression	in vitro.78		A	polyamide-
4
Figure 1.10  The	chemical	structure	and	model	of	a	synthetic	protein-DNA	dimerizer	(4).	
The	dimerizer	consists	of	a	DNA-binding	pyrrole-imidazole	polyamide	conjugated	 to	a	
heptapeptide	containing	a	YPWM	motif	 that	 recruits	Exd	 to	 the	adjacent	major	groove.	
The	 illustrative	model	was	 constructed	 from	a	 representative	polyamide-DNA	structure	
(PDB	code	365D)	and	the	Ubx/Exd/DNA	structure	(PDB	code	B8I).
peptoid	activation	domain	has	very	recently	been	discovered	to	activate	gene	expression	
of	a	transiently	transfected	luciferase	gene	in	cell	culture,79  but a cell-permeable, artificial 
transcription	factor	that	activates	an	endogenous	gene	has	yet	to	be	reported.
5
1.8 Scope of this Work
	 This	 thesis	 describes	 efforts	 toward	 determining	 the	 essential	 components	 of	
protein-DNA	dimerizer	transcription	factor	mimics	that	should	enable	them	to	function	in	
living	cells.	 	Chapter		details	experiments	involving	that	minimization	of	protein-DNA	
dimerizer	4 paying	 particular	 attention	 to	 the	 protein-binding	 domain.	 	This	 led	 to	 the	
discovery	that	the	orginial	FYPWMKG	heptapeptide	can	be	reduced	to	a	WM	dipeptide.	
Inverting	the	tryptophan	stereochemistry,	from	the	natural	L-from	to	the	unnatural	D-form,	
made	the	dimerizer	less	sensitive	to	temperature	increases.		Chapter	3	shows	that	the	shape	
of	protein-DNA	dimerizers	 can	be	changed	 from	branched	 to	 linear	which	expands	 the	
range	of	DNA	sites	 and	orientations	 for	 dimerization.	 	The	optimal	DNA	site	 spacings	
and	 necessary	 protein-binding	 elements	 were	 determined,	 which	 lead	 to	 the	 discovery	
that	 a	WMK	 tripeptide	works	 as	 a	 protein-binding	 domain	 in	 this	 context.	 	 In	 chapter	
4 fluorescent, cell-permeable protein-DNA dimerizers are presented that incorporate the 
minimization	efforts	from	the	previous	chapters.	
	 Chapter	5	details	the	progress	towards	the	development	of	a	general,	cell-permeable	
artificial transcription factor that mimics the natural HIF-1α protein.  In the native system, 
endogenous HIF-1α binds to the hypoxia response element (HRE) of the VEGF promoter 
in	response	to	hypoxia.80		HIF-1α then recruits the enormous co-activator CREB binding 
protein	 (CBP)	 which	 then	 activates	 gene	 expression.	 	 The	 design	 strategy	 for	 a	 small	
molecule HIF-1α mimic employs a polyamide known to bind the VEGF HRE conjugated 
to compounds that bind CBP.  Thus, an effort was made to artificially recruit CBP to the 
VEGF	promoter	and	activate	gene	expression	in	cell	culture	experiments.
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Chapter 2
Minimization of a Protein-DNA Dimerizer
The text of this chapter was taken in part from a manuscript co-authored with Hans-
Dieter Arndt,† Mary Brezinksi,‡ Aseem Z. Ansari‡ and Peter B. Dervan† (Caltech† and 
University of Wisconsin, Madison‡)
(Stafford, R. L., Arndt, H.-D., Brezinski, M., Ansari, A. Z., Dervan, P. B. J. Am. Chem. 
Soc. 2007,	129,	660-668.)	
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Abstract   
 A protein-DNA dimerizer constructed from a DNA-binding polyamide and the 
peptide FYPWMKG facilitates the binding of a natural transcription factor Exd to an 
adjacent DNA site.  The Exd binding domain can be reduced to a dipeptide WM attached 
to the polyamide through an ε-aminohexanoic acid linker with retention of protein-DNA 
dimerizer activity.  Screening a library of analogues indicated that the tryptophan indole 
moiety is more important than methionine’s side-chain or the N-terminal acetamide. 
Remarkably, switching the stereochemistry of the tryptophan residue (L to D) stabilizes 
the dimerizer•Exd•DNA ternary complex at 37 °C.  These observations provide design 
principles for artificial transcription factors that may function in concert with the cellular 
regulatory circuitry.
	
3
2.1 Introduction
	 Multivalent	 interactions	 are	
frequently	 encountered	 in	 biological	
systems.	 	 Typically,	 the	 monovalent	
elements	 that	 mediate	 these	 molecular	
interactions	 use	 a	 small	 surface	 area	
and	 bind	 weakly.	 	 These	 monovalent	
elements	 are	 repeated,	 and	 the	 resulting	
multivalency	 improves	 the	 association	
between	the	interacting	molecules.	 	Dimerization	is	a	key	regulatory	event	in	numerous	
biochemical	settings,	notably	 in	signal	 transduction	and	 the	 regulation	of	 transcription.	
Divalent	small	molecules	called	chemical	inducers	of	dimerization	or	dimerizers	have	been	
used	 to	 facilitate	 protein-protein	 interactions.,3	 	Recently,	we	described	 a	 protein-DNA	
dimerizer, where one module binds a specific DNA sequence while the other interacts 
with a specific DNA binding protein (Figure 2.1).4	 	This	molecule	generates	a	bidentate	
surface	 that	enhances	 the	association	of	 the	 targeted	protein	with	 its	cognate	DNA	site.	
This divalent molecule improves the affinity of the targeted DNA-binding protein for its 
specific DNA sequence, whereas it is ineffective at sites where the DNA sequence does not 
match	the	preferred	site	of	the	target	protein.		Our	long	term	goal	is	to	ask	whether	protein-
DNA dimerizers could serve as artificial regulators of gene expression in a living cell.4-7
	 Transcription	 factors	 are	 modular	 in	 structure	 and	 combine	 DNA-binding	
domains	with	other	functional	domains	and	lead	to	the	activation	or	repression	of	genes.a	
Transcriptional	activators	themselves	can	be	viewed	as	dimerizers	composed	of	DNA	and	
protein	binding	 surfaces.3a	 	 Polyamides	 are	 ideal	DNA-binding	domains	 since	 they	 can	
be	programmed	to	bind	to	a	broad	repertoire	of	DNA	sequences	using	an	aromatic	amino	
acid	pairing	code.8		A	hairpin	polyamide-YPWM	conjugate	facilitates	the	binding	a	natural	
transcription	 factor	 Extradenticle	 (Exd)	 to	 an	 adjacent	 DNA	 site.4	 	 The	 protein-DNA	
Figure 2.1		Protein-DNA	dimerizer	
facilitating	the	binding	of	a	protein	to	an	
adjacent	DNA	site.		
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Figure 2.2		(a)	Dimerizer	1	structure.		(b)	(left)	MPE	footprint	titration	of	conjugate	1	on	a	
fragment	of	pHDA	in	the	presence	(40	nM,	lanes	-8)	and	absence	of	Exd	protein	(lanes	
9-5)	and	00	µM	base	pair	calf	thymus	DNA.		Lane	:	Exd	only	(	µM).		Lanes	-8:		0.0,	
0.03,	0.,	0.3,	,	3,	0	µM	conjugate	1 all	with	40	nM	Exd.		Lanes	9-5:		0.0,	0.03,	0.,	
0.3,	,	3,	0	µM	conjugate	1.		Lane	6:	MPE	standard.		Lane	7:	Intact	DNA.		Lane	8:	
G-sequencing	lane.	Lane	9:	A-sequencing	lane.	(middle)	MPE	footprint	titration	of	Exd	in	
the	presence	of	dimerizer	1	and	00	µM	base	pair	calf	thymus	DNA.		Lanes	-7:	0.0,	0.03,	
0.,	0.3,	,	3,	0	µM	Exd	all	with		µM	conjugate	1.		Lane	8:	G-sequencing	lane.	Lane	9:	
A-sequencing	lane.		(right)	Sequence	of	fragment	of	pHDA	used	for	MPE	footprinting.	
(c)	Structural	model	of	dimerizer	1	 in	a	complex	with	DNA	and	Exd.	 	A	key	 is	 shown	
below	with	a	dimerizer	ball-and-stick	model	which	indicates	where	the	MPE	protection	
pattern was observed. (filled circle = N-methylimidazole,	empty	circle	=	N-methylpyrrole,	
diamond	=	β-Ala,	half	circle	with	plus	=	N,N-dimethylaminopropylamine,	half	circle	=	γ-
aminobutyric	acid)
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dimerizer	1	mimics	the	homeobox	(HOX)	transcription	factor	Ultrabithorax	(Ubx)	(Figure	
.a).9a	 	Ubx	cooperatively	binds	 to	DNA	with	 the	HOX	cofactor	protein	Exd.0	 	Their	
interaction is primarily mediated through Ubx’s conserved YPWM peptide motif, which 
crosses	 the	DNA	minor	groove	 to	 the	major	groove	binding	Exd.9	 	Similarly,	 in	human	
homologs	as	well,	the	YPWM	motif	is	highly	conserved	within	the	HOX	protein	family	
and	is	often	referred	to	as	a	hexapeptide	φYPWMK,	as	the	central	YPWM	tetrapeptide	is	
often flanked by a hydrophobic residue (φ)	and	a	charged	residue,	such	as	Lys	or	sometimes	
Arg.
	 In	this	study,	we	address	what	are	the	minimum	requirements	for	Exd	recruitment.	
The	Trp	residue	is	strictly	conserved	and	a	conservative	mutation	of	Trp	to	Phe	has	been	
shown	to	lead	to	HOX	proteins	that	no	longer	cooperatively	bind	to	DNA	with	their	cofactor	
proteins.		Met	to	Ile	and	Tyr	to	Leu	mutations	to	the	YPWM	motif	of	HoxB4	has	also	
been	shown	to	eliminate	cooperative	binding.3		The	crystal	structures	of	Ubx/Exd/DNA,	
HoxB/Pbx/DNA	 and	HoxA9/Pbx/DNA	 complexes	 show	 the	Trp	 indole	 deep	 in	 the	
protein	binding	pocket	with	an	adjacent	Met	or	Leu	side-chain	reinforcing	this	interaction	
and	mediating	 important	 protein	 contacts.9	 	 Thus,	 our	 efforts	 to	minimize	 the	 protein-
binding	domain	have	centered	on	the	Trp	and	Met	residues.
The	Exd	binding	domain	was	 reduced	 to	 the	dipeptide	WM	and	 tethered	 to	 the	
polyamide	DNA-binding	domain	through	an	ε-aminohexanoic	acid	linker.		We	report	here	
that this conjugate with a smaller protein binding domain retains significant dimerizing 
activity	with	Exd.	 	A	set	of	dipeptide	analogues	were	screened	to	assess	the	importance	
of	 the	 remaining	moieties.	 	Minimized	 conjugates	were	 then	 studied	 at	 physiologically	
relevant temperatures for fruit fly (20 °C) and human cell lines (37 °C). 
2.2 Results
Protein-DNA Dimerizer•Exd Sequence Specificity		
 Exd is expected to bind 5’-TGAT-3’ as found in the Ubx/Exd/DNA crystal structure,9a	
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and	the	hairpin	polyamide	ImImPyPy-γ-ImPyPyPy codes for the sequence 5’-WGWCCW-
3’, where W equals A or T.8	 	 Exd	 (underlined)	 and	 polyamide	 sites	were	 combined	 to	
create a composite site 5’-TGATTGACCA-3’ to study Exd recruitment by polyamide-
FYPWMKG	conjugate	1 (Figure	.a).4  To confirm both the orientation preference of 
Exd recruitment as well as the specificity with respect to mismatch sites, MPE footprinting 
titrations4	 have	 been	 carried	 out	 on	 a	DNA	 fragment	 featuring	 a	 polyamide	mismatch	
site I (5’- TGATGGATTG-3’) and Exd upstream II (5’-TGATTGACCA-3’), as well as 
downstream III (5’-TGACCATGAT-3’) orientations (Figure 2.2b, right).  An MPE footprint 
titration	of	dimerizer	1 without Exd protein present confirmed its highly specific binding, 
with	an	identical	protection	pattern	for	both	sites	II	and	III.		Binding	to	site	I,	which	is	a	
single	base	pair	mismatch	for	the	polyamide	DNA-binding	domain	in	1,	only	occurred	at	
≥ 10 µM	concentration,	indicating	a	selectivity	of	better	than	50-fold	(Figure	.b,	left).	
When	40	nM	Exd	was	present	with	1,	the	MPE	protection	pattern	was	observed	at	a	3-fold	
lower	concentration	exclusively	at	site	II,	enhancing	the	selectivity	over	the	site	I to	50-
fold and the Exd downstream site III to 3-fold.  Furthermore, despite the presence of five 
sites	for	Exd	on	the	DNA	fragment,	Exd	alone	at		µM	concentration	did	not	give	rise	to	
detectable	binding.		These	results	provide	evidence	for	cooperative	enhancement	of	binding	
of the dimerizer and Exd only when Exd’s site is located upstream from the polyamide’s. 
Subsequent experiments using DNA microarrays confirm that 1	prefers	to	recruit	Exd	to	
the consensus site 5’-NGANWGWC-3’ over other Exd-dimerizer DNA site spacings and 
orientations.4c		
The	Exd	 protein	 binding	 site	 in	 the	 presence	 of	 dimerizer	1 was	 determined	 to	
single	base	pair	resolution	(Figure	.b,	middle).	At	low	concentrations	of	Exd,	dimerizer	
1	 occupied	 the	polyamide	 site.	With	 increasing	Exd	 concentration,	 the	MPE	protection	
pattern became enlarged by four base pairs in the 3’-direction (3P-labeled	strand).	Taking	
into account that an MPE footprint is generally observed 2 base pairs shifted to the 3’-end,4	
this maps protein-binding to 5’-TGAT-3’ and dimerizer-binding to the 5’-TGACCA-3’ 
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(Figure	.c).		Notably,	no	additional	protein-induced	protection	was	evident	at	mismatch	
site	I	or	on	the	downstream	arrangement	site	III.	This	observation	supports	the	selectivity	
of	the	dimerization	event,	both	for	sequence	composition	and	arrangement	of	the	respective	
half-sites.
Analyzing Changes to the Protein-binding Domain on Dimerization (4 °C)		
	 The	binding	of	Exd	to	DNA	in	the	presence	of	various	dimerizers	was	measured	at	
4 °C by electrophoretic mobility shift assays (EMSA).  Exd protein binding was studied 
on	a	3P-labeled	47	base	pair	double-stranded	DNA	duplex	containing	a	match	composite	
Figure 2.3		Structures	of	compounds	2-22	and	the	synthesis	of	minimized	polyamide-
dipeptide	conjugates	15-22:	i)	6 (R=H), HBTU, DMF, excess DIEA, 20 °C, 1-3 h.
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binding site (5’-TGATTGACCA-3’) identical to site II in Figure 2b in the presence of 
compounds	1-5	and	15-22	(Figures	.3	and	.4).		For	comparison,	a	control	titration	with	
Exd	alone	was	performed	(top	left,	Figure	.4).		Negligible	Exd	binding	was	observed	up	
to	00	nM	concentrations,	however,	multiple	Exd	molecules	appear	to	bind	weakly	and	
non-specifically at 1 µM, in line with previous findings.4		Thus,	subsequent	titrations	were	
kept	below	this	threshold	and	performed	in	the	0	pM	to	00	nM	range.
Figure 2.4  Representative gel shift assays at 4 °C all done in triplicate.  Autoradiograms 
are	shown	for	Exd	titrations	with	a	47-base	pair	3P-labeled	dsDNA	probe	containing	both	
Exd (underlined) and dimerizer binding sites (5’-TGATTGACCA-3’).  (a)	The	upper	left	
image	shows	increasing	concentrations	of	Exd	only	from	left	to	right	at	00	pM,	500	pM,	
	nM,	5	nM,	0	nM,	50	nM,	00	nM,	500	nM,	and		µM.		In	all	other	experiments	the	
indicated	 compound	was	 applied	 at	 50	nM,	 and	 increasing	 concentrations	of	Exd	were	
studied	from	left	to	right:	0	pM,	50	pM,	00	pM,	500	pM,		nM,	5	nM,	0	nM,	50	nM,	
and	00	nM.		The	upper	band	consists	of	the	Exd-dimerizer-DNA	complex	while	the	lower	
band	 consists	 of	 the	 dimerizer-DNA	 complex.	 	 (b) Isotherms for Exd binding at 4 °C 
organized	into	groups.
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Upon	 the	 addition	 of	 50	 nM	 of	
conjugate	 1,	 the	 Exd	 DNA	 equilibrium	
association	 constant	 (Ka)	 was	 enhanced	
(Ka	 =	 .5	 ±	 0.3	×	 09	M-),5	 yielding	 a	
nearly	 complete	 band	 shift	 (i.e.,	 Θapp	
≥ approximately 0.93±0.01) at 5 nM 
Exd	 (Table	 .).	 	Thus, the presence of 
dimerizer 1 enhances Exd’s DNA affinity 
by 1000-fold.4	 	 In	 controls,	 experiments	
with	 50	 nM	 of	 the	 parent	 polyamide	
2,	 which	 contains	 no	 peptide	 but	 has	
been shown previously by DNase footprinting experiments to bind specifically to the 
DNA-binding	domain	match	site,6 appears to enhance Exd’s DNA affinity for DNA, as 
evidenced	by	 the	partial	band	shift	 (i.e.,	Θapp	=	0.5±0.).7	 	The	mismatch	polyamide	3,	
which	is	not	expected	to	bind	the	polyamide	match	site,8	does	not	lead	to	any	measurable	
enhancement of Exd’s DNA affinity.  Thus, the DNA-binding polyamide bound by itself 
to the match site appears to facilitate Exd’s binding to DNA, but is insufficient for stable 
complex formation.  As a further control, modified hairpin 4	was	investigated	to	evaluate	
the	effect	of	the	proximal	linker	domain.	The	propylacetamide	linker	appeared	to	reduce	
the polyamide’s contribution relative to hairpin 2.		Exd	titrations	in	the	presence	of	50	nM	
of	the	YPWM	peptide	5 did not lead to any measurable enhancement of Exd-DNA affinity, 
indicating	that	the	polyamide	DNA-binding	domain	is	indispensable	for	dimerization.
	 The	truncated	dipeptide-dimerizer	15 exhibited a similar binding affinity for DNA to 
1 (see	DNase	I	footprinting	data	below),	so	50	nM	concentration	was	used	for	the	dipeptide	
analogues	to	saturate	the	DNA	binding	site	and	ensure	direct	comparisons	could	be	made	
to	changes	to	the	presumed	Exd	binding	domain.		Polyamide-Ac-WM-dipeptide	conjugate	
15 enhanced Exd’s DNA affinity almost 50% as effectively as the larger conjugate 1 (Ka	
Table 2.1  Exd-DNA-dimerizer stabilities at 4 °C
Compound Ka	of	Exd	[0
9	m−]a	 Θmaxb
1 .5	±	0.3 0.93	±	0.0
15 0.7	±	0. 0.84	±	0.06
16 .0	±	0. 0.9	±	0.03
19 0.6	±	0. 0.84	±	0.04
20 0.5	±	0. 0.77	±	0.08
21 0.7	±	0. 0.7	±	0.0
22 0.7	±	0. 0.65	±	0.07
a Mean of ≥ 3 titrations of Exd at 50 nM compound.
Data fit to a Hill equation with n=1 (R > 0.98).
b Determined	at	least	three	times	at	00	nm	Exd	and
50	nm	dimerizer.
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=	7	±		×	08	M-),	with	high	levels	of	complex	formation	(Θapp	=	0.84	±	0.06).		When	the	
stereochemistry	of	 the	Trp	 residue	was	 inverted	 (16), Exd’s DNA affinity remained the 
same	(Ka	=	.0	±		×	09	M-)	with	a	slightly	higher	amount	of	complex	formation	(Θapp	=	
0.9	±	0.03).		Substituting	the	Trp	with	Phe	(17)	or	Ala	(18) lowered Exd’s DNA affinity 
so	it	qualitatively	appeared	to	be	as	effective	as	polyamide	2 by	itself.		In	contrast	to	what	
was	observed	with	 the	Trp	residue,	 the	Met	residue	could	be	converted	 to	Ala	(19)	and	
Gly	(20) without strongly affecting Exd’s DNA affinity (Ka’s = 6 ± 1 ×	08	M-	and	5	±	
	×	08	M-,	respectively)	or	the	levels	of	complex	formation	(Θapp > 0.75).  Noting that 
the	 stereochemistry	 of	 the	Trp	 could	 be	 inverted	 (15	 to	16),	we	 examined	whether	 the	
stereogenic	acetamide	might	be	eliminated.		Both	conjugates	21	and	22	maintained	similar	
Exd binding affinities (both Ka’s = 7 ± 1 ×	08	M-),	albeit	with	slightly	reduced	levels	of	
complex	formation	(Θapp	=	0.7	±	0.0	and	0.65	±	0.07,	respectively).	 	Interestingly,	all	
of	the	minimal	dimerizers	that	showed	strong	Exd	recruitment	yielded	binding	constants	
within	3-fold	of	conjugate	1.
Analyzing Selected Dimerizers for Exd Binding at Higher Temperatures		
 The initial screen of dimerizers at 4 °C by gel shift yielded the promising minimal 
dimerizers	 15	 and	 16,	 which	 were	 further	 investigated	 (Figure	 .5	 and	 Table	 .).	
Specifically, the ability of conjugates 15	and	16	to	recruit	Exd	at	higher	temperatures	will	
be relevant to planned experiments in fruit flies (20 °C) and in human cell lines (37 °C).9	
Furthermore,	the	weak	contribution	of	the	DNA-binding	domain	by	itself	was	investigated	
at	these	higher	temperatures	using	compound	2.  The change from 4 °C to 20 °C did not 
Table 2.2 Exd-DNA-dimerizer stabilities at 20 °C and 37 °C
Compound Ka of	Exd	[0
9	M−1]
at 20 °Ca Θmax at 20 °C
b Ka of	Exd	[0
9	M−1]
at 37 °Ca Θmax at 37 °C
b
1 .9	±	0. 0.9	±	0.0 .	±	0. 0.9	±	0.0
15 .3	±	0. 0.65	±	0. -c 0.30	±	0.
16 .7	±	0. 0.86	±	0.0 0.9	±	0. 0.75	±	0.06
a Mean of ≥ 3 titrations of Exd at 50 nM compound.  Data fit to a Hill equation with n = 1 (R > 0.99). b Determined	at	least	three	times	
at	00	nm	Exd	and	50	nm	dimerizer.	cNot	determined	because	no	stable	complex	was	detected	(i.e.,	mean	Θmax	≤ 0.5).
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Figure 2.5  (a)	 Representative	 gel	 shift	
assays at 20 °C and 37 °C all done in 
triplicate	shown	in	the	same	format	as	in	
Figure	4.		(b) Isotherms	for	Exd	binding	at	
20 °C and 37 °C organized into groups.
Figure 2.6  Quantitative	 DNase	 I	
footprinting	 titration	 of	 minimized	
dimerizer	 15	 on	 a	 restriction	 fragment	
containing a match site IV (5’-TGGTCA-
3’) and three mismatch sites I-III, (5’-
AGCTCA-3’), (5’-TGGGCA-3’), and 
(5’-TGGCCA-3’), respectively.  The 
analyzed	 binding	 site	 locations	 are	
indicated	by	square	brackets	and	correlated	
to	 the	 sequence	 on	 the	 left.	 Lane	 -3:	
500,	00,	00,	50,	0,	0,	5,	,	,	0.5,	0.,	
0.,	and	0.050	nM	of	compound	15.		Lane	
4:	Intact	DNA.		Lane	5:	A-sequencing	
lane.		Lane	6:	G-sequencing	lane.		Lane	
7:	DNase	I	standard.		The	isotherms	for	
binding	to	sites	I	(×),	III (■), and IV (○) 
are	shown	below.
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significantly change Exd’s Ka	in	the	presence	of	compounds	1,	15,	and 16,	but	markedly	
reduced	 the	apparent	effect	seen	by	 the	polyamide	DNA-binding	domain	2.	 	 Increasing	
the temperature further to 37 °C did not significantly affect Exd’s Ka	for	compounds	1	and	
16,	but	considerably	impaired	compound	15’s ability to recruit Exd.  Remarkably the only 
structural	difference	between	compound	15	and	16	is	the	stereochemistry	at	the	tryptophan	
residue,	which	apparently	leads	to	a	more	stable	ternary	complex.
Conjugate DNA Binding Affinity and Sequence Specificity		
 The DNA affinity and sequence selectivity of conjugate 15 at 20 °C in the absence 
of	Exd	was	determined	by	DNase	 I	 footprinting	 (Figure	.6	 and	Table	.3).4	 	Binding	
energetics	for	compounds	1-3	have	been	reported	previously.4a,6,8		Experiments	with	15	
were performed using the same 3’-radiolabeled 250-base pair restriction fragment of a 
plasmid	that	was	previously	used	for	conjugate	1.  This fragment contains a 5’-TGGTCA-
3’ match site IV as well as three single base-pair mismatch sites I-III, 5’-AGCTCA-3’, 
5’-TGGGCA-3’, and 5’-TGGCCA-3’, respectively.  The attachment of the glycine-linked 
Ac-FYPWMK-	peptide	to	the	DNA-binding	domain	of	conjugate	1	was	previously	found	
to reduce the affinity approximately 100-fold with respect to the parent polyamide.4a	
Furthermore, the sequence specificity of 1	was	diminished	with	respect	to	mismatch	sites	I	
and	III,	but	it	was	still	able	to	discriminate	against	mismatch	site	II	by	about	0-fold.		The	
affinity of the minimized hairpin polyamide-WM (15)	for	its	match	site	IV	was	improved	
by	approximately	three-fold	(Ka	=	5.	±	.0	×	08	M-).  The sequence specificity was also 
found	to	be	more	than	5-fold	for	the	match	site	IV	with	respect	to	mismatch	sites	I	through	
Table 2.3 Conjugate-DNA equilibrium association constants Ka’s [108 M−1]a 
Compound 5’-TGGTCA-3’ 5’-TGGCCA-3’ 5’-TGGGCA-3’ 5’-AGCTCA-3’
1b .8	±	0. .3	±	0.	[.4] ≤ 0.1 [>18] .5	±	0.3	[.]
15 5	±	 0.	±	0.	[5] ≤ 0.1 [>50] 0.	±	0.05	[4]
								a Specificity ratio with respect to Match Site IV (5’-TGGTCA-3’) shown in brackets.
										b See	reference	0.
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III.	Hence	the	reduction	in	the	size	of	the	protein	binding	domain	of	the	conjugate	fully	
restored	the	intrinsic	DNA	sequence	selectivity	of	the	protein-DNA	dimerizer.
2.3 Discussion
The observation that a dipeptide WM is sufficient for Exd recruitment is remarkable 
given	that	the	YPWM	motif	is	highly	conserved	with	the	consensus	sequence	φYPWMK	
(where	 φ	 denotes	 a	 hydrophobic	 residue)	 in	 the	 majority	 of	 HOX	 proteins,	 and	 that	
residues flanking the motif have been shown to contribute to the interaction.d		The	total	
solvent-accessible	surface	area	buried	between	Exd	and	the	YPWM	peptide	of	Ubx	is	~570	
Å	where	on	average	the	buried	surface	area	between	more	stable	protein-protein	interfaces	
is	about	000	Å.9,0		From	the	crystal	structures	of	the	Ubx/Exd/DNA	and	HoxB/Pbx/
DNA	ternary	complexes	it	was	clear	however,	that	the	majority	of	the	contacts	involved	
the	Trp	indole	substituent,	with	the	Met	residue	reinforcing	the	interaction.9		Moreover,	a	
related	crystal	structure	of	the	HoxA9/Pbx/DNA	complex	reveals	a	divergent	AANWLH	
interaction	motif	bound	in	an	entirely	different	conformation.		The	only	distinct	structural	
similarity	 between	 the	AANWLH	motif	 of	HoxA9	 and	 the	 other	YPWM	motifs	 is	 the	
orientation	of	the	Trp	side-chain	in	the	protein	binding	pocket.
In line with these findings, the data presented here underscore the importance of the 
Trp	side	chain	and	to	a	lesser	extent	the	Met	residue.		A	“conservative”	change	of	Trp	to	Phe,	
which	reduces	the	hydrophobic	interaction	surface	area	and	should	eliminate	the	hydrogen	
bond	to	the	main-chain	carbonyl	of	Leu3a	(Exd	homeodomain	numbering),9	abrogates	the	
efficacy of the protein-binding domain of the dimerizer.  Similarly, a Trp to Ala substitution 
is	 not	 tolerated.	 	Truncating	 the	Met	 side-chain	 to	 a	methyl	 or	 hydrogen	only	 partially	
reduces efficacy, but still provides a functional protein-binding domain.  Inverting the 
stereochemistry	of	the	Trp	residue	enhances	stability,	particularly	at	higher	temperatures.	
It	is	likely	that	the	indole	moiety	adopts	a	similar	position	in	the	Exd	binding	pocket	as	in	
the	crystal	structures.9		Thus,	the	structural	change	enforced	by	the	stereochemical	switch	
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(15	and	16)	probably	positions	the	acetamide	in	a	favorable	position	for	hydrogen	bonding	
contacts with Tyr25 of Exd, the DNA, or the dimerizer’s linker domain.  Analogues lacking 
the acetamide retained some efficacy when compared to the L-Trp	dimerizer	15,	but	do	not	
lead	to	further	insight	into	why	the	unnatural	peptide	of	16	is	an	improvement	over	15.
Our	results	support	the	notion	that	the	geometry	of	the	Exd	protein	and	the	protein-
binding	module	in	the	DNA-dimerizer-protein	complex	do	not	deviate	substantially	from	
the	structurally	characterized	ternary	DNA-protein-protein	complexes.		Furthermore,	MPE	
footprinting established Exd’s DNA binding site in the ternary DNA-dimerizer-protein 
complex as the expected 5’-TGAT-3’ match sequence upstream of the polyamide binding 
site 5’-TGACCA-3’.  Using this information, a model of dimerizer 15	was	constructed	by	
superimposing	a	representative	polyamide	structure	(PDB	code	365D)	on	the	Ubx/Exd/
DNA	ternary	complex.	(PDB	code	8BI)9a		The	DNA	was	replaced	with	an	idealized	B-
form duplex (5’-AGGTGATTGACCACCAC-3’) created with 3DNA	and	after	making	
the	requisite	chemical	changes,	local	energy	minimization	was	performed		(Figure	.7).3	
The three α-helix homeodomain of Exd is shown bound to the DNA major groove at 5’-
TGAT-3’ adjacent to the minor groove-binding polyamide at 5’-TGACCA-3’ where the 
dimerizer	 protein-binding	 domain,	which	was	 previously	 part	 of	Ubx,	 is	 attached	 by	 a	
linker	to	an	internal	pyrrole	subunit	in	the	hairpin.
	Interestingly,	the	polyamide	DNA-binding	domain	by	itself	was	shown	to	contribute	
to the enhancement of Exd’s DNA affinity at low temperatures even though there are likely 
to	be	no	direct	contacts	between	the	protein	and	the	polyamide.		The	DNA	minor	groove	
is	 likely	 altered	 by	 the	 polyamide	 binding	 event,	which	may	 affect	 the	 adjacent	major	
groove	binding	site	for	Exd.		Polyamides	have	been	shown	to	expand	the	width	of	the	DNA	
minor	groove.4		The	minor	groove	polyamide	binding	site	is	also	widened	in	the	Exd/Ubx/
DNA	structure.9a		The	polyamide-DNA	binding	event	appears	to	play	an	allosteric	role	in	
enhanced	Exd	binding.		Undoubtedly,	other	changes	cannot	be	ruled	out,	such	as	locally	
dampened	structural	dynamics,	distortion	of	 the	nitrogenous	bases,	 and	 reorientation	of	
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Figure 2.7	(a)	Model	of	the	protein-DNA	dimerizer	15	(sticks)	bound	to	the	minor	groove	
of	DNA	(yellow	cartoon	and	surface)	adjacent	to	the	recruited	major	groove-binding	Exd	
homeodomain	 (pink	 cartoon	 and	 surface).	Attached	 by	 a	 linker	 to	 a	 polyamide	 pyrrole	
residue,	 the	Ac-WM-dipeptide	 protein-binding	 domain	 of	 15	 projects	 out	 of	 the	 DNA	
minor	groove	and	interacts	with	the	Exd	binding	pocket.		(b)	Closer	view	of	the	modeled	
interaction	 of	 15	 (sticks),	 Exd	 (transparent	 red	 surface),	 and	DNA	 (transparent	 yellow	
surface)	 centered	 on	 the	 Exd	 binding	 pocket.	 	 Select	 Exd	 homeodomain	 residues	 are	
numbered.9a		(white	=	carbon;	dark	blue	=	nitrogen;	red	=	oxygen)		Images	were	generated	
using	PyMOL.34		(c)	Modeled	interaction	of	16,	Exd,	and	DNA	with	same	color	coding	as	
in	panel	b.
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the	phosphate	backbone.		We	note	that	a	seemingly	innocuous	propylacetamide	linker	on	
a pyrrole subunit appears to eliminate the polyamide’s weak energetic contribution, which 
underscores	that	small	structural	changes	are	at	play.	 	It	 is	unclear	if	a	simple	dipeptide	
motif	would	be	functional	in	the	context	of	a	natural	protein	such	as	Ubx.
In	earlier	studies	we	observed	that	the	DNA	binding	selectivity	for	the	polyamide-
peptide	conjugate	1	was	reduced	relative	 to	 the	parent	hairpin	2.4  The DNA specificity 
of	the	conjugate	was	restored	by	changing	both	the	Trp	and	Met	residues	to	Ala,	which	
suggested that the Trp or Met might be responsible for the reduced recognition specificity.4a	
It	 is	 now	 clear,	 however,	 that	 a	 polyamide-peptide	 conjugate	 containing	 Trp	 and	Met	
residues	can	exhibit	sequence	selectivity	as	evidenced	by	the	footprinting	of	polyamide-
WM	conjugate	15.  The diminished DNA binding affinity and specificity of polyamide-
FYPWMKG	 conjugate	1	might	 be	 related	 to	 the	 overall	 size	 or	 hydrophobicity	 of	 the	
peptide which suggests minimization may be a way to ensure specificity of DNA binding 
in	the	construction	of	polyamide	conjugates	and	protein-DNA	dimerizers	in	general.
2.4 Conclusion
Small-molecule	protein-DNA	dimerizers	allow	the	cooperative	recruitment	of	the	
transcription factor Exd to a specific DNA sequence.  Although the polyamide itself was 
found to contribute to Exd’s DNA binding, the dipeptide WM protein binding domain 
was	 required	 for	 stable	 complex	 formation.	 	 Covalently	 linking	 polyamides	 to	 small-
molecule	 protein	 binders	 could	 emerge	 as	 a	 general	 strategy	 for	 the	 construction	 of	
artificial transcription factors.5-7		The	conjugate	with	the	unnatural	D-Trp	is	expected	to	
reduce	 sensitivity	 to	 endogenous	 proteases	 and	 should	 function	 at	 biologically	 relevant	
temperatures.	 	 Although	 these	 minimized	 dimerizers	 might	 be	 further	 optimized,	 for	
instance	through	iterative	changes	to	the	linker	length,	composition	of	the	polyamide,	and	
various	substitutions	to	the	Trp	indole,	biologically	driven	projects	utilizing	the	minimized	
dimerizers are in progress.  Developmental processes in fruit flies have been perturbed 
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using	polyamides.8	The	question	arises	whether	the	polyamide-WM	dimerizer	can	interfere	
specifically with the normal function of Exd leading to distinct fruit fly phenotypes0a	which	
will	be	reported	in	due	course.
	
2.5 Experimental
Abbreviations.	 	 Acetylated	 bovine	 serum	 albumin	 (BSA),	 N,N-dimethylformamide	
(DMF),	 N,N-diisopropylethylamine	 (DIEA),	 rac-dithiothreitol	 (DTT),	 N-[-
Hydroxyethyl]piperazine-N’-[2-ethanesulfonic acid] (HEPES), 2-(1H-benzotriazole-1-
yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), trifluoroacetic acid (TFA), 
Trishydroxymethylaminomethane	(TRIS),	ethylenediaminetetraacetic	acid	(EDTA).
Materials.  Wang	resin	and	Fmoc-protected	amino	acids	were	purchased	from	Novabiochem	
unless	stated	otherwise.		Super	Acid	Sensitive	Resin	(SASRIN)	was	purchased	from	Bachem.	
Boc-β-Ala-PAM resin was purchased from Peptides International.  Trifluoroacetic acid (TFA) 
was	purchased	from	Halocarbon.		Molecular	biology	grade	EDTA,	potassium	glutamate,	
and	acetylated	BSA	were	purchased	from	Sigma.		The	compound	3-indolepropionic	acid	
was	 purchased	 from	Aldrich.	 	 DTT	 was	 purchased	 from	 ICN.	 	 Other	 chemicals	 were	
purchased from Aldrich or EM Sciences and used without further purification.  All other 
solvents	were	purchased	from	EM	Sciences	and	were	reagent	grade.		Water	(8	MΩ)	was	
purified using a Millipore MilliQ water purification system.  Biological experiments were 
performed	 using	Ultrapure	Distilled	Water	 (DNase/RNase	 free)	 purchased	 from	Gibco.	
The	pH	of	buffers	was	adjusted	using	a	Beckman	340	pH/Temp	Meter.		All	buffers	were	
sterilized by filtration through either a Nalgene 0.2 µm cellulose nitrate filtration device 
or	a	Pall	Acrodisc	Syringe	Filter	HT	Tuffryn	membrane	(0.	µm).		DNA	oligonucleotides	
were	 obtained	 from	 the	 Biopolymer	 Synthesis	 and	 Analysis	 Facility	 at	 the	 Beckman	
Institute,	California	Institute	of	Technology.		Radiolabeled	nucleotides	[α-3P]-thymidine-
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5’-triphosphate (≥3000 Ci/mmol) and [α-3P]-deoxyadenosine-5’-triphosphate (≥6000 Ci/
mmol)	were	purchased	from	DuPont/NEN	and	[γ-3P]-adenosine-5’-triphosphate (≥6000 
Ci/mmol)	was	obtained	from	ICN.	Calf	thymus	DNA	was	from	Amersham	and	all	enzymes	
were	obtained	from	Roche.	
Methods.  UV	 spectra	 were	 recorded	 in	 water	 using	 a	 Beckman	 Coulter	 DU	 7400	
Spectrophotometer.	 	All	 polyamide	 concentrations	were	determined	using	 an	 extinction	
coefficient ε	 =	 69,500	 M-·cm-	 at	 a	 λmax	 near	 30	nm.	 	 Peptides	 concentrations	 were	
determined using an extinction coefficient of ε 	=	5,500	M-·cm-		at	λmax	equal	to	80	nm.	
Matrix-assisted, LASER desorption/ionization time of flight mass spectrometry (MALDI-
TOF	MS)	 was	 performed	 using	 a	Applied	 Biosystems	Voyager	 DE	 Pro	 Spectrometer.	
Electrospray	 ionization	 (ESI)	mass	 spectrometry	was	performed	using	a	Finnigan	LCQ	
ion	trap	mass	spectrometer.		Analytical	high-pressure	liquid	chromatography	(HPLC)	was	
performed	with	 a	Beckman	Gold	 system	equipped	with	 a	diode	 array	Detector	using	 a	
Varian	Microsorb-MV	300	C8	column	 (8	µm	particle	 size,	 50	×	4.6mm).	 	Preparative	
HPLC	was	performed	with	a	Beckman	Gold	system	equipped	with	a	single	wavelength	
Detector	 monitoring	 at	 30	nm	 using	 a	 Waters	 DeltaPak	 C8	 reversed	 phase	 column	
(00	µm,	5	×	00mm).		For	both	analytical	and	preparative	HPLC,	solvent	A	was	0.%	
(v/v)	aqueous	TFA	and	solvent	B	was	acetonitrile.		Compound	purity	was	assessed	using	
an	HPLC	analytical	method	employing	a	gradient	of	~4.%	B/min	starting	from	0%	B	
with a flow rate of 1.5 mL/min.  Initial preparative HPLC was performed with a gradient of 
to	60%	B	over	90	min.		If	the	purity	of	the	compound	was	less	than	95%,	a	second	HPLC	
purification was performed employing a slow gradient through the previous % B elution 
of	the	compound.		
Synthesis.  Polyamide	monomers	were	prepared	as	described	previously.9,30	 	Conjugate	
1	 was	 synthesized	 as	 described	 previously.4a	 	 1: (MALDI-TOF)	 [M+H]+	 calc.	 for	
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C08H37N3O9S
+	8.,	observed	8.0.  Polyamides	2,	3 and 6 were	synthesized	on	
PAM resin using published BOC-based protocols and purified by reverse phase HPLC.9	
2: (MALDI-TOF)	[M+H]+	calc.	for	C57H7NO0+	3.6,	observed	3.6. Polyamide	3: 
(MALDI-TOF)	 [M+H]+	 calc.	 for	C58H7NO0
+	 .6,	 observed	 .6. Polyamide	4: 
(MALDI-TOF)	[M+H]+	calc.	for	C6H78N3O
+	308.6,	observed	308.7.  Peptide	5	was	
synthesized	by	coupling		equivalents	of	propanolamine	with	.	equivalents	HBTU	and	
.	equivalents	DIEA	 in	DMF	 to	a	previously	 reported	protected	peptide4a	 followed	by	
deprotection and purification by reverse phase HPLC as described. Peptide 5:	(ESI,	pos.)	
[M+H]+	calc.	for	C5H7N0O0S
+	07.5,	observed	07.5.		Polyamide	6	(R	=	H):	(MALDI-
TOF)	calc.	for	C59H76N3O0
+	66.6,	observed	66.5.		The	peptides	7-12	were	synthesized	
by	manual	solid	phase	synthesis	on	Wang	resin	using	standard	Fmoc	chemistry.3		7:	(ESI,	
neg.)	[M-H]-	calc.	for	C4H33N4O5S
-	489.,	observed	489.. 8: (ESI,	neg.)	 [M-H]-	calc.	for	
C4H33N4O5S
-	489.,	observed	489.. 9: (ESI,	neg.)	[M-H]-	calc.	for	CH3N3O5S-	450.,	
observed	 450.. 10: (ESI,	 neg.)	  [M-H]-	 calc.	 for	C6H8N3O5S-	 374.,	 observed	 374.. 
11: (ESI,	neg.)	[M-H]-	calc.	for	CH9N4O5-	49.,	observed	49.. 12: (ESI,	neg.)	 [M-
H]-	calc.	for	CH7N4O5
-	45.,	observed	45.. The	peptides	13-14	were	synthesized	by	
manual	solid	phase	synthesis	on	SASRIN	resin	using	standard	Fmoc	chemistry	acylating	
the	 N-terminal	 residue	 with	 3-indolepropionic	 acid	 activated	 with	 HBTU	 in situ.	 	 13: 
(ESI,	neg.)	 [M-H]-	exact	mass	calc.	 for	CH30N3O4S
-	43.,	observed	43..	 	14: (ESI,	
neg.)	[M-H]-	exact	mass	calc.	for	C9H4N3O4
-	358.,	observed	358..		Following	cleavage	
from	 resin,	 crude	 peptides	 7-14	 were	 activated	with	HBTU	 and	 coupled	 to	 polyamide	
6	 (R=H)	 to	generate	polyamide	conjugates	15-22,	 respectively.	 	Then	conjugates	15-22	
were purified by reverse phase HPLC to ≥	95%	purity	(UV).		Mass	spectra	of	15,	16,	17,	
18,	and	21	displayed	the	presence	of	small	amounts	(<5%)	of	methionine	sulfoxide.		15: 
(MALDI-TOF)	[M+H]+	calc.	for	C83H08N7O4S
+	738.8,	observed	738.9.		16: (MALDI-
TOF)	 [M+H]+	 calc.	 for	 C83H08N7O4S
+	 738.8,	 observed	 738.8.	 	 17: (MALDI-TOF)	
[M+H]+	calc.	for	C8H07N6O4S
+	699.8,	observed	699.9.		18: (MALDI-TOF)	[M+H]+	
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calc.	for	C75H03N6O4S
+	63.8,	observed	63.9.		19: (MALDI-TOF)	[M+H]+	calc.	for	
C8H04N7O4
+	678.8,	observed	678.9.		20: (MALDI-TOF)	[M+H]+	calc.	for	C80H0N7O4+	
664.8,	observed	664.9.	 	21: (MALDI-TOF)	[M+H]+	calc.	for	C8H05N6O3S+	68.8,	
observed	68.8.	 	22: (MALDI-TOF)	 [M+H]+	calc.	 for	C78H99N6O3+	607.8,	observed	
607.8.		
Protein expression and characterization.	 	The	Drosophila Melanogaster	extradenticle	
(Exd)	 homeodomain	 and	 fourth	 extended	 helix	 (residues	 38-30)9	was	 expressed	 and	
FPLC purified following the precedent of Passner and Aggarwal and stored in 25% glycerol 
at -20 °C.9  The protein domain identity was confirmed by selective protease cleavage (Lys-
C	achromobacter	peptidase)	and	MALDI-TOF	MS,	identifying	8	of	9	predicted	fragments.	
MALDI-TOF	MS	of	 the	 undigested	 protein	 fragment	was	 consistent	with	 the	 isolation	
of	 Exd	 residues	 38-30	 (calculated	 mass,	 9495.7	 m/Z;	 observed	 mass,	 9496.0	 m/Z).	
Protein	concentration	was	determined	by	measuring	the	UV	absorption	at	80	nm	using	a	
calculated3 extinction coefficient of ε 	=		,600	M-·cm-.		See	appendix	C	for	details	of	
the	expression	procedure	and	protein	characterization.
Preparation of 3’-labeled DNA for DNase I footprinting.  Plasmids	pHDA	or	pDEH9	
(5	µg)	were	digested	using	restriction	enzymes	PvuII	and	EcoRI	to	yield	 the	crude	50	
base	 pair	 or	 308	 base	 pair	 restriction	 fragments.4a The 3’-overhang regions were filled 
with	[α-3P]-dATP	and	[α-3P]-dTTP	using	the	Klenow	fragment	of	DNA	polymerase	or	
Sequenase.  The radiolabeled oligonucleotides were purified by band extraction from a 
preparative	6%	non-denaturing	polyacrylamide	gel,	diluted	to	0	kcpm/µL,	stored	at	-78	
°C and used within 2 weeks.
Preparation of 5’-labelled DNA for MPE footprinting. A 5’-3P-end	labeled	(see	below)	
primer 5’-ttc aca cag gaa aca gct atg acc-3’ and an unlabelled primer 5’-cgg gga tcc ata 
4
cat gat tt-3’ were used to amplify a 5’-lower strand labeled PCR-fragment from pHDA1 
following	published	procedures.4 The radiolabeled oligonucleotides were purified by band 
extraction	from	a	preparative	6%	non-denaturing	polyacrylamide	gel,	diluted	to	0	kcpm/
µl, stored at -78 °C, and used within 2 weeks.
Preparation of 32P-labeled synthetic oligonucleotides for EMSA.  Synthetic	
oligonucleotides were either labeled by (a) 3’-overhang fill-in or (b) 5’ kinase end labeling. 
Three synthetic oligonucleotides were used: (1) UExdOpt: 5’-gatctcccgg cgaatgattg 
accatatcgg cgccactgtc acccgga-3’, (2) LExdOpt: 5’-tccgggtgac agtggcgccg atatggtcaa 
tcattcgccg ggagatc-3’, and (3)  LSExdOpt: 5’-tccgggtgac agtggcgccg atatggtcaa tcattcgccg 
ggag-3’.  Annealing was accomplished by mixing equimolar quantities in water, heating 
to 95 °C for 5 min, and slowly cooling to room temperature over 2 hours. 3’ fill-in was 
accomplished	 by	 annealing	 UExdOpt	 and	 LSExdOpt	 DNA	 (~60	 pmol)	 followed	 by	
treatment	with	[α-3P]-ATP	and	[α-3P]-dTTP	and	Klenow	fragment	of	DNA	polymerase.	
5’ end labeling was accomplished by annealing UExdOpt and LExdOpt followed by 
labeling	with	[γ-3P]-ATP and polynucleotide kinase using standard protocols.  Both 3’- and 
5’-labeled oligonucleotides were then purified by gel electrophoresis and band extraction 
from	a	6%	non-denaturing	polyacrylamide	gel,	diluted	to	0	kcpm/µl, stored at -78 °C, and 
used	within		weeks.
Electrophoretic Mobility Shift Assay (EMSA).  EMSA	experiments	were	performed	as	
described	previously.4a Polyamide conjugates were pre-incubated with ≤5 kcpm/reaction 
of	3P-labeled oligonucleotides at room temperature (~20 °C) in buffer for 1 hour.  Exd 
protein was then added to the reaction solution in a cold room (~4 °C), at room temperature 
(~20 °C), or in an incubator (~37 °C) for 1 more hour.  The final concentrations were 
30	mM	potassium	glutamate,	0	mM	HEPES,	0.	mM	DTT,	0%	glycerol,	and	0.	mg/
mL	BSA	(Sigma).	0	µL	of	 the	binding	solution	was	 loaded	onto	a	non-denaturing	9%	
4
polyacrylamide	(9:	acrylamide:bisacrylamide)	/	3%	glycerol	/	X	TBE	(89	mM	tris	base,	
89	mM	boric	acid,		mM	EDTA,	pH	8.3)	0.8	mm	thick	gel	and	developed	at	80-90	V	
and 13-15 mA for 1.5 hours pre-equilibrated to the same temperature in which the final Exd 
incubation was performed (i.e., 4 °C, 20 °C, or 37 °C).  Gels were then dried and exposed 
to	a	phosphor	 screen	overnight,	which	were	 scanned	with	a	Molecular	Dynamics	400S	
Phosphorimager.	All	experiments	were	done	at	least	in	triplicate.
The	 amount	 of	 Exd	 bound	 to	 the	 DNA	 template,	 i.e.,	 the	 apparent	 fractional	
occupancy	 (Θapp),	 was	 calculated	 from	 the	 measured	 intensity	 volumes	 of	 the	 shifted	
(Vshifted)	and	the	unshifted	bands	(Vunshifted):
																																Θapp	=	Vshifted /	(Vshifted	+	Vunshifted).																																												()
The data were then fitted to the Hill equation:33
																							Θ
fit
	=	Θmin	+	(Θmax	-	Θmin)[(Kan[Exd]n)/(	+	Kan[Exd]n)],	 	 					()
where	 [Exd]	 is	 the	 Exd	 concentration,	Ka	 is	 the	 equilibrium	 association	 constant,	 n	 is	
the	Hill	constant,	and	Θmin	and	Θmax	are	the	experimentally	determined	Θapp	values	where	
binding	is	absent	or	maximally	saturated,	respectively.		KaleidaGraph	software	was	used	to	
fit the data to equation (2) using a least-squares fitting procedure minimizing the difference 
between	Θapp	and	Θfit	with	Ka,	Θmax,	and	Θmin	as	the	variable	parameters.		Fitting	the	data	to	
equation	()	with	free	n did not increase the quality (R ≥ 0.98 in either case), so n	=		was	
kept	for	all	analysis.
		
Affinity determination by quantitative DNase I footprinting.		Reactions	were	carried	out	
in	a	volume	of	400	µL	in	aqueous	TKMC	buffer	according	to	published	protocols4	using	
a 3’ 3P-labeled		50	base	pair	EcoRI/PvuII	restriction	fragment	of	the	plasmid	pDEH9.4a	
Developed	gels	were	imaged	using	storage	phosphor	autoradiography	using	a	Molecular	
Dynamics	400S	Phosphorimager.	Equilibrium	association	constants	were	determined	as	
previously	described.4	
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MPE footprinting in the presence of Exd protein.	MPE	footprinting	was	carried	out	in	
40	µL	reaction	volumes	according	to	published	procedures.4		Reactions	were	carried	out	
in	a	total	volume	of	40	µL in aqueous TKMC buffer containing 10% glycerol using the 3’ 
3P-labeled	308	base	pair	EcoRI/PvuII	restriction	fragment	of	the	plasmid	pHDA.	DNA	
was pre-incubated with dimerizer overnight at 20 °C. in 4 µL	glycerol,	8	µL	5x	TKMC,		
µL	DNA	(0	kcpm),	4	µL	dimerizer	(0x).	Exd	protein	(0.6	µM,		µL)	was	introduced,	
gently mixed, and the mixture was incubated for 30 min at 4 °C before digestion was 
initiated.	 	Final	concentrations	were	5	mM	TrisOAc,	0	mM	NaCl,	00	µM	base	pair	
carrier	DNA	(calf	 thymus),	0	mM	DTT,	0	µM	MPE	x	FeSO4,	0%	glycerol,	pH	7.0.	
Cleavage	reactions	were	stopped	after	0	min.
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Chapter 3
Defining the Reach of Linear Protein-DNA Dimerizers
The text of this chapter was taken in part from a manuscript coauthored with Peter B. 
Dervan (Caltech).
(Stafford,	R.	L,	Dervan,	P.	B.	“The	Reach	of	Linear	Protein-DNA	Dimerizers”	submitted 
to J. Am. Chem. Soc. 2007)	
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Abstract
	 A	 protein-DNA	 dimerizer	 constructed	 from	 a	 DNA-binding	 pyrrole-imidazole	
polyamide	and	the	peptide	FYPWMK	facilitates	binding	of	the	natural	transcription	factor	
Exd	to	an	adjacent	DNA	site.		Previous	dimerizers	have	been	constructed	with	the	peptide	
attached	to	an	internal	pyrrole	monomer	in	an	overall	branched	oligomer.		Linear	oligomers	
constructed	by	attaching	the	peptide	to	the	polyamide	C-terminus	expand	the	range	of	protein-
DNA	dimerization	to	six	additional	DNA	sites.		Replacing	the	FYPWMK	hexapeptide	with	
a	WM	dipeptide,	which	was	previously	functional	in	branched	compounds,	does	not	lead	to	
a	functional	linear	dimerizer.		Instead,	inserting	an	additional	lysine	generates	a	minimal,	
linear	 WMK	 tripeptide	 conjugate	 that	 maintains	 the	 activity	 of	 the	 larger	 FYPWMK	
dimerizers	in	a	single	DNA-binding	site	orientation.		These	studies	provide	insight	into	the	
importance	of	linker	length	and	composition,	binding	site	spacing	and	orientation,	and	the	
protein-binding	domain	content	that	are	important	for	the	optimization	of	protein	DNA-
dimerizers	suitable	for	biological	experiments.
5
3.1 Introduction
	 Transcription	in	living	cells	is	controlled	by	precise	spatial	and	temporal	recognition	
of	DNA	by	protein	transcription	factors.		These	proteins	often	bind	to	DNA	as	homo-	and	
heterodimers	 or	 larger	 complexes	which	 increases	 their	 overall	DNA-binding	 site	 size,	
specificity, and affinity.	 	Transcription	 factors	 are	usually	modular,	whereby	 the	DNA-
binding	 and	 dimerization,	 or	 protein-binding	 domains,	 are	 functionally	 and	 structurally	
independent.3  Small molecules called artificial transcription factors have been reported to 
mimic	the	modular	components	of	these	endogenous	proteins.4		Protein-DNA	dimerizers	
are a type of artificial transcription factor which facilitate binding of proteins to an adjacent 
DNA	site,	mimicking	natural	multiprotein-DNA	complexes.5		Our	long-term	goal	is	to	ask	
whether protein-DNA dimerizers can serve as artificial regulators of gene expression in a 
living	cell.		From	a	design	point	of	view,	we	are	exploring	what	is	the	minimum	size	and	shape	
(branched	or	linear)	that	will	be	optimal	for	cell	uptake	with	adequate	functional	potency	
in	the	transcriptional	apparatus.	 	It	has	been	previously	shown	that	branched	dimerizers	
facilitate	protein	binding	at	three	different	binding	sites	(Figure	3.a).5c		Here,	we	describe	
linear	structural	motifs	which	expand	the	number	of	recognition	sites	targetable	by	protein-
DNA	dimerizers.		The	optimal	DNA	site	spacings	and	necessary	protein-binding	elements	
have	also	been	determined,	which	culminated	in	the	discovery	of	a	minimal,	three	amino	
acid	protein-binding	domain	that	yields	strong	dimerization	at	DNA-binding	sites	reaching	
6	base	pairs	apart.
	 Protein-DNA	 dimerizers	 can	 mimic	 homeobox	 (HOX)	 transcription	 factors	 by	
binding	cooperatively	to	DNA	with	the	protein	extradenticle	(Exd).5		The	conserved	class	
of	HOX	transcription	factors	is	known	to	bind	relatively	short	DNA	sites	by	themselves,	
but	 in	complex	with	cofactor	proteins,	 they	bind	 larger	DNA	sequences.6	 	The	 increase	
in	 their	composite	DNA	recognition	site	 is	 thought	 to	be	important	for	 their	function	in	
developmental	pathways.6		For	instance	in	D. melanogaster,	the	HOX	protein	ultrabithorax	
(Ubx) binds the site 5′-TTAT-3′ alone, but in complex with Exd the composite site increases 
5
Figure 3.1		Design	of	linear	protein-DNA	dimerizers.		(a)	Comparison	of	branched	polyamide-
peptide	conjugates	to	linear	conjugates,	both	used	as	protein-DNA	dimerizers	for	Exd.		(open	
circles	=	N-methylpyrrole,	dark	circles	=	N-methylimidazole,	half	circle	=	γ-aminobutyric	
acid,	 diamond	 =	 β-alanine,	 half	 circle	 with	 plus	 =	 N,N-dimethylaminopropylamine,	
freehand	line	=	linker	domain,	and	black	triangle	=	protein-binding	domain).		(b)		Diagram	
of	a	linear	conjugate	in	the	proximal	orientation	with	the	protein-binding	domain	directed	
toward Exd’s DNA-binding site.  (c)  Diagram of a linear conjugate in the distal	orientation	
with the protein-binding domain directed away from Exd’s DNA-binding site.  (d)  An 
illustrative	model	of	the	linear	protein-DNA	dimerizer	1	in	complex	with	Exd	and	DNA	as	
shown	schematically	in	panel	b.
53
by four base pairs to 5′-TGATTTAT-3′.7a		A	crystal	structure	of	the	ternary	Ubx/Exd/DNA	
complex revealed how both Ubx and Exd’s major groove binding homeodomains interact 
via Ubx’s N-terminal YPWM peptide motif.7a	 	The	 conserved	YPWM	motif	 spans	 the	
DNA	minor	groove	between	the	two	proteins	and	inserts	a	hydrophobic	tryptophan	into	
the	complementary	Exd	binding	pocket.		Additional	crystal	structures	of	HoxB/Pbx/DNA	
and	HoxA9/Pbx/DNA	which	contain	human	homologues	of	Ubx	and	Exd	have	also	been	
reported	in	which	the	conserved	tryptophan	of	the	YPWM	motif	mediates	the	majority	of	the	
protein-protein	contacts.7b-c		Protein-DNA	dimerizers	have	been	constructed	by	replacing	the	
natural	DNA-binding	homeodomain	of	Ubx	with	a	synthetic	pyrrole-imidazole	polyamide	
which	binds	the	DNA	minor	groove.5		Polyamides	are	ideal	small-molecule	DNA	binding	
domains	since	they	can	be	programmed	to	bind	to	a	broad	repertoire	of	sequences	using	an	
aromatic	amino	acid	pairing	code.8
	 In	this	study	we	explore	the	range	of	DNA	sites	in	which	Exd-DNA	dimerization	
is	observed	in	the	presence	of	linear	polyamide-peptide	conjugates	using	a	series	of	DNA	
duplexes	containing	incremental	A,T	base	pair	spacings	between	the	polyamide	and	Exd	
binding	 sites.	 	 Linear	 oligomers	were	 generated	 by	 attaching	 an	 FYPWMK	peptide	 to	
the	 polyamide	 C-terminus	 incorporating	 linkers	 of	 different	 lengths	 and	 composition,	
i.e.,	 1	 and	 2 (Figure	 3.).	 	 Once	 the	 scope	 of	 recognition	 sequences	with	 these	 larger	
constructs was defined, efforts were made to discover a minimal protein-binding domain 
for dimerizers in this linear configuration.  It is shown that WM dipeptides (with both L and 
D	stereochemistry	of	the	W)	which	previously	enhanced	Exd-DNA	binding	in	the	branched	
oligomer5d	 failed	 to	 yield	 stable	 Exd-DNA	 complexes.	 	 Exd	 dimerization	 activity	 was	
recovered	by	inserting	a	lysine	back	into	the	peptide	to	generate	minimal	WMK	tripeptide	
conjugates.		The	presence	of	a	positively	charged	ammonium	ion	in	the	linker	and	lysine	
seem	to	be	favorable	for	complex	formation	possibly	due	to	interactions	with	the	negatively	
charged	DNA	backbone.
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Figure 3.2  Structures	of	compounds	1	through	14.
3.2 Results and Discussion
Dimerization in Proximal and Distal Orientations
 Exd is expected to bind 5′-TGAT-3′ as found in the Ubx/Exd/DNA crystal 
structure7a and the hairpin polyamide ImImPyPy-γ-PyPyPyPy-β- codes for the sequence 
5′-WGGWWW-3′ (where W = A or T).8		In	the	proximal	orientation,	the	polyamide	binding	
site	is	oriented	such	that	the	protein-binding	YPWM	peptide	is	projected	adjacent	to	Exd	
(Figure	3.b).		In	the	distal	orientation,	the	polyamide	binding	site	was	inverted	such	that	
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the	peptide	is	projected	away	from	Exd	(Figure	3.c).		For	dimerization	of	Exd	at	a	given	
DNA	 site	 to	 occur,	 the	 protein-binding	 peptide	 must	 project	 over	 the	 DNA	 phosphate	
backbone	and	interact	favorably	with	the	binding	pocket	of	the	major	groove	binding	Exd	
protein	(Figure	3.d).		Dimerization	was	expected	to	be	dependent	on	both	the	length	and	
composition	of	 the	 linker	between	 the	polyamide	and	 the	YPWM-containing	peptide	as	
well as the size of the spacer region between the polyamide’s and protein’s binding sites.
	 Accordingly,	two	polyamide-peptide	conjugates	were	constructed	that	incorporated	
either	a	tertiary	amine	(1)	or	a	PEG	linker	(2).		The	distance	between	the	terminal	amine	
of	 the	 linker	 to	 the	 carbonyl	 carbon	 of	 the	methionine	 of	 the	 peptide	 was	 determined	
computationally	in	the	gas-phase	for	MM-energy	minimized	linkers	to	be	approximately	
3	 and	30	Å	 for	1	 and	2,	 respectively.	 	A	 series	of	DNA	duplexes	which	 contained	an	
incremental	A,T	spacer	region	were	screened	by	electrophoretic	mobility	shift	(EMSA),	
or	 gel	 shift	 assays,	 to	 determine	 the	 range	 of	 protein	 recruitment	 to	 the	DNA	 at	 room	
temperature (20 °C).  A total of nine different duplexes in the proximal orientation with 
spacer	regions	between	-	and	7	bps	were	used,	covering	distances	between	the	polyamide	
and	expected	protein-binding	domain	position	from	approximately		to	30	Å.		Negative	
spacer	regions	indicate	an	overlap	in	the	expected	binding	sites.		
	 It	might	be	expected	that	since	2	contains	a	longer	linker	than	1,	it	would	facilitate	
Exd	binding	at	sites	further	away	from	the	polyamide	binding	site.		Instead,	it	was	observed	
that	1	dimerizes	Exd	effectively	on	composite	sites	containing	spacer	regions	between		
to	6	base	pairs,	whereas	2	only	dimerizes	Exd	on	sites	with	spacer	regions	of	4	to	5	base	
pairs	(Figure	3.3	and	Table	3.).		Thus,	compound	2 has a narrower recognition profile, in 
contrast	to	1	which	is	more	promiscuous.		The	greater	tolerance	for	multiple	binding	sites	
by	compound	1	may	be	due	to	its	chemical	composition.		It	is	possible	that	the	presence	of	
the	positively	charged	ammonium	ion	in	1	may	interact	more	favorably	with	the	phosphate	
backbone	than	the	PEG	linker	of	2.		Control	experiments	at	all	of	these	sites	show	that	Exd	
by itself, or in the presence of parent polyamide ImImPyPy-γ-PyPyPyPy-β-Dp 15,	or	the	
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Figure 3.3 	Representative	gel	shift	results	for	Exd	in	the	presence	of	linear	protein-DNA	
dimerizers	with	differently	sized	linkers	on	two	proximally	oriented	DNA	sites.		Conjugate	
1 has	an	amine-containing	linker	(~3	Å	long)	and	conjugate	2 has	a	PEG-type	linker	(~30	
Å	 long).	 	 (a)	 Schematic	 of	 the	 positions	 of	 the	Exd	 and	polyamide	DNA-binding	 sites	
showing	the	A,T	spacer	region	which	was	varied.		(b)		Gel	shift	experiments	show	that	1	
forms	a	stable	complex	with	Exd	and	DNA	with	site	spacings	between	-6	bps,	whereas	
2	only	forms	stable	complexes	from	4-5	bps.		A	concentration	of	50	nM	of	the	indicated	
compound	was	added	to	all	lanes	and	Exd	was	titrated	from	0	pM	to	00	nM.
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double	alanine	mutants	3	and	4,	does	not	lead	to	stable	complex	formation	(Figure	F.).	
Thus,	the	polyamide	domain	by	itself	does	not	appear	to	contribute	to	the	binding	of	Exd	
through	allosteric	interactions	as	observed	in	previously	reported	systems.5d		Furthermore,	
these	 control	 experiments	 show	 that	 dimerization	 of	 Exd	 is	 dependent	 on	 the	 central	
tryptophan	and	methionine	residues	in	this	context.
	 In	the	distal	orientation,	5	different	spacer	regions	were	investigated	from	-	to		
bps	covering	a	theoretical	distance	of	approximately	5	to	30	Å	between	the	polyamide	
and	expected	protein-binding	domain	position.		In	this	arrangement,	Exd	dimerization	was	
observed	only	with	compound	1	at	the	-	spacer	site	(Figure	3.4	and	Table	3.).		Control	
experiments	at	 the	 -	 site	 show	 that	Exd	by	 itself,	 in	 the	presence	of	parent	polyamide	
ImImPyPy-γ-PyPyPyPy-β-Dp 15,	 or	 double	 alanine	 mutant	 3,	 does	 not	 lead	 to	 stable	
complex	formation	(Figure	F.).		
Minimization of the Protein-Binding Domain
	 As	mentioned	above,	we	have	previously	reported	that	in	the	context	of	a	branched	
Table 3.1	Summary	of	select	proximal	orientation	gel	shiftsa
Base	pairs	between	
binding	sites
Estimated	proximal	
distance	(Å)b
Exd-DNA	binding	
with	1
Exd-DNA	binding	
with	2
- 3.8 - -
0 0.0 - -
 5.0 - -
 . + -
3 . + w
4 4. + +
5 9.4 + +
6 5.4 + -
7 9.8 w -
a A ‘+’, ‘w’, and ‘-’ indicate a strong, weak, or no complex, respectively.  Binding 
constants	(Ka’s) for ‘+’ entries varied between 0.8 ± 0.3 to 2.7 ± 1.0 M
-	(Figure	F.5).
b	measured	from	the	Met	C	to	the	linker	N
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polyamide-peptide	conjugate,	the	protein-
binding	domain	could	be	reduced	to	a	WM	
dipeptide.5d	 	Thus,	 compounds	5-8	were	
synthesized	to	see	if	an	analogous	linear	
dipeptide	conjugate	would	also	dimerize	
Exd.		Gel	shift	experiments	with	5	and	6 
using	DNA	duplexes	with	 spacings	of	0	
to	6	in	the	proximal	orientation,	and	-	in	
the	distal	orientation	did	not	 lead	 to	any	
significant gel shift (Figure F.3).  A weak 
complex	was	observed	with	compound	6	
at the 3 bp proximal spacing (Θapp	=	0.3	
±	0.	at	00	nM	Exd	and	50	nM	6),	but	
was not significant enough to reliably 
determine the Exd-DNA binding affinity. 
Similarly,	the	WM	conjugates	bearing	the	
PEG	linker	(7	and	8)	failed	to	yield	any	
discernible	gel	shift	with	DNA	duplexes	
containing	 proximal	 spacings	 of	 	 to	 6	
bps	or	at	the	-	bp	distal	spacing	(Figure	
F.3).		
	 It	 was	 noted	 that	 the	 substitution	
of	 FYPWMK	 (1	 and	 2)	 with	 WM	 (5-
8)	 eliminated	 the	 lysine	 between	 the	
presumed	linker	domain	and	the	core	WM	dipeptide	of	the	YPWM	motif.		Thus,	WMK	
tripeptide	conjugates	9-12	were	synthesized	to	ensure	identical	linker	length	and	composition	
Figure 3.4  Representative	 gel	 shift	
results	 for	 Exd	 in	 the	 presence	 of	
linear	 protein-DNA	 dimerizers	 with	
differently	 sized	 linkers	 on	 two	distally	
oriented	 DNA	 sites.	 	 (a)	 Schematic	 of	
the	positions	of	 the	Exd	and	polyamide	
DNA-binding	 sites	 showing	A,T	 spacer	
region	which	was	varied.		(b)		Gel	shift	
experiments	 show	 that	1	 forms	a	 stable	
complex	with	Exd	and	DNA	when	there	
is	a		bp	overlap,	i.e.,	a	site	spacing	of	-
,	between	the	two	sites,	whereas	2	does	
not	 form	a	complex	with	Exd	at	any	of	
these	sites.		A	concentration	of	50	nM	of	
the	indicated	compound	was	added	to	all	
lanes	and	Exd	was	 titrated	 from	0	pM	
to	00	nM.
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Figure 3.5  Representative	gel	shift	results	for	Exd	in	the	presence	of	linear	WMK	
tripeptide	conjugates	on	 select	proximally	 oriented	DNA	sites.	 	 (a)	Schematic	of	
the	positions	of	the	Exd	and	polyamide	DNA-binding	sites	showing	the	A,T	spacer	
region	which	was	varied.		(b)		Gel	shift	experiments	show	that	both	9 and	10	form	
stable	complexes	with	Exd	and	DNA	only	when	 there	 is	 a	6	bp	 site	 spacing.	 	A	
concentration	of	50	nM	of	the	indicated	compound	was	added	to	all	lanes	and	Exd	
was	titrated	from	0	pM	to	00	nM.
Table 3.2	Summary	of	select	distal	orientation	gel	shiftsa
Base	pairs	between	
binding	sites
Estimated	distal	
distance	(Å)b Exd	binding	with	1 Exd	binding	with	2
- 5. + -
- 9.5 - -
0 3.8 - -
 8. - -
 3.5 - -
a	A	“+”	and	“-”	indicate	the	presence	or	absence	of	a	complex,	respectively.		The	binding	
constant	(Ka)	for	the	“+”	entry	is	.5	±	.8	M
-.
b	measured	from	the	Met	C	to	the	linker	N
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between	 the	polyamide	and	 the	WM	moiety.	 	These	compounds	were	examined	by	gel	
shift	using	duplexes	with	proximal	spacings	between	3	and	6	bps	shown	above	to	enable	
dimerization	of	Exd	with	the	larger	conjugates	1 and	2.	 	Both	tertiary	amine	containing	
WMK	conjugates	(9 and	10)	yielded	a	complex	with	Exd	only	at	the	6	bp	proximal	site,	
but	the	PEG	containing	WMK	conjugates	(11	and	12)	did	not	lead	to	an	observable	shift	
in	any	of	the	orientations	(Figure	3.5	and	Figure	F.4b).		Both	9	and	10	at	the	proximal	6	bp	
spacing site yielded similar binding affinities (Ka	=	9.	±	0.6	×	0
8	M-	and	7	±		×	08	M-,	
respectively)	and	amounts	of	complex	formed	(0.50	±	0.0	and	0.53	±	0.05,	respectively)	
indicating no significant difference in Exd binding by either the L-	or	D-tryptophan	peptides	
in this context.  The binding affinities of Exd in the presence of 9	and	10 are	within	4-fold	
of	 those	observed	for	 the	larger	conjugates	1	and	2	 (Tables	3.	and	3.).	 	 In	comparing	
9 and	10 to	1, however, it appears that the use of smaller and presumably lower-affinity 
protein-binding	 domains	 leads	 to	 a	 narrower	 site	 spacing	 tolerance.	 	 In	 general,	 larger	
higher-affinity protein-binding domains may tolerate suboptimal linker distances and may 
generate	more	promiscuous	protein-DNA	dimerizers.		
	 Finally,	 to	 determine	 the	 principal	 role	 of	 the	 lysine	 in	 the	 WMK	 tripeptide	
conjugates	9	and	10,	their	lysine	side-chains	were	acetylated	to	create	conjugates	13 and	
14,	respectively.		These	compounds	retain	the	same	linker	length	as	9	and	10 between	the	
polyamide	and	 the	core	WM	dipeptide,	but	 should	eliminate	 the	positive	charge	on	 the	
lysine	while	maintaining	comparable	steric	bulk.		Both	13	and	14	were	not	able	to	form	
a	complex	in	the	presence	of	Exd	(Figure	F.4c).		This	suggests	that	the	lysine	side-chain	
makes	a	favorable	electrostatic	interaction	to	stabilize	the	Exd-DNA-dimerizer	complex.	
Although	 a	 direct	 interaction	 with	 the	 Exd	 protein	 cannot	 be	 ruled	 out,	 the	 presumed	
requirement	for	the	linker	domain	to	traverse	the	DNA	backbone	suggests	that	the	primary	
role	of	this	lysine	group	may	be	to	interact	favorably	with	the	negatively	charged	phosphate	
groups	of	DNA.		In	comparing	to	natural	systems	it	was	observed	that	Ubx	contains	an	
alanine	at	this	position,7a	but	lysine	and	arginine	are	often	found	immediately	adjacent	to	
6
Figure 3.6  A	series	of	estimated	distance	
measurements	 are	 shown	 between	 the	
polyamide	tail	and	the	methionine	carbonyl	
of	 the	 YPWM	 protein-binding	 domain	
which	each	dimerizer	linker	domain	must	
traverse.	 	The	models	of	 the	polyamides	
binding	 to	 the	 DNA	 were	 generated	 by	
superimposing	 the	 DNA-binding	 site	
from	 a	 representative	 polyamide-DNA	
crystal	structure	(PDB	code	=	365D)	over	
the	Ubx/Exd/DNA	crystal	structure	(PDB	
code	B8I)	and	deleting	the	Ubx	protein	
except	 for	 its	 YPWM	 protein-binding	
domain.	 	 In	 the	 proximal	 orientation,	
there	exists	a	minimum	distance	of	~	Å	
between	the	site	spacings	of	-3	bps	which	
increases	 non-linearly	 in	 each	 direction	
as	the	polyamide	slides	along	the	helical	
DNA	minor	groove.
the	C-terminal	end	of	the	YPWM	motif	in	many	HOX	proteins.9
Calculation of Distances
 The	superposition	of	a	polyamide	crystal	structure0 (PDB code 365D) over specific 
DNA	sites	 in	 the	Ubx/Exd/DNA	crystal	 structure7a	 (PDB	code	B8I)	 readily	allows	 the	
measurement	of	theoretical	distances	between	
the	 polyamide	 tail	 and	 the	YPWM	 peptide	
that	the	linker	domain	must	traverse	(Figure	
3.6	and	Tables	3.	and	3.).		In	the	proximal	
orientation	 the	 shortest	 distance	 occurs	
somewhere	between	the		and	3	bp	spacings	
(~	Å)	and	increases	in	both	directions	in	a	
non-linear	fashion	due	to	the	helical	nature	of	
the	DNA	grooves.	 	In	the	distal	orientation,	
the	 polyamide	 positions	 the	 linker	 past	 the	
6
minimum	 distance	 of	 approximately	 	
Å	 observed	 in	 the	 proximal	 orientation.	
Thus,	even	at	a		bp	overlap	in	the	distal	
orientation	the	distance	is	approximately	
5	Å,	which	 is	 longer	 than	 the	 shortest	
distance	in	the	proximal	orientation.		
	 The	 results	 cannot	 be	 completely	
rationalized	using	distance	measurements,	
however.	 	 For	 instance,	 comparing	
proximal	 sites	 with	 spacers	 of	 similar	
distances,	 such	 as	 	 and	 4	 bps	 (4-5	
Å),	or	0	and	5	bps	(9-0	Å)	reveal	that	
sites	with	similar	distance	constraints	do	
not	 necessarily	 lead	 to	 similar	 abilities	
to	 enhance	 Exd	 binding	 to	DNA.	 	This	
apparent	discrepancy	could	be	explained	
by	 the	 fact	 that	 the	 measured	 distances	
do	 not	 account	 for	 the	 interference	 by	
the	phosphate	backbone	which	the	linker	
domain	must	cross	 to	place	 the	protein-
binding	domain	in	the	necessary	location.	
Additionally,	 the	 linker	 domain	 must	
bend back approximately 180° in the 1 
and	 0	 bp	 sites	 to	 bring	 the	 protein-binding	 domain	 into	 the	 correct	 binding	 orientation	
whereas	the	4	and	5	bp	sites	project	the	protein-binding	domain	directly	toward	its	Exd	
binding	pocket.		Such	bending	of	the	linker	domain	may	be	energetically	unfavorable.
	 Similarly,	 in	 spite	 of	 the	 overlapping	 range	 of	 possible	 distances	 for	 the	 distal	
Figure 3.7	 	 Models	 of	 linear-protein	
DNA	 dimerizers.	 	 (a)	 A	 proximally	
oriented	binding	site	with	a	5	bp	spacer	
with	dimerizer	1	is	shown.		(b)		A	distally	
oriented	binding	orientation	with	a		bp	
overlap	(i.e.,	 -	bp	spacer)	between	 the	
polyamide	 and	Exd	DNA-binding	 sites	
is	shown	for	dimerizer	1.
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binding	orientations	(~-30	Å)	when	compared	to	the	proximal	sites	(~5-30	Å),	only	the	
-	bp	distal	site	led	to	a	stable	complex	with	Exd.		Unfortunately,	greater	overlap	sites	in	
the	distal	orientation	cannot	be	addressed	without	changing	the	structure	of	the	polyamide	
which	was	held	constant	for	the	purposes	of	this	study.		Movement	of	the	polyamide	binding	
site	to	the	-3	bp	site	may	still	lead	to	a	functional	binding	orientation,	but	the	overlapped	
-4	bp	site	will	probably	not	be	tolerated	since	Arg	of	the	Exd	homeodomain	contacts	the	
thymine	base	at	this	location	in	the	minor	groove.7a
	 Interestingly,	a	complex	was	observed	at	the	6	bp	(strong	complex)	and	7	bp	(weak	
complex) proximal arrangements (≥25 Å spacing) with compound 1	even	though	the	fully	
extended	linker	(~3	Å)	was	predicted	not	to	reach	in	either	case.		This	suggests	there	may	
have	been	some	structural	adaptation	by	the	complex	to	enable	the	YPWM-Exd	interaction.	
It	is	noted	that	TATA	DNA	sequences	are	known	to	be	bent	by	TATA-binding	protein	and	it	
is thought that such sequences are inherently flexible.		Thus,	the	use	of	a	variable	poly-AT	
spacer	may	have	enabled	such	DNA	distortions.		Either	the	Exd	structure	or	the	placement	
of	the	YPWM	peptide	in	the	Exd	binding	pocket	may	also	allow	structural	deviations.	
3.3 Conclusions
	 A	set	of	linear	polyamide-peptide	conjugates	have	been	created	which	expand	the	
recognition	scope	of	protein-DNA	dimerizers	targeted	towards	Exd.		In	particular,	conjugate	
1 was shown to enhance Exd’s binding to DNA when the protein and polyamide binding 
sites	were	-,	,	3,	4,	5,	and	6	bps	apart.		We	have	previously	reported	branched	dimerizers	
that	facilitate	Exd	binding	to	-,5c	0,5	and		bp5c	orientations.		Thus,	a	set	of	solutions	from	
-	to	6	bps	has	been	completed	using	these	linear	conjugates.		Furthermore,	the	protein-
binding	domain	was	minimized	to	a	WMK	tripeptide	(9	and	10)	that	functioned	nearly	as	
well	as	the	larger	conjugates	(1 and	2).	 	Remarkably,	the	range	of	tolerated	orientations	
appears	to	be	tunable	not	only	by	the	length	and	chemical	nature	of	the	linker	(compare	1	
to	2),	but	also	by	the	content	of	the	protein-binding	domain	(compare	1	to	9).		
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	 In	 combination	 with	 the	 previous	 results	 for	 branched	 dimerizers,5	 the	 work	
presented	here	provides	design	principles	for	dimerizers	suitable	for	use	in	cell	culture	and	
fruit fly experiments.  Developmental processes in fruit flies have been perturbed using 
polyamides.3	 	The	question	arises	whether	a	 linear	or	branched	protein-DNA	dimerizer	
can interfere specifically with the normal function of Exd and lead to distinct fruit fly 
phenotypes.		All	compounds	in	this	study	function	at	temperatures	suitable	for	experiments	
in fruit flies (20 °C) and the unnatural D-Trp	WMK	conjugate	(10)	is	expected	to	be	resistant	
to	endogenous	proteases.	4		
3.4 Experimental Section
General.  Fmoc	protected	amino	acids	and	-chlorotritylchloride	resin	was	purchased	from	
Novabiochem.		Super	Acid	Sensitive	Resin	(SASRIN)	was	purchased	from	Bachem.		DNA	
oligonucleotides	were	obtained	from	Integrated	DNA	Technologies.		[γ-3P]-adenosine-5’-
triphosphate (≥ 6000Ci/mmol) was obtained from Perkin Elmer.  Polynucleotide kinase 
(PNK)	was	obtained	from	Roche.	 	UV	spectra	were	recorded	in	water	using	an	Agilent	
8453	 UV-Visible	 spectrophotometer.	 	 Analytical	 high-pressure	 liquid	 chromatography	
(HPLC)	was	performed	with	a	Beckman	Gold	system	equipped	with	a	diode	array	68	
Detector	and	a	5	Solvent	module	using	a	Phenomenex	Gemini	C8	column	(5	µm	particle	
size,	50	×	4.60	mm).		Preparative	HPLC	was	performed	with	a	Beckman	Gold	system	
equipped	with	a	7P	Solvent	Module	and	a	single	wavelength	66P	Detector	monitoring	
30	nm	using	a	Waters	DeltaPak	C8	 reverse-phase	column	 (00	µm	particle	 size,	5	×	
00mm)	or	a	Phenomenex	Gemini	C8	reverse-phase	column	(5	µm	particles,	0	Å	pore,	
50	×	.	mm).	 	For	both	analytical	and	preparative	HPLC,	solvent	A	was	0.%	(v/v)	
aqueous TFA and solvent B was acetonitrile.  Final preparative HPLC purification was 
performed	by	ramping	from	0	to	55%	B	over	75	min	using	the	Gemini	column.		If	the	
purity of the compound was less than 95%, a second HPLC purification was performed 
employing	a	slow	gradient	through	the	previous	%	B	elution	of	the	compound.		All	other	
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general	procedures	are	the	same	as	described	in	Chapter	.
Synthesis.  Polyamide	monomers	were	prepared	as	described	previously.6	 	Polyamides	
were	synthesized	according	to	standard	synthetic	procedures,6	and	cleaved	from	the		resin	
with either 3,3’-diamino-N-methyl-dipropylamine,	 4,7,0-trioxa-,3-tridecanediamine,	
or	 3-(dimethylamino)-propylamine.	 	 Before	 conjugation	 to	 peptides,	 polyamides	 were	
HPLC purified and characterized by MALDI-TOF MS, UV-Vis spectroscopy, and 
analytical	HPLC.	 	Protected	peptides	were	 synthesized	using	SASRIN	or	-chlorotrityl	
resin	using	standard	Fmoc	protocols7	and	characterized	by	ESI	MS	and	analytical	HPLC.	
Polyamide-peptide	conjugates	were	prepared	as	described	previously	using	0.	M	DIEA	
in	DMF	using	excess	PyBOP	(~5	equivalents)	followed	by	deprotection	with	80%	TFA,	
5%	TIS,	5%	EDT,	and	0%	DCM.5a  Conjugates were then purified by preparative HPLC 
and	 characterized	 by	 MALDI-TOF	 or	 ESI	 MS,	 UV-Vis	 spectroscopy,	 and	 analytical	
HPLC.		1: (MALDI-TOF)	[M+H]	calcd	for	C3H46N3O9S	74.,	observed	74.0;	2: 
(MALDI-TOF)	[M+H]	calcd	for	C6H5N30OS	349.,	observed	349.0;	3: (MALDI-
TOF)	[M+H]	calcd	for	C03H37N30O9	099.,	observed	098.8;	4: (MALDI-TOF)	[M+H]	
calcd	for	C06H4N9O	74.,	observed	74.0;	5: (ESI)	[M+H]	calcd	for	C84H09N6O4S	
737.8,	 observed	 737.6;	 6: (MALDI-TOF)	 [M+H]	 calcd	 for	 C84H09N6O4S	 737.8,	
observed	 737.4;	 7: (ESI)	 [M+H]	 calcd	 for	 C87H4N5O7S	 8.9,	 observed	 8.5;	
8: (MALDI-TOF)	 [M+Na]	 calcd	 for	 C87H3N5O7SNa	 834.8,	 observed	 834.6;	 9: 
(MALDI-TOF)	[M+H]	calcd	for	C90HN8O5S	865.9,	observed	865.5;	10: (MALDI-
TOF)	 [M+H]	 calcd	 for	 C90HN8O5S	 865.9,	 observed	 865.8;	 11: (MALDI-TOF)	
[M+H]	 calcd	 for	 C93H6N7O8S	 94.0,	 observed	 94.0;	 12: (MALDI-TOF)	 [M+H]	
calcd	for	C93H6N7O8S	94.0,	observed	940.9.		Acetylated	compounds	13	and	14	were	
synthesized	by	treating	00-300	nmol	of	9	and	10,	respectively,	with	8-9	equivalents	of	
acetic anhydride in 0.1 M DIEA in DMF and purified by preparative HPLC.  13: (MALDI-
TOF)	[M+H]	calcd	for	C9H3N8O6S	907.9,	observed	908.;	14: (MALDI-TOF)	[M+H]	
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calcd	 for	C9H3N8O6S	907.9,	observed	908.0;	15:	 (MALDI-TOF)	 [M+H]	calcd	 for	
C58H7NO0	.6,	observed	.7.
Electrophoretic mobility shift assays (EMSAs).  EMSA,	or	gel	shift,	experiments	were	
performed at 20 °C essentially as described in Chapter 2.5d	 The final concentrations of 
the	 components	were	50	nM	of	 the	 indicated	 compound,	 30	mM	potassium	glutamate,	
10 mM HEPES, 0.2 mM DTT, 10% glycerol, and 0.1 mg/mL acetylated BSA.  The final 
concentrations	 for	Exd	were	 the	 following:	0	pM,	50	pM,	00	pM,	500	pM,		nM,	5	
nM,	0	nM,	50	nM,	and	00	nM.		Recombinant	Exd	(residues	38-30)	was	expressed5	
and	characterized5d	as	described	in	appendix	C.		The	Exd	concentration	was	determined	
by	measuring	 the	 UV	 absorption	 at	 80	 nm	 using	 a	 calculated8 extinction coefficient 
of	,600	M-·cm-.		The	amount	of	Exd	bound	to	the	DNA	template	was	determined	as	
described	previously5d and fit to the Hill equation9 with n = 1.  All binding affinities were 
measured	in	triplicate.						
Theoretical distance measurements.  The	illustrative	models	shown	in	Figure	3.6	were	
created	by	superimposing	the	DNA	backbone	of	the	atomic	coordinates	from	a	representative	
polyamide-DNA	crystal	 structure0	 (PDB	code	365D)	over	 the	desired	site	on	 the	DNA	
backbone	from	the	Ubx/Exd/DNA	crystal	structure7a (PDB code 1B8I) using a fit algorithm 
from	SwissPDB	Viewer	(version	3.7).		The	DNA	from	the	polyamide	crystal	structure	and	
the	Ubx	homeodomain	were	 then	deleted	 to	generate	 a	model	 from	which	 the	distance	
measurements	were	be	made.
 The illustrative models shown in Figure 7 were made by first superimposing a 
polyamide-DNA	crystal	structure	as	described	above.		The	linker	between	the	polyamide	and	
the FYPWMA peptide from Ubx, the linker, and the γ-aminobutyric acid of the polyamide 
hairpin,	the	lysine	side-chain,	and	the	acetyl	moiety	were	constructed	and	minimized	using	
an augmented MM3 force field and short molecular dynamics simulations (<100 ps) with 
all	other	coordinates	locked	using	CAChe	Workspace	(ver.	6...33).		The	DNA	shown	in	
the figure is the same as the DNA from the Ubx/Exd/DNA structure.
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Chapter 4
Cell-Permeable Protein-DNA Dimerizers
Work on the synthesis of polyamide-peptide-FAM conjugates 13 and 16 was done in 
collaboration with Rachel Wang (Dervan Group; Caltech).
7
Abstract
 In general, polyamide-peptide-fluorescein conjugates have shown poor cell 
uptake.	This	chapter	describes	how	such	conjugates	can	be	made	 to	 localize	 to	 the	cell	
nucleus through subtle structural changes.  Specifically, cell-permeable conjugates are 
described that incorporate smaller peptides with the fluorescein attached to the polyamide 
C-terminus.  Similar peptides conjugated to fluorescein without a polyamide, exhibited 
primarily	extracellular	localization	which	suggests	that	the	polyamide	confers	the	nuclear	
localization to the conjugate.  Polyamide-peptide-fluorescein and polyamide-peptide-
isophthalic	acid	conjugates	also	retain	protein-DNA	dimerization	activity	in vitro.		These	
experiments	provide	a	foundation	for	performing	experiments	in	cell	culture	with	protein-
DNA	dimerizers.
7
4.1 Introduction to Polyamide Conjugate Cell Uptake
	 Several	 conjugates	 containing	 pyrrole-imidazole	 polyamides	 and	 peptides	 have	
been	reported	to	have	a	variety	of	functions	in vitro	such	as	gene	activation-3	and	protein-
DNA	dimerization.4-7  Experiments in cell culture have experienced difficulty partly due 
to	 the	 poor	 cellular	 permeability	 of	 such	 conjugates.	 	 Polyamides	 by	 themselves	 often	
localize	to	the	cell	nucleus8-9	which	suggests	that	the	addition	of	peptides	hinders	uptake.	
The	utilization	of	non-peptide	moieties	does	not	render	them	cell	permeable	though.		For	
example,	a	polyamide	conjugated	to	the	small-molecule	wrenchnolol	exhibits	extracellular	
localization.0		Wrenchnolol-	and	the	polyamide9	are	independently	cell-permeable	so	it	
is	intriguing	that	the	resulting	conjugate	is	not.		Thus,	it	seems	that	the	overall	conjugate	
structure	must	govern	the	propensity	towards	nuclear	uptake.
	 Extensive	 studies	 into	 the	 structural	 determinants	 for	 nuclear	 localization	 of	
polyamide-fluorescein conjugates have shown that seemingly minor structural variation 
can	 lead	 to	dramatic	changes	 in	cellular	 localization.9	 	One	notable	example	 is	 that	 the	
polyamide ImImPyPy-γ-ImPyPyPy-FITC	 localizes	 to	 the	 nucleus,	 but	 the	 compound	
ImImPyPy-γ-ImPyPyPy-β-FITC,	which	contains	an	additional	β-alanine,	is	extracellular.9	
To complicate matters, changing a single Im to a Py (ImImPyPy-γ-PyPyPyPy-β-FITC)	
recovers	 the	 nuclear	 localization.9	 Consequently,	 the	 complex	 interplay	 of	 structural	
variables	 that	 affect	 cellular	 localization	 of	 polyamides	 has	 yielded	 only	 a	weak	 set	 of	
guidelines.
	 Nevertheless,	 it	 is	 apparent	 that	 tiny	 structural	 changes,	 i.e.,	 as	 simple	as	 an	 Im	
to	Py	substitution,	can	yield	conjugates	with	desirable	nuclear	localization.		Accordingly,	
the	attempts	described	in	this	chapter	to	discover	cell-permeable	protein-DNA	dimerizers	
involved simply moving to the attachment point of the fluorescein moiety to the polyamide 
and using smaller peptide domains.  These efforts yielded a polyamide-peptide-fluorescein 
conjugate	that	localizes	to	the	nucleus	of	living	HeLa,	MCF-7,	and	PC3	cells	and	retains	
the	ability	to	dimerize	Exd	to	DNA.		The	effect	of	the	size	of	the	peptide	moiety	was	probed	
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by	synthesizing	larger	peptides,	but	it	is	unclear	if	the	upper	limit	has	been	reached.
4.2 Previous Polyamide-Peptide Conjugate Uptake Studies
	 In	order	to	assess	the	cell	uptake	of	series	of	polyamide-FYPWMKG	conjugates,	
Hans-Dieter Arndt attached fluorescein-isothiocyanate (FITC) to the N-termini of the 
peptide	moieties	via	a	six-carbon	linker	to	give	compounds	such	as	1 (Figure	4.).3		Laser-
scanning	 confocal	 microscopy	 in	 live	 cells,8-9	 showed	 that	 these	 compounds	 localized	
primarily	 outside	 of	 human	 cancer	 cell	 lines	 (HeLa,	 SKBr4,	 CEM-CCL,	 NB4)	 and	
Figure 4.1	 Summary	 of	 previous	 uptake	 results	 in	 HeLa	 cells.	 	 Polyamide-peptide-
fluorescein conjugate 1 and the related peptide-fluorescein conjugate 2	show	extracellular	
localization.		Conjugate	3	is	exhibits	extracellular	and	vesicular	staining.	(Scale	bar	=	50	
μm)
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Drosophila cells (Kc167, S2).  Similarly, the peptide-fluorescein conjugate 2	 localized	
outside of cells.  The use of the MDR pump inhibitor verapamil (100 μM), which has been 
shown	to	cause	nuclear	localization	of	some	polyamides,4	did	not	cause	redistribution	of	1	
or	2.3  In other efforts to artificially induce cellular uptake, a pre-loaded plasmid (pDEH9) 
was	 incubated	 with	 polyamide	 1	 (500	 nM)	 and	 a	 number	 of	 commercially	 available	
transfection	 reagents,	 including	 ExGen500	 (Fermentas),	 Metafectene	 (Biontex),	 Escort	
(Sigma),	and	Polyfect	(Qiagen),	before	loading	the	compounds	onto	live	cells.		Using	the	
manufacturer’s recommended upper and lower concentrations for the transfection reagents 
was	not	effective.3
 Tim Best also investigated several polyamide-peptide-fluorescein conjugates, 
including	3,	in	which	similar	peptides	were	attached	to	the	polyamide	C-terminus	(Figure	
4.).5	 	 Unfortunately,	 compound	 3	 which	 contains	 a	 PWMK	 tetrapeptide	 between	 the	
polyamide	 and	 FITC	 does	 not	 show	 nuclear	 localization	 in	 	 cell	 lines	 (MCF,	HeLa,	
PC3,	LN-CaP,	DLD-,	786-O,	Jurkat,	CEM,	MEG-0,	MEL,	and	NB4).5		Conjugates	of	
similar	architecture	bearing	peptides	of	different	sequences	(DWMK	and	RY,	with	several	
unnatural	forms	of	tyrosine)	also	yielded	extracellular	localization	except	for	a	couple	of	
instances	in	CEM	cells	with	the	RY-containing	compounds.5
	 Some	control	experiments	with	compounds	4-6	performed	by	Hans-Dieter	Arndt,3	
suggested	that	attachment	of	the	FITC	directly	to	the	polyamide	C-terminus	might	be	more	
favorable	for	cell	uptake	(Figure	4.).		Most	notably,	conjugate	6 which	contains	a	tryptamine	
conjugated	to	an	internal	pyrrole	yielded	a	modest	degree	of	nuclear	localization.0		The	
structural	difference	is	small	between	the	appendage	off	the	internal	pyrrole	of	6	and	the	
WM	conjugates	described	in	Chapter	.	 	Thus,	a	related	polyamide-WM	conjugate	was	
investigated,	replacing	the	tryptamine	and	eight-carbon	linker	of	6	with	a	WM	dipeptide	
and	a	six-carbon	linker.
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Figure 4.2		Summary	of	more	previous	uptake	results	in	HeLa	cells.		Branched	polyamide-
FITC	 conjugate	 4	 shows	 extracellular	 and	 membranous	 staining.	 	 Polyamide-FITC	
conjugates	5	and	6 both show partial nuclear staining. (Scale bar = 50 μm)
4.3 Discovery of Cell-Permeable Protein-DNA Dimerizers
 To synthesize the desired conjugates, resin-bound ImImPyPy-γ-ImPyPyPy- 
polyamide	7	was	cleaved	by	treating	with	the	mono-BOC	protected	diamine	8 (Figure	4.3).	
The	resulting	C-terminally	BOC-protected	polyamide	9	was	coupled	to	the	desired	peptide,	
deprotected with TFA, and conjugated to fluorescein via an amide bond (FAM).  This 
strategy	was	used	to	synthesize	of	a	series	of	polyamide-peptide-FAM	conjugates	10-16	
for	cell	uptake	studies	(Figures	4.4	to	4.5).		The	natural	WM	conjugate	10	yielded	a	strong	
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Figure 4.3  Synthesis of polyamide-peptide-fluorescein conjugates: i)	17,	HBTU,	0.	M	
DIEA	in	DMF,	ii)	50%	TFA/DCM,	and	iii) 5-carboxyfluorescein succinimidyl ester.
nuclear fluorescence stain in HeLa, MCF-7 and PC3 cells (Figure 4.4). The AM conjugate 
11 also showed nuclear fluorescence albeit with higher levels in the media, suggesting the 
tryptophan	may	positively	impact	nuclear	localization.		Unnatural	peptide	conjugates	12	
(D-Trp-L-Met)	 and	13	 (D-Trp-D-Met)	 yielded	 similarly	 strong	 nuclear	 localization	 to	10	
(L-Trp-L-Met)	suggesting	 that	 the	stereochemistry	of	 the	 tryptophan	and	methionine	can	
be	altered.		This	may	be	useful	for	future	biological	studies	given	that	previous	work	has	
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Figure 4.4  Uptake	results	in	HeLa	cells	for	polyamide-dipeptide-fluorescein conjugates. 
All	compounds	10-13	show	primarily	nuclear	localization,	but	the	Trp	to	Ala	conversion	
(10	to	11) decreases the apparent nuclear fluorescent intensity relative to the media. (Scale 
bar = 50 μm)
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shown	D-Trp-L-Met conjugates can dimerize Exd at higher temperatures (up to 37 °C) than 
natural	dipeptides7	and	unnatural	peptides	should	be	resistant	to	proteolysis	by	endogenous	
proteases.
	 Analogous	polyamide-YPWM	tetrapeptide	conjugates	(14-16)	were	investigated	to	
probe	the	upper	size	limit	for	the	peptide	(Figure	4.5).		The	YPWM	conjugate	14	yielded	
strong nuclear fluorescence with some vesicular and membranous staining also apparent. 
Similar	to	the	results	with	the	AM	conjugate	11,	the	YPAM	conjugate	15	showed	higher	
levels of fluorescence in the media than YPWM conjugate 14.		Complete	conversion	of	the	
amino	acids	of	the	YPWM	peptide	to	the	unnatural	D-form	(16)	had	a	markedly	negative	
impact on nuclear localization, with only modest levels of nuclear fluorescence visible. 
The	apparent	difference	 in	uptake	of	14 and	16	 can	be	 explained	at	 least	 two	different	
ways.		First,	it	may	be	possible	that	the	peptide	of	14,	but	not	16, is	degraded	by	proteases	
to	generate	smaller	metabolites	which	render	it	cell	permeable.		Alternatively,	the	peptide	
may	directly	interact	with	some	stereoselective	protein	involved	in	active	uptake.6
 To determine the uptake of peptide-fluorescein conjugates without polyamides 18	
and	20	were	investigated	(Figure	4.6).		The	conjugates	were	synthesized	by	coupling	17	
or	19	to	mono-BOC	protected	diamine	8,	deprotected	with	TFA,	and	conjugated	to	FAM.	
Both	 peptide-FAM	 conjugates	 18	 and	 20 exhibit primarily extracellular fluorescence 
(Figure	4.7).		This	suggests	that	the	polyamide	of	10	and	14 is responsible for trafficking 
the	conjugate	to	the	nucleus.
4.4 Dimerization of Exd with Cell-Permeable Conjugates
	 Electrophoretic	mobility	shift	assays	were	then	performed	to	determine	the	ability	of	
cell-permeable	conjugates	to	dimerize	Exd.		Polyamide-isophthalic	acid	(IPA)	conjugates	
have	 been	 recently	 reported	 to	 possess	 similar	 cell	 permeability	 to	 their	 corresponding	
fluorescein conjugates.7 Thus, a non-fluorescent IPA-polyamide-peptide conjugate 21 as	
well	 a	 control	 IPA	 conjugate	without	 a	 peptide	22	were	 also	 investigated	 (Figure	 4.8).	
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Figure 4.5		Uptake	results	in	HeLa	cells	for	polyamide-tetrapeptide-fluorescein conjugates. 
The	natural	YPWM	conjugate	14	shows	nuclear,	membranous,	vesicular	and	extracellular	
localization.	 	The	YPAM	conjugate	15	shows	weaker	nuclear	and	extracellular	staining.	
The	unnatural	YPWM	conjugate	16	shows	a	strong	vesicular	and	a	weak	nuclear	staining	
pattern. (Scale bar = 50 μm)
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Polyamide-WM-FAM	 conjugate	 10 
yielded a significantly higher gel shift 
than	AM	conjugate	11	or	Exd	alone	at	4	
°C (Figure 4.9).  Although Exd’s binding 
affinity in the presence of 10 (Ka	=		±		
×	09	M-)	was	comparable	to	that	of	the	
similar	conjugate	lacking	the	FAM	(Ka	=	
7	±		×	08	M-,	Chapter	)7,	the	fraction	
of	DNA	 shifted	 by	10 was significantly 
lower (Θapp	 =	 0.54	 ±	 0.0	 compared	 to	
0.84	±	0.06,	Chapter	)7	even	at	this	lower	
temperature.  At a higher temperature (20 °C) polyamide-WM-FAM and -IPA conjugates 
with	the	unnatural	D-Trp	(12	and	21) yielded lower binding affinities (Ka’s = 4 ± 2 and 2 ± 1 
×	08	M-)	but	with	higher	fractions	of	complex	formation	(0.74	±	0.08	and	0.74	±	0.04).
Figure 4.6  Synthesis of YPWM and WM peptide-fluorescein conjugates.  i)	17 or 19,	
HBTU,	0.	M	DIEA	in	DMF,	ii)	50%	TFA/DCM,	and	iii) 5-carboxyfluorescein succinimidyl 
ester.
Figure 4.7		Uptake	results	in	HeLa	cells	
for peptide-fluorescein conjugates.  Both 
the	WM	(18)	and	YPWM	(20)	conjugates	
show	 primarily	 extracellular	 staining.	
(Scale bar = 50 μm)
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Figure 4.9	 	Gel	shift	experiments	with	conjugates.	 	Polyamide-WM-FAM	conjugate	10	
shows a significant complex formation with Exd at 4 °C when compared to the AM control 
compound	11	or	Exd	alone.		Polyamide-WM-FAM	(12)	and	-IPA	(21)	conjugates	which	
contain	an	unnatural	D-Trp show significant complex formation with Exd at 20 °C compared 
to	the	no	peptide	IPA	control	(22).		Conjugates	were	added	at	a	concentration	of	50	nM	and	
Exd	was	titrated	from	0	pM	to	00	nM.
Figure 4.8		Structures	of	polyamide-peptide-isophthalic	acid	(IPA)	conjugates.
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4.5 Conclusions
	 Intriguingly,	the	stereochemistry	of	the	dipeptide	conjugates	did	not	appear	to	affect	
their	nuclear	localization,	but	the	unnatural	tetrapeptide	conjugate	exhibited	substantially	
reduced	nuclear	staining	compared	 to	 the	natural	enantiomer.	 	 It	 is	unclear	what	causes	
the	 tetrapeptide	 conjugates	 to	 yield	 such	 apparent	 differences	 in	 cell	 uptake,	 but	 it	 is	
possible	that	the	natural	peptides	are	unstable	in	cell	culture.		Nonetheless,	the	presumably	
stable	 unnatural	 dipeptide	 conjugates	 localize	 to	 the	 nucleus	 and	 dimerize	Exd.	 	Thus,	
cell-permeable	 polyamide-peptide	 conjugates	 have	 been	 created	 that	 retain	 the	 ability	
to	 facilitate	Exd-DNA	dimerization	 in vitro.	 	These	 compounds	provide	 the	 foundation	
for cell culture and fruit fly experiments in an ongoing collaboration with the Ansari Lab 
(University	of	Madison,	Wisconsin).
4.6 Experimental Details
General Synthetic Procedures.  Polyamide	monomers	were	synthesized	by	previously	
reported	 procedures.8,9	 	 Polyamides	 were	 synthesized	 on	 either	 PAM,8	 oxime,0	 or	
Marshall-Liener	 resin	 (Appendix	D).	 	All	 peptides	were	 synthesized	using	Fmoc-based	
protocols	on	SASRIN	(Bachem)	or	Wang	resin	(Novabiochem).	 	All	polyamides	were	
purified by preparative HPLC with either a Waters  C18 Delta-Pak (15 μm, 25 × 100 
mm,	300	Å),	Varian	Dynamax	Microsorb	C8	(50	×	.4	mm,	300	Å),	or	Phenomenex	
C18 Gemini (5 μm, 250 × 21.2 mm, 110 Å) ramping from 10% A buffer (0.1% TFA in 
water) with acetonitrile as the B buffer.  In general, the best purification was obtained 
with	the	Gemini	column.		Analytical	High-Pressure	Liquid	Chromatography	(HPLC)	was	
performed	with	a	Beckman	Gold	system	equipped	with	a	diode	array	68	Detector	and	a	
5	Solvent	module	using	a	Phenomenex	Gemini	C8	column	(5	µm	particle	size,	50	×	
4.60 mm).  All conjugates were ≥95% pure before cell uptake and gel shift experiments 
were	performed.
N-Boc-3,3′-diamino-N′-methyldipropylamine (8).	 	 This	 compound	 was	 prepared	 as	
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described	previously.
ImImPy(propylamine)Py-γ-ImPyPyPy-(+)-BOC (9).   This	 polyamide	 was	 synthesized	 on	
oxime	resin	according	to	standard	procedures.0		55.	mg	resin	cleaved	with	8 (~300 μL) 
in 1 mL DMF at 50 °C for 13.5 h.  Total yield, 7.66 μmol of a white powder (9.2% yield). 
(MALDI-TOF	MS)	[M	+	H]+	calcd	for	C63H84N3O
+	338.7,	observed	338.7.
ImImPy(Trp-Met-εAhx-propylamine)Py-γ-ImPyPyPy-(+)-FAM (10).	 	 The	 peptide	 Ac-Trp(Boc)-
Met-εAhx-OH (2.0 mg, 3.4 μmol) was dissolved in 200 μL 0.1 M DIEA in DMF and 
activated at 20 °C for ~5 min with 200 μL of a solution of PyBOP (total 5.4 mg, 10.5 μmol). 
The	polyamide	9 (1.47 μmol) was dissolved in 200 μL of 0.1 M DIEA in DMF and added 
to	 the	 activated	 peptide.	 	 The	 resulting	 polyamide-peptide	 conjugate	 intermediate	 was	
precipitated	with	diethyl	ether	(0	mL)	cooled	on	dry	ice	and	centrifuged	for	0	min	at	0	
°C.  The supernatant was decanted and the resulting pellet was dried briefly (<30 sec) with 
N(g).		The	Boc	moiety	was	removed	by	treating	with	50%	TFA/DCM	and	incubating	at	0	
°C for 25 min.  The deprotected conjugate was precipitated with diethyl ether, collected 
by centrifugation, and dried as before.  The pellet was dissolved in 800 μL 1.0 M DIEA 
in DMF and 3 μmol of 5-carboxyfluorescein succinimidyl ester (Molecular Probes) was 
added as a 0.1 M solution in DMSO.  The resulting compound was purified by preparative 
HPLC	and	lyophilized	to	yield	364	nmol	a	yellow-orange	solid	(~5%	yield).		(MALDI-
TOF	MS)	[M	+	H]+	calcd	for	C03H8N7O9S
+	068.9,	observed	068.9.
ImImPy(Ala-Met-εAhx-propylamine)Py-γ-ImPyPyPy-(+)-FAM (11).  The	conjugate	was	synthesized	
in	a	similar	manner	to	conjugate	10 using the peptide Ac-Ala-Met-εAhx-OH (2.1 mg, 5.6 
μmol) activated with PyBOP (5.4 mg, 10.4 μmol) coupled to polyamide 9 (1.47 μmol). 
The resulting intermediate was then coupled to 5-carboxyfluorescein succinimidyl ester 
(3.0 μmol).  The final product was purified by preparative HPLC and lyophilized to yield 
67	nmol	of	a	yellow-orange	solid	(~46%	yield).		(MALDI-TOF	MS)	[M	+	H]+	calcd	for	
C95H3N6O9
+	953.8,	observed	953.9.
ImImPy(D-Trp-Met-εAhx-propylamine)Py-γ-ImPyPyPy-(+)-FAM (12).	 	 The	 conjugate	 was	
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synthesized	 in	a	similar	manner	 to	conjugate	10	using	 the	peptide	Ac-D-Trp-Met-εAhx-
OH (~1.9 μmol) activated with PyBOP (6 μmol) coupled to polyamide 9 (1.0 μmol).  The 
resulting intermediate was then coupled to 5-carboxyfluorescein succinimidyl ester (1.5 
μmol).  The final product was purified by preparative HPLC and lyophilized to yield 411 
nmol	 of	 a	 yellow-orange	 solid	 (~4%	 yield).	 	 (MALDI-TOF	MS)	 [M	 +	H]+	 calcd	 for	
C03H8N7O9S
+	068.9,	observed	069.0.
ImImPy(D-Trp-D-Met-εAhx-propylamine)Py-γ-ImPyPyPy-(+)-FAM (13).	 	 The	 conjugate	 was	
synthesized	in	a	similar	manner	to	conjugate	10	using	the	peptide	Ac-D-Trp-D-Met-εAhx-
OH (2.3 mg, 3.9 μmol) activated with PyBOP (5.4 mg) coupled to polyamide 9	 (.35	
μmol).  The resulting intermediate was then coupled to 5-carboxyfluorescein succinimidyl 
ester (1.5 μmol).  The final product was purified by preparative HPLC and lyophilized to 
yield	4	nmol	of	a	yellow-orange	solid	(~7%	yield).		(MALDI-TOF	MS)	[M	+	H]+	calcd	
for	C03H8N7O9S
+	068.9,	observed	068.8.
ImImPy(Tyr-Pro-Trp-Met-εAhx-propylamine)Py-γ-ImPyPyPy-(+)-FAM (14).	 	 The	 conjugate	 was	
synthesized	 in	 a	 similar	manner	 to	 conjugate	10	 using	 the	 peptide	Ac-Tyr(OtBu)--Pro-
Trp(BOC)-Met-εAhx-OH (~3 μmol) activated with PyBOP (~6 μmol) coupled to polyamide 
9 (1.7 μmol).  The resulting intermediate was then coupled to 5-carboxyfluorescein 
succinimidyl ester (3 μmol).  The final product was purified by preparative HPLC and 
lyophilized	to	yield	448	nmol	of	a	yellow-orange	solid	(~6%	yield).		(MALDI-TOF	MS)	
[M	+	H]+	calcd	for	C7H34N9OS
+	39.0,	observed	39.0.
ImImPy(Tyr-Pro-Ala-Met-εAhx-propylamine)Py-γ-ImPyPyPy-(+)-FAM (15).	 	 The	 conjugate	 was	
synthesized	in	a	similar	manner	to	conjugate	10	using	the	peptide	Ac-Tyr(OtBu)-Pro-Ala-
Met-εAhx-OH (~3 μmol) activated with PyBOP (~6 μmol) coupled to polyamide 9	(.7	
μmol).  The resulting intermediate was then coupled to 5-carboxyfluorescein succinimidyl 
ester (3 μmol).  The final product was purified 2x by preparative HPLC and lyophilized to 
yield	68	nmol	of	a	yellow-orange	solid	(~4%	yield).		(MALDI-TOF	MS)	[M	+	H]+	calcd	
for	C09H9N8O
+	4.0,	observed	4..
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ImImPy(D-Tyr-D-Pro-D-Trp-D-Met-εAhx-propylamine)Py-γ-ImPyPyPy-(+)-FAM (16).  The	 conjugate	
was	synthesized	in	a	similar	manner	to	conjugate	10	using	the	peptide	Ac-D-Tyr(OtBu)-
D-Pro-D-Trp(Boc)-D-Met-εAhx-OH (6 mg, ~6.6 μmol) activated with PyBOP (5.4 mg) 
coupled	 to	 polyamide	 9 (1.32 μmol).  The resulting intermediate was then coupled to 
5-carboxyfluorescein succinimidyl ester (4 μmol).  The final product was purified by 
preparative	HPLC	and	lyophilized	to	yield	4	nmol	of	a	yellow-orange	solid	(~7%	yield).	
(MALDI-TOF	MS)	[M	+	H]+	calcd	for	C7H34N9OS
+	39.0,	observed	38.8.
Trp(Boc)-Met-εAhx-OH (17).  The	peptide	was	 synthesized	by	Fmoc	methods	using	
SASRIN	resin	and	cleaved	with	.5	mL	of	cleavage	mixture	(89:5:5:	DCM:EDT:TES:
TFA)	4x	for	5	min	each.		Each	.5	mL	cleavage	mixture	was	cooled	on	an	ice	bath	and	
neutralized by the addition of 50 μL pyridine.  The peptide was partitioned between 100 
mL	of	M	KHSO4	and	00	mL	EtOAc.		The	organic	layer	was	washed	x	with	00	mL	
of brine, dried over anhydrous sulfate, filtered and evaporated under reduced pressure to 
give a yellow film.  Added a minimal amount (<1 mL) of MeOH to dissolve the film which 
then	added	to	~45	mL	of	ice	cold	water	to	precipitate	the	peptide	which	was	frozen	and	
lyophilized	to	give	a	white	powder	(estimated	80%	purity	by	analytical	HPLC).		(ESI-MS)	
[M-H]-	calcd	for	C9H4N4O7S
-	589.3,	observed	589..
Trp-Met-εAhx-(+)-FAM (18).		Peptide	17 (2.2 mg, 3.7 μmol) was activated with PyBOP 
(10.3 mg, 19.8 μmol) in 0.1 M DIEA in DMF (200 μL) for ~5 min at RT before adding 
to	amine	8 (6 μmol).  After ~1 hour, the solution was added to 3 mL of saturated NH4Cl	
extracted	3x	with	3	mL	of	DCM.		The	combined	organic	layer	was	dried	with	anhydrous	
sodium sulfate, filtered, and dried under reduced pressure to yield an oil.  The Boc group 
was	 removed	with		mL	of	50%	TFA/DCM	for	5	min	at	RT	and	dried	under	 reduced	
pressure.	 	Benzene	(~	mL)	was	added	to	azeotrope	the	solvent	under	reduced	pressure	
to give a crude film which was dissolved in 2 mL of 1 M DIEA in DMF.  The fluorescent 
moiety 5-carboxyfluorescein succinimidyl ester (3.7 μmol as a 0.05 M solution in DMSO) 
was added and the resulting crude product was purified by preparative HPLC to give 1.42 
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μmol of a yellow-orange solid (~38% yield).  (ESI-MS) [M+H]+	calcd	for	C5H6N7O0S
+	
976.4,	observed	976..
Tyr(OtBu)-Pro-Trp(Boc)-Met-εAhx-OH (19).	 	The	peptide	was	 synthesized	by	Fmoc	
methods	 using	 SASRIN	 resin	 and	 cleaved	 by	 treating	 the	 resin	 4x	with	 the	 cleavage	
mixture (1:1:98 TFA:EDT:DCM) draining into a flask cooled on ice.  50 μL of pyridine was 
added	to	neutralize	the	solution	after	each	cycle.		The	resin	was	rinsed	with	3-5	mL	of	DCM	
(x)	and	MeOH	(x)	twice	and	the	solvent	was	removed	under	reduced	pressure,	dissolved	
in MeOH (~8 mL), and purified by preparative HPLC.  Fractions with the peptide were 
pooled	and	lyophilized	to	give	a	white	powder.		(ESI-MS)	[M-H]-	calcd	for	C47H66N6O0S
-	
905.5,	observed	905.4.
Tyr-Pro-Trp-Met-(+)-FAM (20).	 	 Peptide	19 (3.3 mg, 3.65 μmol) was activated with 
PyBOP, deprotected, and coupled to fluorescein as described for conjugate 18	to	yield	.4	
μmol of a yellow-orange solid (~38% yield).  (ESI-MS) [M+H]+	calcd	for	C66H78N9O3S
+	
36.5,	observed	36.4.
ImImPy(D-Trp-Met--εAhx-propylamine)Py-γ-ImPyPyPy-(+)-IPA (21).	 	 Based	 on	 previously	
published	procedures,7	 the	conjugate	was	synthesized	 in	a	similar	manner	 to	conjugate	
10	using	the	peptide	Ac-D-Trp-Met-εAhx-OH (~3.4 μmol) activated with PyBOP (6 μmol) 
coupled	to	polyamide	9 (1.0 μmol).  The resulting intermediate was then coupled to excess 
isophthalic acid (IPA, 20 μmol) pre-activated (~1-2 min) with PyBOP (40 μmol) in 600 μL 
1 M DIEA in DMF.  The final product was purified by preparative HPLC and lyophilized 
to	yield	504	nmol	of	a	white	solid	(~50%	yield).		(MALDI-TOF	MS)	[M	+	H]+	calcd	for	
C90HN7O6S
+	858.9,	observed	858.8.
ImImPyPy-γ-ImPyPyPy-(+)-IPA (22).  Based	on	previously	published	procedures,7	the	
parent polyamide ImImPyPy-γ-ImPyPyPy-(+)-NH (~1.1 μmol) was coupled to excess 
isophthalic acid (IPA, 20 μmol) pre-activated (~1-2 min) with PyBOP (40 μmol) in 600 μL 
1 M DIEA in DMF and purified by preparive HPLC.  The final product was lyophilized to 
yield	44	nmol	of	a	white	solid	(~37.6%	yield).		(MALDI-TOF	MS)	[M	+	H]+	calcd	for	
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C64H75NOS
+	343.6,	observed	343.4.
Cell culture and confocal microscopy experiments.	 	 All	 cell	 culture	 and	 confocal	
microscopy	was	performed	essentially	as	described	previously.9  Briefly, MCF-7 and PC3 
cells	were	cultured	in	0%	FBS,	%	penicillin/streptomycin	supplemented	RPMI	640	at	
37 °C in an incubator with 5% CO	according	to	ATCC	recommended	procedures.		HeLa	
cells	were	cultured	in	similarly	supplemented	DMEM	under	the	same	conditions	according	
to	ATCC	recommended	procedures.		Before	confocal	microscopy,	cells	were	trypsinized	
for 5 min at 37 °C, centrifuged for 5 min at 900 g, and resuspended to a concentration 
of	3.33	×	05 cells/mL, and 150 μL was plated on glass bottom culture plates (MatTek) 
and	allowed	to	adhere	for	4	hours.		The	medium	was	removed	and	replaced	with	fresh	
medium supplemented with the desired conjugate (150 μL final media volume with 2 μM 
final conjugate concentration).  Cells were incubated as described above for 10-14 hours 
before imaging on a Zeiss LSM 5 Pascal inverted laser scanning micrscope.  The optical 
slice was set to 2.2 μm (pinhole size = 181) and images were line averaged 4 or 8 times 
using a 40× oil immersion lens (plan-neofluor) using standard fluorescein filters.  Stock 
solutions	of	conjugates	usually	contained	small	amounts	of	precipitate	that	was	apparent	
upon	centrifugation.		Higher	percentages	of	DMSO	led	to	complete	solubilization,	but	the	
localization	results	remained	the	same	regardless.	 	Thus,	stock	solutions	were	sonicated	
and vortexed immediately prior to use and the lowest possible final DMSO concentration 
in the media was employed at ≤0.2% for all samples (usually much lower).
Gel shift experiments.	 	 Gel	 shift	 experiments	 shown	 in	 Figure	 4.9	 were	 performed	
according to previously described procedures at 4 or 20 °C (Chapter 2).7		
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Chapter 5
Toward a Synthetic HIF-1α Mimic
This project was done in collaboration with Nick Nickols and Mike Brochu (Dervan 
Group; Caltech).
The synthesis of polyamides 11, 20 and all RT-PCR experiments were done by Nick 
Nickols (Dervan Group; Caltech).
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Abstract
	 The	ability	to	up-regulate	any	desired	gene	through	the	rational	design	cell-permeable	
small	molecules	would	be	an	incredibly	useful	tool	and	potentially	have	therapeutic	value.	
This chapter describes efforts towards this goal that builds on the Dervan group’s previous 
success	at	targeting	the	hypoxia	response	element	(HRE)	in	the	promoter	region	of	vascular	
endothelial growth factor (VEGF).  In living cells, hypoxia inducible factor (HIF-1α) 
binds	to	the	VEGF	HRE	and	recruits	a	co-activator,	CREB	binding	protein	(CBP),	which	
activates gene expression.  To mimic HIF-1α, polyamides that bind to the VEGF HRE have 
been	conjugated	to	small	molecules	that	bind	to	CBP.		Several	small-molecule-polyamide	
conjugates	with	different	 shapes	 (branched	and	 linear)	 have	been	 synthesized	 and	 their	
DNA-binding	and	cell-permeability	properties	have	been	determined.	Each	compound	has	
also	been	assessed	for	its	ability	to	affect	VEGF	gene	expression	in	cell	culture	experiments.	
Remarkably,	 the	 small	 molecules	 without	 the	 polyamide	 activated	 gene	 expression	 by	
themselves.	
9
5.1 Introduction
	 The	ability	to	up-regulate	the	expression	of	any	given	gene	using	small	molecules	
would	be	a	powerful	tool	for	molecular	biology.-4		Cells	up-regulate	gene	expression	by	
using modular transcription factors that possess a sequence specific DNA binding domain 
and	an	activation	domain	 that	 is	 capable	 recruiting	 the	RNA	polymerase	 II	 complex	 to	
the	gene	promoter.5		RNA	polymerase	II	subsequently	transcribes	the	coding	region	into	
mRNA.6-7  Promoter regions are loosely defined as -3000 to +300 base pairs from the 
start	 site	 of	 a	 given	 gene.8	 	Activation	 domains	 of	 transcription	 factors	 can	 recruit	 the	
RNA	polymerase	 complex	 through	direct	 physical	 association	or	 indirectly	 through	co-
activator	proteins	which	mediate	the	interaction.9-0		This	chapter	describes	efforts	toward	
the	development	of	synthetic	transcription	factor	mimics	that	are	designed	to	recruit	a	co-
activator	to	the	promoter	region	of	vascular	endothelial	growth	factor	(VEGF)	in	a	living	
cell.	
	 In	the	presence	of	low	oxygen	VEGF	is	activated	by	the	hypoxia-inducible	factor	
1-α (HIF-1α)/aryl hydrocarbon receptor (ARNT) heterodimer transcription factor complex	 	 	 	 	 	 	 	
that	binds	the	hypoxia	response	element	(HRE)	in	the	VEGF	promoter.-		Under	hypoxic	
conditions HIF1-α becomes hydroxylated and is transported from the cytoplasm to the	 	 	 	 	 	 	 	 	 	 	
nucleus	where	it	binds	to	the	HRE	of	VEGF.3  HIF-1α activates VEGF indirectly using the 
co-activator	CREB	binding	protein	(CBP)	to	mediate	the	recruitment	of	the	RNA	polymerase	
II	 complex.4	 	CBP	 is	 a	 general	 co-activator	 known	 to	mediate	 the	 interaction	between	
numerous	transcription	factors	and	RNA	polymerase	II.5		Several	small	molecules	have	
been	reported	to	bind	to	CBP	or	the	related	co-activator	p300	(Figure	5.).6-0		Furthermore,	
at least two small molecules have been reported to bind specifically to the HRE of VEGF, 
including the polyamide CtPyPyIm-γ-PyImPyPy-(+)-FITC.-	 	 The	 design	 of	 small-
molecule mimics of HIF-1α incorporated both CBP and HRE-binding small molecules 
into	conjugates	intended	to	recruit	CBP	to	the	HRE	of	VEGF	to	activate	gene	expression	
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(Figure	5.).		
	 Polyamide	 conjugates	 have	 been	
shown to act as artificial activators of 
transcription.0,3-6	 	 Several	 peptide	
activation	 domains	 have	 been	 shown	 to	
be	 able	 to	 activate	 gene	 expression	 in 
vitro.3-5		Wrenchnolol,	a	small	molecule	
that	 binds	 to	 the	 Sur-	 co-activator,	 has	
also	been	shown	to	serve	as	an	activation	
domain.6	 	 Recently,	 polyamide-peptoid	
conjugates	that	were	designed	to	recruit	CBP	have	been	reported	to	modestly	activate	a	
transiently	transfected	luciferase	gene	in	cell	culture.0		This	chapter	describes	conjugates	
between	putative	small-molecule	activation	domains	(AD)	1-3	which	are	known	to	bind	
to CBP at different sites (Figure 5.3).  Each compound has been modified (4-6)	to	allow	
conjugation to the polyamide CtPyPyIm-γ-PyImPyPy.  Fluorescent analogues were 
Figure 5.1		The	binding	sites	on	the	large	(~65	kDa)	co-activator	CREB	binding	protein	
(CBP)	for	several	small	molecules.
Figure 5.2	 	Design	of	a	 small-molecule	
mimic of HIF-1α. A DNA-binding 
polyamide	 that	 binds	 the	 hypoxia	
response	element	(HRE)	is	conjugated	to	
a	CBP-binding	 small	molecule	 intended	
to	recruit	RNA	Polymerase	II	and	activate	
VEGF	gene	transcription.
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found	 to	 localize	 to	 the	nucleus	of	 living	cells	 in	 the	presence	of	verapamil.	 	A	couple	
of	 conjugates	 were	 also	 shown	 to	 bind	 the	 HRE	 of	 the	 VEGF	 promoter	 by	 DNase	 I	
footprinting.		None	of	the	polyamide	conjugates	reproducibly	activated	VEGF	expression	
in	cell	culture.		Surprisingly,	the	ADs	1	and	3	by	themselves	were	found	to	activate	VEGF	
gene	expression.
Figure 5.3  Small	molecules	that	bind	CBP	used	as	putative	activation	domains	(i.e.,	AD	
-	AD3).		The	top	row	shows	compounds	(1-3)	that	were	originally	reported	to	bind	CBP.	
The	lower	row	shows	compounds	(4-6) that were modified so that they can be attached to 
a	polyamide.
5.2 Synthesis of Small Molecule Activation Domains
 Before	conjugating	to	polyamides,	the	CBP-binding	small	molecules	needed	to	be	
synthesized.		The	compounds	1-3 were chosen for their efficacy and synthetic accessibility. 
ICG-00 (1)	binds	to	the	nuclear	receptor	binding	domain	(NRBD)	of	CBP	and	inhibits	
the CBP/β-catenin interaction with an IC50	of 25 μM in cell culture.
7		KG-50 (2) binds	
to	 the	kinase	inducible	domain	(KIX)	of	CBP	and	inhibits	KID/KIX	complex	with	a	Ki	
of approximately 90 μM.8		MS797	(3)	binds	to	the	bromodomain	(BRD)	of	CBP	with	a	
dissociation constant of 19.6 ± 1.9 μM.9
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Figure 5.4	 	Synthesis	of	AD	(i.e.,	1	and	4):	 	 i)	-naphthalenemethylamine,	DMSO,	 ii)	
Fmoc-Tyr-OH,	DIC,	HOAt,	iii)	0%	piperidine	in	DMF,	iv) Fmoc-βAla-OH, DIC, HOBt, 
v)	 0%	 piperidine	 in	 DMF,	 vi)	 4-nitrophenyl	 chloroformate,	 vii)	 benzylamine	 or	 m-
xylylenediamine,	viii) formic acid, 20 °C, ~24 hours
Figure 5.5		Synthesis	of	AD3	(i.e.,	6):	i)	suberic	anhydride,	NaH,	DMSO
	 The	synthesis	of	AD	(1	and	4)	was	performed	on	solid-phase	using	bromoacetal	
resin	 as	 described	 previously	 (Figure	 5.4).7,7-9  Briefly, the resin-bound bromine was 
displaced	with	a	naphthylamine	and	two	cycles	of	standard	Fmoc	peptide	chemistry	were	
performed to add tyrosine and β-alanine amino acids.  Following urea formation with either 
benzylamine	or	m-xylylenediamine,	treatment	with	formic	acid	led	to	concomitant	resin	
cleavage	and	tandem	cyclization	reactions	to	yield	1	and	4,	 respectively.	 	The	synthesis	
suitably	protected	analogues	of	AD	(2	and	5)	was	performed	by	Mike	Brochu.30		Also,	
the	 synthesis	 of	AD3	 (3)	 with	 a	 suitable	 linker	 (6)	 was	 performed	 in	 one	 step	 from	 a	
commercially	available	carbazole	7	by	acylating	with	suberic	anhydride	(Figure	5.5).
5.3 Rationale for Linker Attachment Position
	 In	modifying	compounds	1-3 to	yield	4-6	to	enable	attachment	to	a	polyamide,	it	
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Figure 5.6		Biotin-conjugate	pull-down	experiments.		On	the	left,	synthesis	of	biotinylated	
analogoues	 of	 AD	 and	 AD3:	 i)	 biotinamidohexanoyl-6-aminohexanoic	 acid	 N-
hydroxysuccinimide ester, DIEA in DMF.  On the right, a Western blot with a CBP-specific 
antibody	 following	 a	 pull-down	 experiment	 is	 shown.	 	Biotinylated-AD	 (8)	 is	 able	 to	
bind	CBP	(~65	kDa)	in	a	mixture	of	SW480	nuclear	extract	and	maintain	this	interaction	
through	thorough	washing.
Figure 5.7  NMR	structure	of	the	bromodomain	of	CBP	with	3	bound	(PDB	code	D8).	
The	acetyl	moiety	projects	away	from	the	binding	pocket	suggesting	this	would	make	a	
reasonable	attachment	point.
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was	unclear	whether	or	not	the	change	would	result	in	elimination	of	their	CBP	binding	
activity.  Thus, a pull-down assay was employed to confirm no loss of activity as was 
previously	described	for	compound	8 (Figure	5.6).7		First,	the	biotinylated	analogue	8	was	
synthesized	from	4	by	treating	with	a	commercially-available	biotin	succinimidyl	ester.		A	
pull-down	assay	involves	treating	streptavidin-coated	magnetic	beads	with	a	biotinylated	
compound	 and	 incubating	 with	 input	 cell	 lysate	 which	 contains	 a	 protein	 of	 interest.	
Following	thorough	washing,	the	bound	protein(s)	is(are)	eluted	by	treated	with	detergent	
(SDS) and heat (95 °C) and the resulting 
mixture	is	separated	on	an	SDS-PAGE	gel	
and	Western	blotted.		Thus,	compound	8 
was confirmed to pull down CBP from the 
input	 SW480	 colon	 cancer	 cell	 nuclear	
extract	 as	 evidenced	by	a	band	near	 the	
expected	 molecular	 weight	 (~65	 kDa)	
that	was	stained	by	an	anti-CBP	antibody	
(Figure	 5.6).	 	 Mike	 Brochu	 has	 shown	
that	a	biotinylated	analogue	of	2	is	able	to	
pull-down	CBP	 from	HeLa	 cell	 nuclear	
extract	 (data	 not	 shown).30	 	Although	 a	
similar	 pull-down	 experiment	 was	 not	
performed	 for	3	 (or	6),	NMR	 structural	
data	suggests	that	the	acetyl	substituent	is	
exposed	 from	 the	CBP	binding	 pocket9	
so	this	was	chosen	as	the	attachment	point	
(Figure	5.7).	
Table 5.1	Frequency	of	match	sites	in	the	
VEGF	promoter
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Figure 5.8  Synthesis of polyamide-AD-fluorescein conjugates for cell uptake studies: i)	
excess	adipic	acid,	PyBOP,	DIEA,	DMF,	ii)	4,	PyBOP,	DIEA,	DMF,	iii)	50%	TFA/DCM,	
iv) fluorescein-5-isothiocyante, DIEA, DMF, v)	suberic	anhydride,	DIEA,	DMF.
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Figure 5.9		Results	for	uptake	experiments	in	HeLa	cells	for	conjugates	12-14.		On	the	left	
it	is	shown	that	all	compounds	exhibit	extracellular	and	vesicular	staining.		On	the	right	it	
is shown that 100 μM verapamil induces partial nuclear localization. (Scale bar = 50 μm)
00
5.4 Cell Uptake of Fluorescent Conjugates
	 To	generate	compounds	suitable	for	confocal	microscopy	cell	uptake	studies,	the	
selectively	 protected	 polyamides	9-11 were synthesized first by standard methods with 
Boc-β-Ala-PAM3	or	oxime	resin3 (Figure	5.8).		The	polyamide	of	10	was	used	because	
analysis of the VEGF promoter showed a high frequency for its match site 5′-WGGWWW-
3′ (Table 5.1).  First, a linker was coupled to the polyamide primary amine using either 
excess	adipic	acid	(6	carbons)	or	suberic	anhydride	(8	carbons).		Then	compound	4	was	
attached through an amide bond, followed by deprotection, and labeling with fluorescein 
isothiocyanate	to	yield	12-14.		Confocal	microcopy	with	12-14	in	HeLa,	MCF-7,	and	PC-3	
cells	showed	exclusively	extracellular	and	vesicular	stains,	but	the	addition	of	the	MDR	
inhibitor verapamil (100 μM) caused a partial redistribution to the cell nucleus (Figure 
Figure 5.10		Quantitative	DNase	I	footprinting	experiments	for	polyamide-AD	conjugates	
on	a	 stretch	of	 the	VEGF	promoter	which	contains	 the	HRE.	 	Compound	14	 shows	no	
apparent	DNA	binding	activity	(i.e.,	Ka ≤ 10
6	M-).		Compounds	16	and	19	bind	to	the	HRE	
with	Ka’s of 6.9 ± 0.6 × 10
8	M-	and	8	±	5	×	07	M-,	respectively.
0
Figure 5.11		Synthesis	of	branched	polyamide-AD	conjugates:	i)	suberic	anhydride,	DIEA,	
DMF,	ii)	4,	PyBOP,	DIEA,	DMF,	iii)	50%	TFA/DCM.
Figure 5.12		Synthesis	of	linear	polyamide-AD	conjugates:	i)	6,	PyBOP,	DMF,	DIEA,	0	
°C, 2 hours.
0
5.9).		Titration	of	verapamil	with	13 in HeLa cells suggested that 10 μM verapamil was 
sufficient to induce nuclear localization so this concentration was used for the RT-PCR 
described	later.
5.5 DNase I Footprinting and Non-Fluorescent Conjugate Synthesis
 DNase I footprinting was used to determine the HRE-affinity of polyamide-AD1-
FITC	conjugate	14 (Figure	5.0).		The	analogous	parent	polyamide-FITC	conjugate	with	
a free chiral amine at the turn has been reported to have an HRE-affinity of 6.3 × 109	M-	
but	conjugate	14	 shows	no	apparent	DNA	binding	 (Ka ≤ 106	M-).	 	Attachment	of	 the	
linker and AD1 appears to be responsible for the reduced DNA affinity.  The placement of 
the	linker	and	AD	over	the	three	Gs	adjacent	to	the	HRE	may	be	particularly	detrimental	
to the binding affinity.  Thus, simpler polyamide conjugates with different shapes were 
designed	 in	hopes	 they	would	possess	better	DNA	binding	properties	 (Figures	5.	and	
5.).		
	 Branched	 conjugate	 16	 was	 synthesized	 from	 parent	 polyamide	 10	 and	 small	
molecule	4 (AD)	after	incorporation	of	an	eight-carbon	linker	(Figure	5.).		The	linear	
conjugate	19	was	synthesized	from	the	parent	polyamide	18	(Figure	5.).		Compounds	16	
and	19 were also footprinted to determine their HRE-binding affinity (Figure 5.10).  The 
presumably	dicationic	polyamide-AD	conjugate	16 showed a higher affinity for the HRE 
(Ka	=	6.9	±	0.6	×	0
8	M-) but bound the DNA non-specifically down to a concentration of 
300	nM.		Linear	polyamide-AD3	conjugate	19 revealed a low affinity for the HRE (Ka	=	
8	±	5	×	07	M-).		Compound	19’s affinity would likely be increased by the addition of a 
chiral	amine	on	the	turn.33		
5.6 Effect of Compounds on VEGF Expression
 A total of all six conjugates representing branched and linear configurations were 
subjected	to	HeLa	cells	(i.e.,	12,	13,	14,	16,	17,	and	19)	under	non-induced	conditions	(no	
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Figure 5.13  RT-PCR	 experiments	 measuring	 the	 effect	 of	 each	 compound	 on	VEGF	
expression in the presence of 10 μM verapamil.  NI = non-induced baseline control and 
I	 =	 induced	 (DFO)	 positive	 control.	 	 Compounds	 16	 and	 17	 previously	 showed	weak	
induction	of	VEGF	gene	expression	(~.5-fold	increase),	but	this	result	was	found	to	be	
not	reproducible	as	shown	here.		Combinations	of	16	and	17	also	do	not	lead	to	activation,	
nor	does	 the	polyamide	control	20.	 	 Intriguingly,	 the	CBP	binding	small-molecule	1	by	
itself	activates	VEGF	gene	expression.
DFO) ranging from concentrations of 1 to 15 μM in the presence of 10 μM verapamil.  The 
branched	conjugate	17 was also tried since it targets 5′-WGGWWW-3′ which is found with 
a	high	frequency	in	the	VEGF	promoter	(Figure	5.	and	Table	5.).	 	Quantitative	real-
time	PCR	(qRT-PCR)	was	used	to	measure	the	effect	of	each	compound	on	VEGF	gene	
expression.		Of	the	compounds	screened,	only	16	and	17	affected	VEGF	expression	(~.5-
fold	increase),	but	this	effect	was	not	reproducible	(data	not	shown).		Experiments	looking	
for	synergistic	effects	using	combinations	of	conjugates	16	and	17 did not lead to a significant 
increase	in	VEGF	mRNA	levels	(Figure	5.3).		Remarkably,	the	small	molecules	1	and	3	
by	themselves,	but	not	2, showed a reproducible and significant increase in VEGF mRNA 
and	protein	levels	(data	not	shown).		This	effect	by	the	small	molecules	themselves	was	
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unanticipated	and	makes	de-convolution	of	experiments	with	their	conjugates	problematic.	
Investigation	into	the	mechanism	of	VEGF	activation	by	1 and	3 is	ongoing.
5.7 Experimental Details
Synthesis
ICG-001, AD1 (1).  Synthesis	was	based	on	described	previously	described	procedures.7,7-
9 	Bromoacetal	resin	resin	(333	mg,	0.5	mmol	scale,	75-00	mesh,	%	DVB	,	~.5	mmol/g,	
Aldrich)	was	loaded	with	-naphthalenemethylamine	(.44	mL)	in	DMSO	(4	mL)	for	0	
hours	at	RT.		Resin	drained	and	rinsed	x	DMF,	x	DCM,	and	x	DMF.		Activated	Fmoc-
Tyr(OtBu)-OH	(Novabiochem,	99	mg,	4	eq)	with	HOAt	(AnaSpec,	7.	mg,	4	eq)	and	
DIC (Aldrich, 310 μL, 4 equivalents) in 5.6 mL of DMF at RT for 20 min before adding to 
the resin.  DIEA (697 μL, 8 equivalents) was added and the reaction was allowed to proceed 
for	4	hours.		Drained	and	rinsed	x	with	DMF.		Fmoc-Tyr(OtBu)-OH	was	coupled	again	
(.5	eq)	for	another	4	hours.		The	partially	unreacted	resin-bound	secondary	amine	was	
capped	with	0	mL	of	4:	DMF:AcO	for	.5	hours.		The	resin	was	rinsed	as	above.		The	
Fmoc	protecting	group	was	removed	with	0%	piperidine	in	DMF	for	5	min	and	rinsed	
as usual.  Fmoc-β-Ala-OH (622.6 mg, 4 equivalents) was pre-activated with HBTU (739.5 
mg, 3.9 equivalents) and DIEA (522 μL) and coupled to the resin overnight.  The resin was 
rinsed	and	deprotected	as	before.	4-nitrophenylchloroformate	(503.9	mg,	5	eq)	was	coupled	
in DCM with DIEA (522 μL, 6 eq) for 1 hour at RT.  Rinsed 2x with DCM and added DMF 
(~3 mL) and benzylamine (218 μL, 4 equivalents) letting the reaction proceed for 5 hours. 
Rinsed	x	DMF,	x	DMF,	x	DCM	and	dried	in vacuo	for	5	min.		Cyclization	and	cleavage	
was performed with formic acid (88%, 8.7 mL) for 10.5 hours at RT.  The resin was filtered 
with a small plastic filter.  The filtrate concentrated under reduced pressure and dissolved in 
0.1% TFA in water and acetonitrile, purified by preparative HPLC, and lyophilized to yield 
25.3 mg of a white powder (46.1 μmol, 9.2% yield measured by UV).  H	NMR	(d6-DMSO,	
300 MHz) �� 2.04-2.09 (m, 2H), �� 3.00-3.15 (m, 3H), �� 3.22-3.28 (m, 1H), �� 3.55 (t, J = 11.4            	 	 	 	 	 	
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Hz, 1H), �� 3.84 (m, 1H), �� 4.13-4.20 (dd, J    	   	 	 	=	6.0	Hz,	J = 15.6 Hz, 1H), �� 4.28-4.35 (dd, J	  	 	 	
=  6.0 Hz, J2 = 15.3 Hz, 1H), �� 4.89 (d, J = 15.3 Hz, 1H), �� 5.12 (d, J = 15.6 Hz, 1H), �� 5.10-                	 
5.13 (m, 1H), �� 5.74-5.78 (d of d, J	 	 	 	 	 	=	3.6	Hz,	J = 10.5 Hz, 1H), �� 6.54 (d, J = 8.7 Hz, 2H),	 	 	 	 	 	 	 	
�� 6.90 (d, J = 8.7 Hz, 2H), �� 7.21-7.38 (m, 6H), �� 7.44-7.60 (m, 4H), �� 7.87-7.97 (m, 2H), ��                    	
8.12-8.14 (m, 1H), �� 9.18 (bs, 1H)�� A	  	 	 ;	 max at 281 nm (ε = 7,860 M
-·cm-	in	0%	acetonitrile	
in	0.%	TFA/water).		(ESI-MS)	[M+H]+ calc’d for C33H33N4O4	549.,	observed	549..
KG-501, AD2 (2).		This	compound	is	a	common	histological	stain	commercially	available	
from	several	sources	(e.g.,	Fluka).
MS7972, AD3 (3).	 	 This	 compound	 is	 commercially	 available	 in	 small	 quantities	
(ChemBridge	Corporation,	San	Diego,	CA).
ICG-001-aminomethyl, AD1-NH2 (4).		The	synthesis	of	this	compound	was	performed	as	
described	for	compound	1	replacing	benzylamine	with	m-xylylenediamine (518 μL).  After 
cleavage from resin and HPLC purification 12.6 mg of a white powder was obtained (~6% 
yield).		H	NMR	(d6-DMSO, 300 MHz) �� 2.06-2.13 (m, 2H), �� 3.01-3.12 (m, 4H), �� 3.57          
(t, 1H, J = 10.8 Hz), �� 3.82-3.86 (m, 1H), �� 3.98 (d, 2H, J = 6 Hz), �� 4.16-4.23 (dd, 1H, J            	   	 	 	 	
=	5.7	Hz,	J = 15.15 Hz), �� 4.25-4.32 (dd, 1H, J	=	5.7	Hz,	J = 15.15 Hz), �� 4.87 (d, 1H, J 
= 15.3 Hz), �� 5.14 (d, 1H, J = 14.7 Hz), �� 5.12-5.17 (m, 1H), �� 5.72 (dd, 1H, J	=	3.9	Hz,	
J = 10.8 Hz), �� 6.54 (d, 2H, J = 8.7 Hz), �� 6.90 (d, 2H, J = 8.7 Hz), �� 7.21 (d, 1H, J = 7.5 
Hz), �� 7.28-7.40 (m, 4H), �� 7.44-7.62 (m, 4H), �� 7.89 (d, 1H, J = 8.1 Hz), �� 7.94-7.97 (m, 
1H), �� 8.11 (bs, 2H), �� 8.11-8.14 (m, 1H), �� 9.18 (s, 1H)�� HRMS (FAB) exact mass calcd 
for	C34H36N5O4	requires	578.767	m/z,	found	578.754	m/z.
MS7972-suberic acid, AD3-CO2H (6).  First,	 ,3,4,9-tetrahydro-H-carbazol--one	 7	
(50	mg,	0.8	mmol,		eq,	Bionet	Research	Intermediates)	was	dissolved	in	DMSO	(	mL,	
anhydrous)	and	sodium	hydride	(64.8	mg,	.6	mmol,		eq,	60%	oil	dispersion)	was	added	
as	a	solution	in	DMSO	(	mL).		The	solution	was	sonicated	to	aid	dissolution.		After	5	min,	
suberic	anhydride	(5.7	mg,	0.97	mmol,	.	eq)	was	added	as	a	solution	in	DMSO	(.5	
mL).		Immediately	a	precipitate	formed	and	the	solution	was	poured	into	0%	citric	acid	
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buffer	and	extracted	3x	with	DCM	(50	mL).		The	organic	layers	were	combined,	dried	with	
anhydrous sodium sulfate, filtered, and dried under reduced pressure to give a thin orange 
film.  The desired product was purified by silica gel chromatography (1:1 EtOAc:Hexanes 
+	0.%	acetic	acid,	Rf ≈ 0.3) and dried under reduced pressure.  The resulting film was 
dissolved in MeOH (500 μL) and added to water to form an off-white precipitate which 
was flash frozen and lyophilized (19.11 mg, 7% yield).  H	NMR	(d6-DMSO,	300	MHz)	
�� 1.20 (pent, J = 3.6 Hz, 4H), �� 1.40 (m, 2H), �� 1.60 (m, 2H), �� 2.10-2.20 (m, 4H), �� 2.64                    	 	
(t, J = 6.9 Hz, 2H), �� 2.86 (t, J = 7.2 Hz, 2H), �� 3.00 (t, J = 6.0 Hz, 2H), �� 7.33 (t, J = 7.8                 	 	 	 	 	 	
Hz, 1H), �� 7.53 (t of d, J	 	 	 	 	 	=		.	Hz,	J = 8.4 Hz, 1H), �� 7.79 (d, J = 8.1 Hz, 1H), �� 7.97 (d,        	 	 	
J = 8.7 Hz, 1H), �� ~12 (bs, 1H)��	 	 	 ;	3C	NMR	(CDCl3, 300 MHz) �� 189.78, 178.89, 175.82,	 	 	  	
39.60,	39.33,	3.38,	30.3,	6.7,	3.8,	.45,	5.93,	39.74,	39.40,	34.0,	9.07,	
8.96,	5.7,	4.79,	3.69,	.38.		HRMS	(FAB)	exact	mass	calcd	for	C0H4NO4	requires	
34.705	m/z,	found	34.77	m/z.		Absorbance	maximum	at	30	nm	in	water	with	%	
DMSO (ε at 308-309 nm = 2.2 ± 0.8 x 104	M-cm-).
ICG-002, AD1-biotin (8).  An	aliquot	of	4 was dissolved in 200 μL of 0.1 M DIEA in 
DMF	and	.3	mg	of	biotinamidohexanoyl-6-aminohexanoic	acid	N-hydroxysuccinimide	
ester (Sigma) was added.  The product formed immediately and was purified by preparative 
HPLC and lyophilized to yield a fine white powder (1.5 μmol).  (MALDI-TOF MS) Calcd 
for	C56H7N9O8S
+	030.5,	observed	03.0.
CtPy(propylamine)PyIm-γ-PyImPyPy-(+)-NHBoc (9).	 	This	 polyamide	was	 synthesized	on	
Marshall-Liener resin and purified by preparative HPLC (Appendix D).  (MALDI-TOF 
MS)	Calcd	for	C63H8ClNOS
+	375.6,	observed	375.7.
ImImPy(propylamine)Py-γ-PyPyPyPy-β-(+)-NHBoc (10).  This	polyamide	was	 synthesized	
on PAM resin (1.94 μmol, 3% overall yield).  (MALDI-TOF MS) Calcd 1408.7, observed 
408.7.
CtPyPyIm-γNH2(R)-PyImPyPy-(+)-NHBoc (11).  This	polyamide	was	synthesized	by	Nick	
Nickols on oxime resin and purified by preparative HPLC.  (MALDI-TOF MS) Calcd for 
07
C6H77ClNOS
+	347.6,	observed	346.5.
CtPy(AD1-C6-propylamine)PyIm-γ-PyImPyPy-(+)-FITC (12).		This	conjugate	was	synthesized	
essentially	as	described	below	for	14.  (ESI MS) Calc’d [M+2H]+	C9H5ClN7O0S+	
75.9,	observed	76..
ImImPy(AD1-C8-propylamine)Py-γ-PyPyPyPy-β-(+)-FITC (13).  Polyamide	10 was	coupled	to	
suberic	anhydride	as	described	for	compound	17 and the resulting intermediate was purified 
by	preparative	HPLC	and	lyophilized	(609	nmol,	3%	yield	over		step).		(MALDI-TOF	
MS)	Calcd	564.8,	observed	564.7.		The	Boc	group	was	removed	and	the	FITC	coupled	
as	 described	 below	 for	 14.  The final product was purified by preparative HPLC and 
lyophilized.	(ESI	MS)	Calcd	[M+H]+	07.5,	observed	07.3.
CtPyPyIm-γ(AD1-C6-NH2(R))-PyImPyPy-(+)-FITC (14).	 Polyamide	 11 (1.55 μmol) was 
treated with excess adipic acid (10 eq) and PyBOP (20 eq) in ~300 μL of 0.1 M DIEA in 
DMF.  The resulting intermediate was purified by preparative HPLC and lyophilized (560 
nmol,	36%	yield	for		step).		(MALDI-TOF	MS)	Calcd	for	C67H84ClNO4SNa
+	496.6,	
observed	496.6.		The	previous	intermediate	was	activated	with	PyBOP	(6.7	mg)	in	600	
μL 0.1 M DIEA in DMF and added to amine 4.	 	The	compound	was	precipitated	 from	
diethyl ether (10 mL) cooled over dry ice, centrifuged, and dried briefly with N(g).		The	
Boc	protecting	group	was	removed	with	50%	TFA/DCM	(	mL)	for	30	min	at	RT	and	the	
compound	was	precipitated	from	ether	and	dried	as	above.		The	pellet	was	redissolved	in		
M DIEA in DMF (600 μL) and fluorescein-5-isothiocyanate (2 μmol) was added.  The final 
product was purified by preparative HPLC and lyophilized to give a yellow-orange solid 
(179 nmol, 32% final 2 steps).  (ESI MS) Calc’d [M+2H]+	C7HClN7O0S
+	6.4,	
observed	6..
ImImPyPy-γ-PyPy(propylamine)PyPy-β-Dp (15).  This polyamide was synthesized on Boc-β-
Ala-PAM	resin.		(MALDI-TOF	MS)	Calcd	for	C60H77NO0S
+	65.6,	observed	65.6.		
CtPy(AD1-C8-propylamine)PyIm-γ-PyImPyPy-(+)-NH3+ (16).  Suberic	 anhydride	 (3	 eq)	 was	
reacted	with	polyamide	9	 as	 described	 for	 compound	17	 below.	 	The	 intermediate	was	
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purified by preparative HPLC and lyophilized (624 nmol, 40% yield over 1 step.)  (MALDI-
TOF	MS)	Calcd	530.7,	observed	530.5.		Amine	4	was	coupled	to	this	intermediate	as	
described	for	14 and the final product was purified by preparative HPLC (193 nmol, 31% 
yield	over		step).		(MALDI-TOF	MS)	Calcd	990.9,	observed	990.9.
ImImPyPy-γ-PyPy(AD1-C8-propylamine)PyPy-β-Dp (17).		Polyamide	15 (1.4 μmol) was treated 
with suberic anhydride (1.5 eq) in 200 μL 0.1 M DIEA in DMF and heated to 35 °C for 
1 hour.  The intermediate was purified by preparative HPLC and lyophilized to give a 
white	powder	(4	nmol,	30%	yield).		(MALDI-TOF	MS)	Calcd	for	C68H89NO3
+	4.7,	
observed	4..		The	previous	intermediate	was	activated	with	PyBOP	(0	equivalents)	in	
600 μL 0.1 M DIEA in DMF and added to amine 4 (1.5 equivalents).  The final product was 
purified by preparative HPLC and lyophilized to give a white powder (145 nmol, 36% yield 
over		step).		(MALDI-TOF	MS)	Calcd	for	C0HN7O6
+	98.0,	observed	980.7.		
CtPyPyIm-γ-PyImPyPy-(+)-NH3
+ (18).  This	polyamide	was	synthesized	on	oxime	resin.	
(MALDI-TOF	MS)	Calcd	3.5,	observed	3.4.		
CtPyPyIm-γ-PyImPyPy-(+)-C8-AD3 (19). 	 	Polyamide	18 (1.19 μmol) was coupled to 
6 (0.85 mg, 2.5 μmol) using PyBOP (6 μmol) in a solution of 0.1 M DIEA in DMF (200 
μL) and purified by preparative HPLC and lyophilized (561 nmol, 47 % yield).  (MALDI-
TOF MS) Calcd 1554.6, observed 1554.7.  The extinction co-efficient of the conjugate was 
assumed to be the sum of the individual components (i.e., ε at 310 nm of 91,500 M-cm-=	
69,500	M-cm-	+	,000	M-cm-).
CtPyPyIm-γNH2(R)-PyImPyPy-(+)-NH3+ (20).  This	 compound	 was	 synthesized	 and	
characterized	by	Nick	Nickols.
Pull-down assay and Western blot.		The	pull-down	was	based	on	a	previously	published	
experiment.7  30 μL of 10 mg/mL Dynabeads M-280 Streptavidin coated (Invitrogen) 
were	aliquoted	into	an	eppendorf	tube	to	which	4	nmol	of	biotin	conjugate	8	was	added	
as a 1:1 solution of DMSO:PBB for a final volume of 30 μL.  (PBB = 20 mM HEPES, 
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00	mM	NaCl,	 0.5	mM	EDTA,	6	mM	MgCl,	 0.5%	Nonidet	P-40	 (Tergitol,	Type	NP-
40, Sigma), 1 tablet complete protease mixture (Roche), 5 mM β-mercaptoethanol added 
immediately	 before	 use,	 pH	 7.9,	 total	 volume	 50	mL)	 	Beads	 incubated	 overnight	 and	
then washed 3x with PBB.  Added 28.5 μL of PBB and 1.5 μL of SW480 nuclear extract 
(.88	mg/mL	Bradford	 concentration)	 obtained	 previously	 from	Pierce	Nuclear	Extract	
Kit	(Cat	#	78833)	and	allowed	to	incubate	for	~	hours	at	RT.		The	tubes	were	put	on	ice	
for	0	min	and	washed	3x	with	cold	PBB	in	the	cold	room.		Added	PBS:Reducing	Agent:
LDS 9.1:1.4:3.5 and heated to 90 °C for 5 min and ran on an SDS-PAGE gel (Invitrogen, 
NuPAGE	0%	bis-TRIS	gel).		The	resulting	gel	was	transferred	to	a	membrane	and	blotted	
with	a	primary	anti-CBP	antibody	(:00,	A-,	sc-369,	Santa	Cruz	Biotechnology)	and	
a	 secondary	goat	anti-rabbit	HRP	(:5000,	Santa	Cruz	Biotech).	 	The	 resulting	gel	was	
visualized	with	SuperSignal	West	Pico	(Pierce)	and	developed	with	a	90-second	exposure	
to light-sensitive film in the dark room. 
Cell culture and confocal microscopy experiments. 	 The	 cell	 culture	 and	 confocal	
microscopy	experiments	were	performed	as	described	in	chapter	4.	 	Racemic	verapamil	
(Aldrich,	98%)	was	added	at	the	same	time	as	the	conjugates.
DNase I footprinting.	 	 Footprinting	was	 performed	 as	 described	 in	Chapter	 	 using	 a	
previously	published	plasmid	of	a	region	of	the	VEGF	promoter	containing	the	HRE.
Quantitative real-time PCR (qRT-PCR).  These	experiments	were	performed	by	Nick	
Nickols	essentially	as	described	previously.,34-35
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Appendix A
Protein-DNA Dimerizers Targeted to a Natural HOX Site
The part of this chapter regarding the DNase I footprinting was taken in part from a 
manuscript co-authored with Rocco Moretti,‡ Leslie J. Donato,‡ Mary L. Brezinski,‡ 
Helena Hoff,‡ Jon S. Thorson,‡ Peter B. Dervan,† and Aseem Z. Ansari.‡ (Caltech† and 
University of Wisconsin, Madison‡)
(Moretti,	R.,	Donato,	L.	J.,	Brezinski,	M.	L.,	Stafford,	R.	L.,	Hoff,	H.,	Thorson,	J.	S.,	
Dervan, P. B., Ansari, A. Z. provisionally titled	Chemical	wedges	reveal	the	contribution	
of	allosteric	DNA	modulation	in	protein-DNA	assembly,	2007,	In preparation.)	
Work on the MPE footprinting of polyamide-peptide conjugates 1-5 was done in 
collaboration with Hans-Dieter Arndt (Dervan Group; Caltech).
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A.1 Targeting an Endogenous HOX Binding Site
	 All	previous	protein-DNA	dimerizers	for	Exd	do	not	target	natural	HOX	binding	
sites.-5	 	Compound	1 was designed to target an endogenous labial response element 5′-
TGATGGATTG-3′ (Figure A.1).6  At this composite site, Exd is expected to bind 5′-
TGAT-3′ and the polyamide DNA-binding domain of 1 was	 designed	 to	 target	 the	 site	
5′-WGGWWW-3′7	and	project	the	peptide	to	the	Exd	binding	pocket	in	a	similar	manner	
to	conjugates	2	and	3 which are targeted to the artificial HOX site 5′-TGATTGACCT-3′. 
A	control	 compound	 for	1	was	 also	 synthesized	 in	which	 the	 crucial	WM	amino	 acids	
were	replaced	with	alanines	(4).		Additionally,	the	parent	polyamide	that	lacks	a	peptide	
altogether	serves	as	a	negative	control	(5).
	 DNase	I	footprinting	of	compounds	1,	4,	and	5 was	performed	to	determine	their	
DNA binding affinities and specificities for their match site (Figure A.2 and Table A.1). 
Footprinting	 of	 compounds	 2	 and	 3 have	 been	 reported	 elsewhere.,4	 	 As	 previously	
observed	with	 conjugate	2,	 the	 labial	FYPWMKG	compound	1	 showed	only	 a	modest	
affinity for its match site 5′-TGGATT-3′ (Ka	=	.4	×	0
8	M-) with no significant sequence 
specificity.  A WM to AA “mutation” of compound 2	was	shown	previously	to	lead	to	a	
recovery of the DNA binding affinity and specificity,	but	a	similar	WM	to	AA	change	to	
the	labial	compound	(i.e.,	1	to	4) did not lead to any significant change in binding affinity 
or specificity.  The polyamide 5 which	contains	only	a	propylamine	appendage	showed	an	
approximately 20-fold higher DNA-binding affinity and >10-fold specificity over single 
base pair mismatches.  The parent polyamide ImImPyPy-γ-PyPyPyPy-β-Dp has previously 
been reported to bind to DNA with an affinity of 5 × 108	M-,	but	it	is	hard	to	compare	this	
to	5 since it was footprinted on the match sequence 5′-TGGTTA-3′.8
 In spite of the modest DNA affinity and lack of specificity of the labial conjugate 
1,	MPE	footprinting	experiments	indicate	that	1 cooperatively binds with Exd specifically 
at	 the	 labial	 binding	 site	 (Figure	A.3).	 	That	 is,	 the	 titration	 of	Exd	 in	 the	 presence	 of	
compound	1	leads	to	an	enlargement	of	the	observed	protection	pattern	exclusively	at	the	
5
Figure A.1  Structures of polyamide-peptide conjugates targeted to artificial and natural 
HOX	 binding	 sites.	 	 (a)	 Conjugate	 1 targets the natural labial HOX binding site (5′-
TGATGGATTG-3′) and 2	and	3 target the artificial site (5′-TGATTGACCT-3′) where the 
Exd	binding	site	is	underlined	and	the	polyamide	binding	site	is	shown	in	bold.		Compounds	
4	and	5 serve	as	negative	controls.		(b)	Schematics	showing	the	binding	orientations	of	the	
artificial and natural cognate DNA sites.
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Figure A.2	 Quantitative	 DNase	 footprinting	 titrations	 of	 compounds	 1,	 4,	 and	 5	 on	
a restriction fragment containing a match site M (5′-TGGATT-3′) and four single base 
pair mismatch sites A-D, (5′-TGGATC-3′), (5′-TGATTT-3′), (5′-TGATTA-3′), and (5′-
TGGTCA-3′), respectively.  a) The DNA sequence of the restriction fragment with the 
location	of	the	match	and	mismatch	sites	is	shown.		b)	Titration	of	compound	1.		Lane	-:	
0.,	0.,	0.5,	,	,	5,	0,	0,	50,	00,	00,	500	nM.		c)	Titration	of	compound	4	labeled	as	in	
panel	b.		d)	Titration	of	compound	5.		Lane	-:	0.00,	0.003,	0.0,	0.03,	0.,	0.3,	,	3,	0,	
30,	00,	300	nM.		DNase	control,	intact	DNA,	and	G-	and	A-sequencing	lanes	are	indicated	
for each gel.  Isotherms are shown below each gel for match site M (○) and mismatch sites 
A (□), B (◊), C (×), and D (+).
7
Figure A.3	 	 Site-selective	 recruitment	 of	 Exd	 to	 the	 natural	 labial	 binding	 site.	 	MPE	
footprinting	 experiments	 show	an	 increase	 in	 binding	 site	 size	 exclusively	 at	 the	 labial	
cognate	site	III	upon	titration	of	Exd	in	the	presence	of	conjugate	1.		In	contrast,	conjugates	
2	 and	 3 which target the artificial site IV show an expansion in the binding site size 
exclusively at the artificial site IV.  
8
labial	match	site	III.		Compounds	2	and	3, which target an artificial HOX binding site, lead 
to	increased	protection	exclusively	at	their	match	site	IV.		The	control	compounds	4	and	
5	did	not	lead	to	increased	protection	at	any	of	these	sites	when	Exd	was	titrated	(data	not	
shown).
A.2 Design of a Cell-Permeable Labial Mimic
	 During	the	process	of	designing	of	a	cell-permeable	labial	mimic,	 the	putatively	
negative C-terminal β-alanine cell uptake determinant was re-evaluated.  Specifically, 
polyamide	 6 which contains a C-terminal β-alanine was synthesized by cleaving the 
corresponding	polyamide	from	resin	using	,3-diaminopropane	followed	by	coupling	to	
fluorescein through an amide bond (FAM).  Polyamide-FAM conjugate 6	was	shown	to	
yield	nuclear	localization	in	HeLa,	MCF-7,	PC3	cells	(Figure	A.4).		The	solubility	of	6	was	
observed	to	be	poor	in	unbuffered	water	likely	due	to	the	lack	of	a	positive	charge	in	the	
C-terminus.		At	pH	7	in	phosphate	buffer	saline	the	compound	was	soluble,	presumably	
due to the complete deprotonation of the carboxylic acid of the fluorescein leading to a net 
negative	charge.		One	potentially	useful	feature	of	compound	6 is	that	it	can	be	synthesized	
using pre-loaded BOC-β-Ala-PAM9	instead	of	oxime	resin.0
	 The	 parent	 polyamide	 7 ImImPyPy-γ-PyPyPyPy-β-C3-BOC	 was	 cleaved	 from	
PAM	using	mono	Boc-protected	,3-diaminopropane	(Figure	A.5).		Following	procedures	
previously	described	in	Chapter	4,	the	desired	conjugate	8 was	made	by	coupling	a	peptide	
to	the	polyamide,	deprotecting	with	TFA,	and	attaching	FAM.	Conjugate	8	showed	nuclear	
localization	 in	HeLa,	MCF-7,	and	PC3	cells	 (Figure	A.6).	 	These	compounds	might	be	
useful for performing cell culture or fruit fly experiments.
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Figure A.4  Uptake results in HeLa cells for polyamide-FAM conjugate with a β-1,3-
diaminopropane tail which shows primarily nuclear staining. (Scale bar = 50 μm)
Figure A.5   Synthesis of polyamide-peptide-fluorescein conjugates targeted to the natural 
labial	binding	site:	i)	peptide,	HBTU,	0.	M	DIEA	in	DMF,	ii)	50%	TFA/DCM,	and	iii)	
5-carboxyfluorescein succinimidyl ester.
0
    Table A.1	DNA	equilibrium	association	constants	Ka’s [×108	M-]
Compound 5’-TGGATT-3’ 5’-TGGATC-3’ 5’-TGATTT-3’ 5’-TGATTA-3’ 5’-TGGTCA-3’
1a .4	±	0.9 .7	±	0.3 .5	±	0.3 .7	±	0.3 3	±	
4a 3	±	 .5	±	0.5 .0	±	0.4 .5	±	0.4 .5	±	0.4
5b 70	±	50 6	±	4 0.6	±	0.3 6	±	4 4	±	
								a Data fit best using a Hill coefficient of 2.
					b Data fit best using a Hill coefficient of 1.
Figure A.6	 	 Uptake	 results	
in	 HeLa	 cells	 for	 polyamide-
peptide-FAM	 conjugate	 8 
shows significant nuclear 
localization.
A.3 Experimental Details
Synthesis
ImImPyPy-γ-PyPy(Phe-Tyr-Pro-Trp-Met-Lys-Gly-propylamine)PyPy-β-Dp (1).		This	polyamide-peptide	
conjugate	was	synthesized	essentially	as	previously	described.  Briefly, the peptide Phe-
Tyr(OtBu)-Pro-Trp(Boc)-Met-Lys(Boc)-Gly-OH (9.6 mg, 7.8 μmol) was activated with 
HBTU (7.5 μmol) and added to the parent polyamide 5 (2.76 μmol) in 1 mL DMF and 
excess	DIEA.		The	solvent	was	evaporated	under	reduced	pressure	and	deprotection	was	
accomplished	with	80%	TFA,	5%	EDT,	5%	TES,	and	0%	DCM	for	0	min	at	RT.		The	
solution	was	added	to	0	mL	of	ice-cold	ether	from	which	a	precipitate	formed	and	collected	
by centrifugation.  The pellet was washed 2x with ether and dried briefly with N(g).		The	
remaining	Trp	carboxylate	was	eliminated	by	dissolving	 the	pellet	 in	0.	M	acetic	acid	
and incubating overnight.  The final compound was purified by preparative HPLC and 
lyophilized	to	give	330	nmol	of	a	white	powder	(~%	yield).		(MALDI-TOF	MS)	[M	+	

H]+	calcd	for	C09H38N3O9S
+	7.0,	observed	6.8.
ImImPy(Phe-Tyr-Pro-Trp-Met-Lys-Gly-propylamine)Py-γ-ImPyPyPy-β-Dp (2).		This	polyamide-peptide	
conjugate	was	synthesized	and	characterized	as	previously	described.
ImImPy(Trp-Met-εAhx-propylamine)Py-γ-ImPyPyPy-β-Dp (3). The	polyamide-peptide	conjugate	
was	synthesized	and	characterized	as	described	previously	in	Chapter	.4
ImImPyPy-γ-PyPy(Phe-Tyr-Pro-Ala-Ala-Lys-Gly-propylamine)PyPy-β-Dp (4).  This	polyamide-peptide	
conjugate	was	synthesized	essentially	as	previously	described.  Briefly, the peptide Phe-
Tyr(OtBu)-Pro-Ala-Ala-Lys(Boc)-Gly-OH (8.0 mg, 8.4 μmol) was activated with HBTU 
(7.5 μmol) and added to the parent polyamide 5  (2.76 μmol) in 1 mL DMF and excess 
DIEA.		The	compound	was	deprotected	as	described	for	compound	1 purified by preparative 
HPLC	and	lyophilized	to	give	440	nmol	of	a	white	powder	(~6%	yield).		(MALDI-TOF	
MS)	[M	+	H]+	calcd	for	C99H9N30O9
+	04.0,	observed	04.0.
ImImPyPy-γ-PyPy(propylamine)PyPy-β-Dp (5).	 	This	 polyamide	was	 synthesized	 on	PAM	
resin	using	standard	protocols	cleaving	with		mL	of	Dp.9   Total yield of 48.0 μmol of an 
off-white	powder.	(MALDI-TOF	MS)	[M	+	H]+	calcd	for	C60H77NO0
+	65.6,	observed	
65.6.
ImImPyPy-γ-ImPyPyPy-β-C3-FAM (6).		This	conjugate	was	synthesized	by	coupling	5-
carboxyfluorescein succinimidyl ester (1 μmol) to the polyamide ImImPyPy-γ-ImPyPyPy-
β-C3-NH (910 nmol) in 200 μL of 0.1 M DIEA in DMF for 20-30 min at RT.  The final 
product was purified by preparative HPLC and lyophilized to give 270 nmol of a yellow-
orange	solid	(~30%	yield).		(MALDI-TOF	MS)	[M	+	H]+	calcd	for	C76H77NO6
+	553.6,	
observed	553.6.
ImImPyPy-γ-PyPy(propylamine)PyPy-β-C3-BOC (7).	 	 This	 polyamide	was	 synthesized	 on	
PAM	resin	using	standard	protocols9	cleaving	with	~	mL	of	N-Boc-,3-diaminopropane.	
Total yield of 1.9 μmol of an off-white powder (~2% yield). (MALDI-TOF MS) [M + H]+	
calcd	for	C63H8NO
+	337.6,	observed	337.7.
ImImPyPy-γ-PyPy(Trp-Met-εAhx-propylamine)PyPy-β-C3-FAM (8).	The	conjugate	was	synthesized	

in	 a	 similar	 manner	 to	 conjugate	 1 using the peptide Ac-Trp(Boc)-Met-εAhx-OH (2.4 
mg)	activated	with	PyBOP	(7.5	mg)	coupled	 to	polyamide	7 (1.5 μmol).  The resulting 
intermediate was then coupled to 5-carboxyfluorescein succinimidyl ester (3.0 μmol).  The 
final product was purified by preparative HPLC and lyophilized to yield 536 nmol of a 
yellow-orange	solid	(~36%	yield).		(ESI	MS)	[M	+	H]+	calcd	for	C03H6N6O0
+	034.4,	
observed	034.9.
N-Boc-1,3-diaminopropane.		Cool	4.8	g	(6.7	mL,	0.	mol)	of	,3-diaminopropane	on	
an	ice	bath	and	add	a	solution	of	di-tert-butyl	dicarbonate	in	a	drop-wise	manner	(4.7	g,	
0.0	mol	in	50	mL	DCM).		Warm	to	room	temperature	over	.5	hours	and	extract	with	
00	mL	of	/4	sat.	NaHCO3.	 	Back	extract	aqueous	 layer	4x	with	50	mL	DCM.	 	Wash	
combined	organic	layers	with	50	mL	saturated	NaHCO3	and	50	mL	brine.	 	Dry	organic	
layer with anhydrous sodium sulfate, filter, and evaporate under reduced pressure with a 
small	amount	of	toulene	to	azeotrope	with	residual	water.		H NMR (DMSO, 300 MHz) �� 
7.8 (br t, 1 H), �� 2.94 (q, 2 H), �� 2.49 (t, 2 H), �� 1.40 (p, 2 H), �� 1.36 (s, 9 H), 1.10 (s, 2 H)�� 
HRMS	(FAB)	exact	mass	calcd	for	C8H9NO
+	requires	m/z	75.447,	found	75.45.
Quantitative DNase I footprinting.  Reactions	were	carried	out	in	a	volume	of	400	µL	in	
aqueous	TKMC	buffer	according	to	published	protocols using a 3’ 3P-labeled		50	base	
pair	EcoRI/PvuII	restriction	fragment	of	the	plasmid	pHDA.		Developed	gels	were	imaged	
using	storage	phosphor	autoradiography	using	a	Molecular	Dynamics	400S	Phosphorimager.	
Equilibrium	association	constants	were	determined	as	previously	described.
MPE footprinting with Exd.  MPE	footprinting	was	carried	out	in	40	µL	reaction	volumes	
according	to	published	procedures.		Reactions	were	carried	out	as	described	in	Chapter		
in	a	total	volume	of	40	µL in aqueous TKMC buffer containing 10% glycerol using the 3’ 
3P-labeled	308	base	pair	EcoRI/PvuII	restriction	fragment	of	the	plasmid	pHDA.
Cell culture and confocal microscopy experiments.	 	 All	 cell	 culture	 and	 confocal	
microscopy	 was	 performed	 essentially	 as	 described	 previously.	 	 See	 Chapter	 4	 for	 a	
detailed	explanation.
3
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Appendix B
Toward a Small-Molecule YPWM Mimic
Compounds 20-26 were synthesized by John Phillips (Dervan Group; Caltech).
5
B.1	Background	
	 Natural	HOX	proteins	 cooperatively	 bind	 to	DNA	with	 cofactor	TALE	proteins	
(Exd	or	Pbx)	via	 a	YPWM	peptide	motif.-3	 	The	development	of	 small	molecules	 that	
competitively	inhibit	the	YPWM-TALE	protein-protein	interaction	could	potentially	be	used	
as	therapeutics	for	the	treatment	of	pre-B	cell	ALL	involving	the	Pbx-EA	oncoprotein.4-
9		A	small	molecule	was	discovered	from	a	library	of	,4-disubstituted	naphthalenes	that	
binds	to	Pbx	(IC50	= 65 μM) and blocks Pbx/HOX/DNA complex formation, but its effect 
on	 Pbx-EA-mediated	 gene	 expression	 is	 unknown.0	 	 Such	 small	molecules	may	 also	
serve	 as	 binding	 domains	 for	 protein-DNA	 dimerizers	which	mimic	HOX	 proteins.-5	
The	protein-binding	domains	for	such	protein-DNA	dimerizers	have	been	peptides	which	
may be susceptible to endogenous proteases in cell-culture and fruit fly experiments.  This 
appendix	describes	three	non-peptidic	mimics	of	the	YPWM	motif	in	the	context	of	Exd	
protein-DNA	 dimerizers	 including	 the	 aforementioned	 ,4-disubstituted	 naphthalene	 in	
search	of	a	metabolically	stable	Exd	protein-binding	domain.
B.2	YPWM β-turn Mimetic 
	 The	YPWM	motif	has	been	highly	conserved	 throughout	 evolution	and	 is	often	
referred	 to	 as	 a	 penta-	 or	 hexapeptide	 motif	 with	 an	 overall	 consensus	 sequence	 of	
φYPWM(K/R)	where	φ	is	a	hydrophobic	residue.6	 Residues flanking the hexapeptide have 
also	been	shown	to	contribute	to	YPWM-protein	interactions.7		The	small	buried	YPWM-
Exd	interface	(~570	Å)	when	compared	to	mean	protein-protein	interfaces	(~000	Å)8-9	
suggested	that	this	motif	was	already	minimal.		Thus,	the	initial	attempt	to	develop	a	small-
molecule	YPWM	mimetic	aimed	at	maintaining	the	entire	peptide	structure.		It	was	noted	
that	the	Exd/Ubx/DNA	and	Pbx/HoxB/DNA	structures	the	YPWM	motif	adopts	either	
a type I β-turn or the closely related type III β-turn (i.e., 30 helix).  Thus, a β-turn mimetic 
was	designed	based	on	a	scaffold	reported	by	the	Burgess	group.0-3		This	scaffold	allowed	
incorporation	of	the	absolutely	conserved	Trp	at	the	i+2	position	and	energy	minimized	
6
Figure B.1  Design of YPWM β-turn mimetic.  a) Wild-type Ubx YPWM tetrapeptide 
depicted schematically in a β-turn conformation.  b) Wild-type Ubx YPWM tetrapeptide 
from	the	Ubx/Exd/DNA	crystal	structure	(PDB	code	B8I).		c)		Designed	YPWM	mimic	
using a β-turn scaffold from the Burgess group.0-3		d)	Energy	minimized	model	(PM3)	of	
the designed YPWM β-turn mimic.
models	(PM3)	suggested	reasonable	structural	similarity	to	the	native	YPWM	motif	(Figure	
B.).
 The synthesis of YPWM β-turn mimetics was performed on a low-loading TentaGel 
PHB	resin	using	procedures	adapted	from	related	macrocycles	(Figure	B.).0-  Briefly, 
standard	 Fmoc	 peptide-synthesis	 was	 employed	 to	 yield	 resin-bound	 intermediate	 1.	
Fmoc deprotection, coupling to 2-fluoro-5-nitro-benzoic acid, and selective removal of 
the	trityl	with	mild	acid,	yielded	resin-bound	intermediate	2.  Macrocycle	formation	was	
accomplished	under	basic	conditions	which	promoted	nucleophilic	aromatic	substitution	
of the serine hydroxyl with the fluorinated benzoic acid derivative.  Treatment of the resin 
with strong acid and HPLC purification of the resulting crude mixture yielded macrocycle 3.	
Low	resin	loading	was	found	to	prevent	the	formation	of	undesired	dimerized	by-products	
and	was	important	for	achieving	good	yields.		Coupling	of	the	macrocycle	carboxylic	acid	
7
Figure B.2  Synthesis of polyamide-YPWM β-turn mimic conjugate: i)	0%	piperidine	
in	DMF,	ii) 2-fluoro-5-nitrobenzoic acid, HATU, DIEA, DMF, iii)	-3%	TFA,	5%	TIS,	in	
DCM,	iv)	KCO3	in	DMF,	v)	85%	TFA,	5%	TIS,	0%	DCM,	vi)	HBTU,	DIEA	in	DMF
3	to	polyamide	amine	4	via	in situ HBTU	activation	yielded	conjugate	5 (Figure	B.3a).		An	
uncyclized	analogue	6	was	synthesized	using	standard	Fmoc	chemistry	and	coupled	to	4	to	
yield	conjugate	7	to	serve	as	a	control	(Figure	B.3b).
 An electrophoretic mobility shift assay (EMSA), or gel shift, with Exd at 4 °C was 
employed	with	conjugate	5	and	7 to	assess	their	ability	to	facilitate	Exd-DNA	dimerization	
(Figure	B.3c).		Although	the	conjugate	5 enhanced Exd’s DNA binding substantially, the 
uncyclized	control	compound	exhibited	a	slightly	higher	Exd-DNA	dimerization	activity.	
This	result	suggested	that	the	presence	of	a	macrocycle	was	unnecessary	for	the	Exd	binding	
activity.		This	directly	inspired	the	experiments	that	showed	only	the	Trp	and	Met	amino	
acids	were	necessary	 for	Exd-DNA	dimerization	 in	 the	 context	 of	 a	 polyamide-peptide	
conjugate.4
8
Figure B.3  Gel shifts experiments with polyamide-YPWM β-turn mimic conjugates.  a) 
Structure of polyamide-YPWM β-turn mimic conjugate.  b) Synthesis of uncyclized β-
turn	mimic	 control	 conjugate:	 i)	4,	HBTU,	DIEA	 in	DMF.	 	 c)	Representative	 gel	 shift	
experiments	 for	cyclized	(5)	and	uncyclized	(7) β-turn mimic conjugates.  d) Isotherms 
for	Exd	binding	in	the	presence	of	5	and	7.		The	uncyclized	analogue	(7)	leads	to	a	higher	
affinity complex than the cyclized compound (5).	 	Gel	shifts	were	performed	at	50	nM	
compound	titrating	Exd	from	0	pM	to	00	nM.
9
B.3 WM Peptoid Analogue
	 One	 type	 of	 synthetic	 peptide	
analogue	is	a	poly-N-substituted	glycine,	
or	 peptoid.4-6	 	 Given	 that	 only	 Trp	
and	 Met	 residues	 were	 necessary	 to	
dimerize	Exd,4	efforts	were	undertaken	
to	generate	a	WM	peptoid	(Figure	B.4).	
Synthesis	 of	 the	 direct	 analogue	 of	
the	 WM	 peptide	 was	 attempted	 using	
the	 submonomer	 method5-6	 with	 -
chlorotrityl	 resin,	 which	 was	 reported	
to	 enable	 the	 synthesis	 of	 peptoid	
carboxylates	 (Figure	 B.5).7	 	 Only	 the	
isolation	of	a	compound	consistent	with	
15	was	observed,	which	was	rationalized	
in	terms	of	an	intramolecular	nucleophilic	
bromine	displacement	by	the	methionine	
thioether	 to	give	 intermediate	13,	which	
probably	resulted	in	the	formation	of	the	
more	 stable	 diketopiperizine	 14.	 	 The	
alkyl	 analogue	 17	 was	 synthesized	 and	
coupled to the polyamide ImImPyPy-γ-
ImPyPyPy-β-Dp to yield conjugate 10.  Gel shift experiments at 20 °C with 10	showed	that	
it	did	not	form	as	stable	of	an	Exd-DNA	complex	as	its	peptide	relative	8 (Figure	B.6).	
B.4 Naphthalene Small Molecule Inhibitor
	 The	 ,4-disubstituted	 naphthalene	 18	 was	 previously	 reported	 to	 competitively	
Figure B.4	 	 Design	 of	 WM	 peptoid	
conjugates.	 	 The	 natural	 WM	 peptide	
conjugate	8	 is	 shown	 for	 comparison	 to	
the	 WM	 peptoid conjugate	 9.	 	 A	 WM	
peptoid	 analogue	 10	 with	 a	 completely	
alkyl	 derivative	 of	 the	 methionine	 side	
chain	is	also	shown.
30
Figure B.5		Synthesis	of	WM	peptoid	analogues.		a)	The	synthesis	of	WM	peptoid	conjugate	
was	ultimately	not	successful	due	to	the	probable	intramolecular	bromine	displacement	by	
the	methionine	as	shown:	i)	0%	piperidine	in	DMF,	ii) α-bromoacetic acid, DIC, DIEA, 
DMF,	 iii)	-(methylthio)ethylamine,	DMSO,	 iv) α-bromoacetic acid, DIC, DIEA, DMF, 
v)	::6	AcOH:TFE:DCM	b)	Standard	submonomer	peptoid	synthesis	using	-chlorotrityl	
resin	 yielded	 the	 desired	 carboxylic	 acid	 17:	 v)	 ::6	AcOH:TFE:DCM,	 vi)	 4,	 HBTU,	
DIEA	in	DMF.
Figure B.6  Gel	 shifts	 experiments	 comparing	 polyamide-WM	 peptoid	 and	 peptide	
conjugates.		a)	The	peptoid	conjugate	10 yielded a lower affinity Exd-DNA complex than 
the	peptide	conjugate	8.		b)	Isotherms	for	Exd	bind	in	the	presence	of	8	and	10.		Gel	shifts	
were	performed	with	50	nM	compound	titrating	Exd	from	0	pM	to	00	nM.
3
inhibit	 Pbx/HOX/DNA	 complex	
formation	 presumably	 by	 competitively	
displacing	 the	 YPWM	 peptide	 (Figure	
B.7).0	 	Although	 no	 rigorous	 structural	
data	 is	 available	 for	 the	 interaction	 of	
18	with	Pbx	or	Exd,	published	modeling	
studies0	 suggested	 the	 formamide	
moiety	 was	 a	 suitable	 attachment	 point	
for	 a	 polyamide	 conjugate	 since	 it	 was	
predicted	to	project	away	from	the	binding	pocket.		Accordingly,	John	Phillips	synthesized	
a suitably modified version (26)	to	enable	direct	coupling	to	a	polyamide.		Starting	from	
commercially	available	naphthyl	aldehyde	19,	carboxylic	acid	20	was	obtained	by	oxidation.	
Coupling	20 to 3-fluoroaniline yielded amide 21	and	the	naphthylmethoxy	was	converted	to	
aromatic	hydroxyl	22 by nucleophilic displacement.  The hydroxyl was condensed with α-
bromomethylacetate	to	give	methyl	ester	23 which was saponified to yield carboxylic acid 
24.		A	four-carbon	linker	was	then	attached	by	amide	bond	formation	to	yield	25,	which	
was	subsequently	hydrolyzed	to	give	the	key	carboxylic	acid	intermediate	26.  The final 
conjugate	27	was	made	via	amide	bond	formation	between	a	polyamide	primary	amine	and	
the	carboxylic	acid	of	26.
 A gel shift experiment at 20 °C with compound 27 did	not	yield	nearly	as	strong	
of	 an	Exd-DNA	 complex	 as	 the	 polyamide-WM	conjugate	8 (Figure	B.9).	 	The	 levels	
of complex formation and Exd affinity were only slightly better than were caused by 
the allosteric effects of the parent polyamide ImImPyPy-γ-ImPyPyPy-β-Dp at the same 
temperature.4		It	is	possible	that	modifying	the	length	or	composition	of	the	linker	or	its	
attachment	point	may	increase	the	amount	of	complex	formed.		
Figure B.7	 	 Structure	 of	 naphthalene	
compound	 18	 previously	 reported	 to	
competitively	 inhibit	 Hox/Pbx/DNA	
complex	 formation	 by	 binding	 to	 the	
YPWM	binding	pocket	of	Pbx.0
3
Figure B.8	 	Synthesis	of	an	analogue	of	18	 suitable	 for	conjugating	 to	a	polyamide:	 i)	
NaClO,	NaHPO4,	HO,	tBuOH,	-methyl--butene,	rt,	4	hours,	 ii)	oxalyl	chloride,	3-
fluoroaniline, DIEA, THF, reflux, iii)	 ethanethiol,	AlCl3, DCM, 0 to 20 °C, iv)	methyl	
bromoacetate,	KCO3, THF, reflux, 1 hour, v)	LiOH,	MeOH,	HO, reflux, 2 hours, vi) γ-
aminobutyric	acid	tert-butyl	ester,	PyBOP,	DIEA,	DMF,	vii)	:	TFA:DCM,	viii)	4,	HBTU,	
DIEA,	DMF.
B.5 Experimental Details
Macrocycle (3).  The synthesis of macrocycles was accomplished using a modified version 
of	previously	published	methods.0		Synthesis	was	performed	using	TentaGel	S	PHB	resin	
(Fluka,	loading	~0.4	meq/g).		Standard	Fmoc	SPPS	was	employed	initially	to	obtain	peptide	
intermediate	1	which	was	deprotected	with	0%	piperidine	in	DMF	for	0	min.		Coupling	
of 2-fluoro-5-nitrobenzoic acid (2.5 equivalents) was performed by in situ	activation	of	the	
free	acid	using	HATU	to	give	the	activated	ester	which	was	then	added	to	the	deprotected	
amine	 of	 the	 previous	 residue.	 	 The	 trityl	 protecting	 group	 on	 the	 serine	 residue	 was	
selectively	removed	by	approximately	5	treatments	of		to	3%TFA	and	5%	TIS	in	DCM	
over	roughly	-3	hours	until	the	yellow	color	dissipated	to	yield	resin-bound	intermediate	
2.	 	Analytical	cleavage	of	from	the	resin	using	the	same	method	described	for	cleavage	
from	Wang	resin	allowed	characterization	of	this	intermediate	by	mass	spectrometry.		After	
standard	rinsing	DMF	(3x)	and	DCM	(3x),	cyclization	was	initiated	with	5	equivalents	of	
finely ground KCO3 in DMF and allowed to proceed at room temperature for >48 hours. 
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Cleavage	from	resin	was	performed	using	
85%TFA,	 5%TIS,	 and	 0%DCM	 (~4x,	
.5	mL)	followed	by	removal	of	most	of	
the	solvent	under	reduced	pressure.		The	
resulting	 solid	was	 dissolved	 in	 a	 small	
volume of DMF (~200 μL) and enough 
0%	 CH3CN/0.%	 TFA	 in	 water	 was	
added	 to	 give	 a	 total	 volume	 of	 	 0mL	
which was purified by preparative HPLC. 
Upon	 lyophilization	 of	 the	 appropriate	
fractions	 yielded	 4.	 mg	 an	 off-white	
solid	 (3.7%	 yield).	 	 (ESI	 MS)	 average	
mass	calculated	for	C30H35N6O9
+	[M+H]+:	
63.6,	 found	 63.8	 and	 calculated	 for	
C30H33N6O9
-	[M-H]-:	6.6,	found	6.8.
ImImPy(propylamine)Py-γ-ImPyPyPy-β-
Dp (4).		The	polyamide	was	synthesized	
according	 to	 standard	 protocols	 on	
BOC-β-Ala-PAM resin.8	 	 65	 mg	 of	
resin	 cleaved	 with	 	 mL	 of	 neat	 N,N-
dimethylaminopropylamine	 (Dp)	 at	 37	
°C for 48 hours, purified by preparative 
HPLC	 and	 lyophilized	 to	 give	 an	 off-
white powder (10.9 μmol, ~17% yield). 
(MALDI-TOF	MS)	calculated	for	C59H76N3O0
+	66.6,	observed	66.7.
ImImPy(macrocycle-propylamine)Py-γ-ImPyPyPy-β-Dp (5).  Excess	polyamide	4 (3.55 μmol, 2.2 
eq)	was	added	to	macrocycle	3 (1 mg, 1.6 μmol, 1 eq) pre-activated (~5 min, RT) with 
Figure B.9	 	 Gel	 shift	 experiments	
comparing	 polyamide-WM	 conjugate	 8	
to	 polyamide-naphthalene	 conjugate	27.	
a)	 Structure	 of	 polyamide-naphthalene	
conjugate.	b)	Representative	gel	shifts	in	
the	 presence	 of	8 and 27.	 	 c)	 Isotherms	
for	Exd	binding	in	the	presence	of	8	and	
27.	 	Gel	 shifts	were	 performed	with	 50	
nM	compound	titrating	Exd	from	0	pM	
to	00	nM.
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HBTU (1 eq) in DMF (~500 μL) and DIEA (8 equivalents).  The resulting compound was 
purified by prepartive HPLC and lyophilzed to give a solid.  (MALDI-TOF MS) [M+H]+	
base	peak	calculated	for	C89H08N9O8
+	87.8,	found	87.8.
Noncycle (6).	 	 This	 control	 compound	was	 synthesized	 on	Wang	 resin	 (0.305	 g,	 0.8	
mmol/g,	0.50	mmol	scale)	using	standard	Fmoc	peptide	chemistry.		The	3-nitrobenzoic	
acid	moiety	(Aldrich,	99%,	3.5	eq)	was	pre-activated	with	HATU	(3.4	eq)	in	DMF	with	
DIEA	(4.5	eq)	and	coupled	for		hours	at	RT.		Cleavage	from	the	resin	was	performed	with	
95% TFA/5% TIS, worked up as usual, and purified by preparative HPLC and lyophilized 
to	give	a	solid.		(ESI	MS)	average	mass	calculated	for	C30H37N6O9
+	[M+H]+:	65.3,	found	
65.4	and	calculated	for	C30H35N6O9
-	[M-H]-:	63.3,	found	63.4.
ImImPy(noncycle-propylamine)Py-γ-ImPyPyPy-β-Dp (7).  Polyamide	4 (0.97 μmol, 1 eq) was 
added	 to	noncycle	6 (4.2 mg, 6.8 μmol, ~7 eq) pre-activated (~5 min, RT) with HBTU 
(3 eq) in DMF (~500 μL) and DIEA (20 eq).  The resulting compound was purified by 
prepartive	HPLC	and	lyophilzed	to	give	a	solid.		(MALDI-TOF	MS)	[M+H]+	calculated	
for	C89H0N9O8
+	87.9,	found	873.0.
ImImPy(Trp-Met-εAhx-propylamine)Py-γ-ImPyPyPy-β-Dp (8).	 	This	 compound	was	 synthesized	
and	characterized	as	described	in	Chapter	.
ImImPy(N-Trp-N-But-εAhx-propylamine)Py-γ-ImPyPyPy-β-Dp (10).		Polyamide	4 (1.5 μmol, 1 eq) 
was	added	to	peptoid	17	pre-activated	(~5	min,	RT)	with	excess	PyBOP	and	DIEA	in	DMF.	
The resulting compound was purified by prepartive HPLC and lyophilzed to give a solid 
(660	nmol,	~44	%	yield).		(MALDI-TOF	MS)	[M+Na]+	calculated	for	C84H09N7O4Na
+	
74.9,	found	74.9.
(15).	This	compound	was	synthesized	using	standard	peptoid	submonomer	procedures5,6	
on	 -cholortrityl	 resin7	 employing	 -(methylthio)-ethylamine	 (Aldrich)	 and	 3-
(aminomethyl)indole	 (97%,	 Carbocore).	 (ESI-MS)	 Calculated	 for	 C3H3NO4S
+	 303.,	
observed	303..
N-Trp-N-Met-εAhx-OH (17).	 	This	compound	was	synthesized	using	standard	peptoid	
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submonomer	procedures5,6		on	-cholortrityl	resin7	employed	butylamine	(Aldrich)	and	
3-(aminomethyl)indole	(97%,	Carbocore).	The	peptoid	was	cleaved	using	6::	DCM:TFE:
AcOH	(	mL,	3x),	rinsed	with	DCM	(	mL),	added	to	hexanes	(5	mL,	x),	and	rotavapped	
to dryness.  The resulting film was dissolved in 500 μL DMF and diluted in 0.1% TFA 
in water and acetonitrile and purified by preparative HPLC.  Fractions with consistent 
mass	spectra	by	MALDI-TOF	MS	were	pooled	and	lyophilized	to	give	a	white	powder.	
(ESI-MS)	[M+Na]+	Calcd	for	C5H36N4O5Na
+	495.3,	observed	495.3.		The	MS/MS	(35%	
collision	energy)	fragmentation	pattern	of	the	isolated	m/z	of	495.3	peak	was	consistent	
with	the	desired	compound.
4-methoxy-1-naphthoic acid (20).  This	reaction	was	performed	based	on	a	previously	
reported	procedure.9		The	starting	4-methoxy--naphthaldehyde	19	(5	g,	6.85	mmol)	was	
dissolved	in	tBuOH	(40	mL)	and	-methyl--butene	(0	mL)	to	give	a	yellow	solution.	
NaClO	(3.95	g	 in	40	mL	ddHO	with	4.80	g	NaHPO4·HO)	was	added	in	a	drop-wise	
manner	 leading	 to	 the	 formation	 of	 a	 white	 precipitate.	 	 The	 reaction	 was	 allowed	 to	
proceed for 24 hours before filtering to collect the solid which was washed with hexanes 
(3x	50mL).		The	solid	was	dissolved	in	0.	N	NaOH	(60	mL)	and	extracted	with	hexanes	
and	EtOAc	(x	hexanes	30	mL,	x	EtOAc	50	mL,	x	hexanes	50	mL).		The	aqueous	phase	
was acidified (pH 2) and the white precipitate was extracted with EtOAc (2 x 60 mL) and 
diethyl	ether	(	x	60	mL).		The	combined	organic	layer	was	washed	with	brine	(x),	dried	
with anhydrous magnesium sulfate, filtered and concentrated to yield 2.4 g of a white 
crystalline	solid	(45%	yield).		H	NMR	(CDCl3, 300 MHz) �� 4.102 (s, 3H), �� 6.87 (d, J 
= 8.7 Hz, 1H), �� 7.58 (t, 1H), �� 7.68 (t, 1H), �� 8.36 (d, J = 8.1 Hz, 1H), �� 8.44 (d, J = 9 
Hz, 1H), �� 9.16 (d, J = 8.7 Hz, 1H)�� HRMS (FAB) exact mass calcd for CHO3	requires	
03.0708	m/z,	found	03.07.
N-(3-fluorophenyl)-4-methoxy-1-naphthamide (21).	 	 The	 following	 procedure	 was	
adapted	from	a	previously	described	reaction.30  Into a dry, ventilated flask under argon the 
carboxylic	acid	20 was	added	(.04	g,	0.4	mmol)	and	dissolved	in	anhydrous	DCM	(0	
36
mL)	to	which	oxalyl	chloride	(0	mL)	was	added	in	a	drop-wise	manner.		The	vigorous	
reaction	was	allowed	to	proceed	for	0.5	hours	and	the	solvent	and	excess	oxalyl	chloride	
was	removed	under	reduced	pressure	in	a	fume	hood	to	give	a	yellow	solid.		The	solid	was	
dissolved in anhydrous THF (20 mL) with DIEA (7.25 mL, 41.6 mmol) and 3-fluoroaniline 
(1.20 mL, 12.48 mmol).  The solution was refluxed for 30 min and the reaction was quenched 
with	aqueous	NH4OH	(0	mL,	30%)	and	the	solvent	was	removed	under	reduced	pressure.	
The	dark	brown	residue	was	dissolved	in	EtOAc	(00	mL)	and	extracted	with	HCl	(	x	
00	mL,	5%),	NaOH	(	x	00	mL,	0.N),	and	brine	(	x	00	mL).		The	combined	organic	
phase	was	removed	under	reduced	pressure	and	the	residue	dissolved	in	minimal	amount	
of EtOAc, precipitated from hexanes (200 mL), and collected by filtration as a white solid 
(.8g,	59%	yield).		H	NMR	(CD3OD, 300 MHz) �� 4.07 (s, 3H), �� 6.91 (t, 1H), �� 6.98 (d, 
1H), �� 7.3-7.6 (m, 4H), �� 7.73 (t, 2H), �� 8.30 (t, 2H)�� HRMS (FAB) exact mass calcd for 
C8H5FNO	requires	96.087	m/z,	found	96.087.
N-(3-fluorophenyl)-4-hydroxy-1-naphthamide (22).  The	 following	 procedure	 was	
adapted	from	a	previously	described	reaction.3  In a dry flask, AlCl3	(.03	g,	5.	mmol,	
3 eq) was added to a solution ethanethiol (5 mL) and DCM (5 mL) cooled at 0 °C.  After 
allowing	 the	 solution	 to	 reach	RT,	 compound	21	 (.5	 g,	 5.08	mmol)	was	 added	 under	
argon.		The	reaction	was	allowed	to	proceed	overnight	and	the	AlCl3	was	quenched	by	very 
slowly	adding	ddHO.		The	resulting	precipitate	was	dissolved	in	EtOAc	(40	mL)	and	the	
combined organic and aqueous phases were acidified to pH 2 with 1 N HCl and extracted 
with	EtOAc	(40	mL,	x).		The	combined	organic	layers	were	washed	with	brine	(x	0	mL),	
dried	with	anhydrous	magnesium	sulfate,	and	concentrated	under	reduced	pressure.		The	
crude residue was purified over silica gel (10-50% EtOac/Hex gradient) and the product 
was	isolated	as	an	off-white	amorphous	solid	(.5	g,	80%).		H	NMR	(CD3OD,	300	MHz)	
�� 6.85-6.88 (m, 2H), �� 7.33-7.60 (m, 4H), �� 7.65 (m, 2H), �� 8.26-8.29 (m, 2H)�� HRMS 
(FAB)	exact	mass	calcd	for	C7H3FNO	requires	8.0930	m/z,	found	8.094.
methyl 2-(4-(3-fluorophenylcarbamoyl)naphthalen-1-yloxy)acetate (23).  The	following	
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procedure	 was	 based	 on	 a	 previously	 described	 reaction.3	 	A	 solution	 of	 hydroxyl	 22	
(50 mg, 178 μmol) was made in THF (1 mL) with KCO3 (37 mg, 196 μmol, 1.5 eq). 
Methylbromoacetate was added (18 μL, 588 μmol, 3.3 eq) and the resulting solution was 
refluxed for more than 3 hours.  The solvent was removed under reduced pressure to give a 
brown	residue	and	the	remaining	methylbromoacetate	was	removed	under	a	high	vacuum	
for		hours.		The	residue	was	dissolved	in	EtOAc	(0	mL),	extracted	with	water	(0	mL,	x)	
and brine (10 mL, 1x), dried over anhydrous magnesium sulfate, filtered, and concentrated 
under reduced pressure.  The yellow crude material was purified over silica gel (10-30% 
hexanes/EtOAc	gradient)	to	yield	white	solid	with	a	yellow	impurity	(60	mg,	95%	yield).	
H	NMR	(CD3OD, 300 MHz) �� 3.8 (s, 3H), �� 5.0 (s, 2H), �� 6.8-6.95 (m, 2H), �� 7.3-7.45 (m, 
2H), �� 7.55-7.65 (m, 2H), �� 7.7 (d, 2H), �� 8.25 (d, 1H), �� 8.4 (d, 1H)�� HRMS (FAB) exact 
mass	calcd	for	C0H7FNO4	requires	354.4	m/z,	found	354.50.
2-(4-(3-fluorophenylcarbamoyl)naphthalen-1-yloxy)acetic acid (24).  The	 following	
procedure	was	based	on	a	previously	described	reaction.0		To	a	solution	of	ester	23	(50	mg,	
142 μmol) in MeOH (2 mL) LiOH was added (213 μL of a 1M solution).  The solution was 
refluxed for 2 hours and the solvent was removed under reduced pressure to yield a crude 
yellow	residue	which	was	dissolved	in	0	mL	of	water	which	was	extracted	with	hexanes	
(10 mL, 1x), EtOac (10 mL, 1x), and hexanes (10 mL, 1x).  The aqueous layer was acidified 
to	pH		with		N	HCl	to	form	a	white	precipitate	which	was	extracted	with	EtOAc	(0	mL,	
3x).  The combined organic layer were dried over anhydrous magnesium sulfate, filtered, 
and	concentrated	to	dryness	under	reduced	pressure	to	give	an	amorphous	off-white	solid	
(45	mg,	94%	yield).		H NMR (d6-DMSO, 300 MHz) �� 4.97 (s, 2H), �� 6.89-6.99 (m, 2H), 
�� 7.33-7.80 (m, 6H), �� 8.23-8.32 (m, 2H), �� 10.63 (s, 1H)�� HRMS (FAB) exact mass calcd 
for	C9H5FNO4	requires	340.0985	m/z,	found	340.0995.
4-(2-(4-(3-fluorophenylcarbamoyl)naphthalen-1-yloxy)acetamido)butanoic acid (26).	
The	following	procedure	was	based	on	a	previously	described	reaction	sequence.33		To	a	
solution	of	carboxylic	acid	24 (45 mg, 133 μmol) in 1 mL anhydrous DMF and DIEA (23 
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μL, 1 eq) PyBOP was added (83 mg, 159 μmol, 1.2 eq) followed by γ-aminobutyric acid 
tert-butyl ester (29 mg, 146 μmol, 1.1 eq) and more DIEA (69 μL, 3 eq).  Reaction was 
allowed	to	proceed	for	8	hours	and	the	solvent	was	removed	under	reduced	pressure	and	
the	residue	was	dissolved	in	DCM	(0	mL)	and	extracted	with	water,	saturated	NaHCO3,	
	N	HCl,	and	brine	(0	mL,	x	each).		The	organic	layer	was	evaporated	to	leave	a	yellow	
residue.	 	The	 ester	was	 hydrolyzed	with	 :	DCM:TFA	 (.5	mL)	 and	 the	 solvent	was	
removed	under	reduced	pressure	to	yield	a	crude	yellow-white	residue	which	was	dissolved	
in a minimum volume of DCM and purified over silica gel (9:1 EtOAc:hexanes + 1% 
AcOH)	to	give	an	off-white	solid	(4.	mg,	73%	yield).		H	NMR	(CD3OD, 300 MHz) �� 
1.98 (p, 2H), �� 2.33 (t, 2H), �� 3.37 (t, 2H), �� 4.80 (s, 2H), �� 6.85-6.99 (m, 2H), �� 7.32-7.45 
(m, 2H), �� 7.56-7.74 (m, 4H), �� 8.29 (d, 1H), �� 8.51 (d, 1H)�� HRMS (FAB) exact mass 
calcd	for	C3HFNO4	requires	45.53	m/z,	found	45.49;		Amax ~230 nm (ε at 230 nm 
≈ 2 × 104	M-·cm- and ε at 310 nm = 104	M-·cm-).
ImImPy(1,4-napthalene-propylamine)Py-γ-ImPyPyPy-β-Dp (27).  Polyamide	4 (2 μmol, 1 eq) was 
added	to	carboxylic	acid	26 (10 mg, 23.6 μmol) pre-activated (~5 min, RT) with HBTU (8 
μmol, 4 eq) in DMF (~280 μL) and DIEA (20 μmol).  The resulting compound was purified 
by	prepartive	HPLC	and	lyophilzed	to	give	a	solid.		(MALDI-TOF	MS)	[M+H]+	calculated	
for	 C8H95FN5O4
+ 1672.8, found 1672.8.  The conjugate’s extinction coefficient was 
assumed	to	be	the	sum	of	the	parent	polyamide	4	and	the	small	molecule	26	components	
(conjugate ε at 310 nm ≈ 79,500 M-·cm-).
Electrophoretic Mobility Shift Assays (EMSAs).  All	 EMSAs,	 or	 gel	 shifts,	 were	
performed at 4 or 20 °C as described in Chapter 2.4
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Appendix C
Exd Expression Protocols
Exd was expressed by the Protein Expression Center (Beckman Institute, Caltech).
Mass spectrometry analysis of the Exd protein fragments was performed by the Peptide/
Protein MicroAnalytical Lab (PPMAL, Beckman Institute, Caltech).
4
C.1 First Exd Preparation Experimental Details
	 A	plasmid	“Exd-C”	was	 received	 from	 the	Ansari	 lab	 (University	of	Wisconsin,	
Madison)	which	was	originally	obtained	from	the	Aggarwal	lab	(Mount	Sinai	School	of	
Medicine) (Figure C.1).  Protein expression and purification was performed by Dr. Peter 
Snow	of	 the	Protein	Expression	Center	(Beckman	Institute,	Caltech).	 	The	plasmid	was	
transformed	into	E. coli	BL-DE3	cells	and	overexpressed	by	treating	with		mM	IPTG.	
Cells were lysed by sonication and crude purification was performed by taking the 50% 
(or	 90%)	 ammonium	sulfate	 cut.	 	The	 crude	preparation	was	dialyzed	 against	 buffer	A	
(50	mM	potassium	glutamate,	50	mM	HEPES,		mM	DTT,	pH	7.0,	5%	glycerol,	00	
mM NaCl).  The dialyzed protein was purified by FPLC (Figure 2a�� flow rate = 0.5 mL/
min,	eluant	A	=	buffer	A,	eluant	B	=	buffer	A	with		M	NaCl,	0.5	mL	fractions).		An	SDS-
PAGE	gel	stained	with	Coomassie	blue	showed	pure	fractions	(9-33)	with	the	predicted	
mass	(~0	kDa)	for	the	desired	Exd	fragment	(Figure	C.b).		Band	excision	(fraction	3)	
followed	by	proteolytic	digestion	(Lys-C	achromobacter)	and	MALDI-TOF	MS	analysis	
was	consistent	with	the	predicted	spectra	using	Sherpa	3.3.	for	Exd	(residues	38-34)	
(Figure	C.3c-d).	 	Mascot	 (Matrix	Science)	 search	 results	 from	LC-MS/MS	data	 for	 the	
digested protein identified Dpbx (i.e., Drosophila Pbx	or	Exd)	as	the	sole	match	protein	
(score	=	63).	 	Fractions	9-33	were	combined	and	dialyzed	against	buffer	A.		A	sizing	
column	(G30)	was	used	to	remove	aggregates.		MALDI-TOF	MS	analysis	of	the	combined	
fractions	of	the	undigested	protein	from	Caltech	was	consistent	with	the	presence	of	Exd	
residues	38-30	(calculated	[M+H]+	9495.7	m/Z,	observed	[M+H]+	9496.0)	(Figure	C.3a).	
An	undigested	“crude”	Exd	preparation	from	the	Ansari	lab	yielded	a	similar	mass	spectrum	
(Figure C.3b).  The stock Exd concentration was determined to be 432 ± 22 μM using the 
method	of	Stoscheck and a calculated extinction coefficient	of	,600	M-cm-	for	Exd	
residues	38-30	(Figure	C.4).		Total	yield	was	4.	mg.
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Figure C.1		Amino	acid	sequence	of	Exd	isoform	C	of	D. Melanogaster.		Bold-faced	type	
indicates	the	region	of	Exd	expressed	(38-30)	and	italicized	type	indicates	the	region	of	
Exd	used	in	the	Ubx/Exd/DNA	crystal	structure	(PDB	code	B8I).		Both	regions	contain	
Exd’s DNA-binding homeodomain.
Figure C.2  Purification and analysis of the first Exd preparation.  a) FPLC trace with major 
peaks A and B labeled.  See text for details of purification.  b) SDS-PAGE gel stained with 
Coomassie	blue	shows	the	content	of	peaks	A	(combined	fractions	-5)	and	B	(fractions	
9-33).
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Figure C.3		MALDI-TOF	MS	analysis	of	different	Exd	preparations.		a)	Mass	spectrum	of	
Exd	expressed	at	the	Caltech	Protein	Expression	Center	by	Peter	Snow.		b)	Mass	spectrum	
of	“crude”	Exd	expressed	by	the	Ansari	lab	and	the	University	of	Wisconsin,	Madison.		c)	
Mass	spectrum	#	of	proteolytic	peptide	fragments	of	Exd	as	determined	at	the	Peptide/
Protein	MicroAnalytical	Lab	(PPMAL)	at	Caltech	by	Gary	Hathaway.		d)	Mass	spectrum	
#	of	proteolytic	peptide	fragments	of	Exd	determined	by	the	PPMAL.		e)	Sequence	of	Exd	
reported	in	the	original	Arndt	et	al	manuscript.3		Bold-faced	type	indicates	the	region	of	Exd	
identified by proteolytical/MS analysis and italicized type indicates the region observed by 
undigested	protein	samples	from	Caltech	and	the	University	of	Wisconsin,	Madison.
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C.2 Second Exd Preparation Experimental Details
	 The	Exd-C	plasmid	was	transformed	in	BL-DE3	cells	as	above	by	Jost	Vielmetter	
and	Gilberto	Salvo	of	the	Caltech	Protein	Expression	Center.		Cells	were	grown	to	an	OD	
of 0.6 at 37 °C and induced with 1 mM IPTG.  Protein over-expression was allowed to 
proceed for 4 hours at 30 °C and cells were collected by centrifugation at 3000g for 30 min. 
For storage the cell pellet was flash frozen and stored at -80 °C.  Cells were lysed in buffer 
B	(X	PBS,		mM	EDTA,	5	mM	benzamidine,	x	PMSF,	x	complete	protease	inhibitor,	
pH	7.4)	by	sonication	(Sonic	Dismembrator	550	with	Microtip	at	level	4	in	pulsar/timer	
mode:		min	duty	cycle	time,	0.5	s	pulses	interupted	with	0.5	s	pauses	on	ice).		Cells	were	
spun 2x at 13,000 rpm, 4 °C, 30 min with a Sorvall SS-34 rotor decanting the lysate into 
a fresh tube.  A total of 5 mL lysate was obtained and stored at -80 °C.  The diluted crude 
lysate	(5	mL)	was	loaded	onto	a	HiTrap	Heparin	HP	column	in	injection	buffer	(5	mM	
TrisHCl,	 pH	7.5,	 00	mM	NaCl,	 	mM	EDTA,	 0%	glycerol)	 and	 eluted	with	 elution	
buffer (25 mM TrisHCl, pH 7.5, 1 M NaCl, 1 mM EDTA, 10% glycerol) with a flow rate 
of		mL/min	collecting		mL	fractions.	 	Fractions	44-77	were	pooled	and	concentrated	
down	to		mL.		No	ammonium	sulfate	fractionation	was	employed.		The	pooled	fractions	
were purified on a MonoS column by FPLC with a flow rate of 0.5 mL/min collecting 1 mL 
fractions	(A	buffer	=	injection	buffer,	B	buffer	=	elution	buffer)	(Figure	C.5).		The	major	
peaks	were	analyzed	by	an	SDS-PAGE	gel	stained	with	Coomassie	blue.		Fractions	5	and	
16 from the monoS column were pooled and 200 μL was loaded onto a sephadex-75 sizing 
column purified by an isochratic methods using the injection buffer (Figure C.6).  Fractions 
17-20 were pooled and concentrated down to ~200 μL.  The concentration was estimated 
to be ~2 mg/mL (~30.2 μM) by Jost Vielmetter from the UV absorbance at 280 nm using a 
nanodrop	spectrometer.		Total	yield	was	~0.4	mg.		An	analytical	sample	showed	a	similar	
DNA binding affinity (within 2-fold) in the presence of a polyamide-FYPWMKG peptide 
conjugate at 20 °C as the preparation described in section C.1.
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Figure C.4  UV-Vis	spectrum	of	a	/0th	dilution	of	 the	Exd	stock	expressed	by	Peter	
Snow	 in	6.0	M	guanadinium	HCl,	 0.0	M	KHPO4,	0.0	M	KHPO4	 (pH	6.5)	used	 for	
concentration	determination.
Figure C.5  Primary purification and analysis of the second Exd preparation.  a) FPLC 
trace.  See text for details of purification.  b) SDS-PAGE gel stained with Coomassie blue 
shows	the	content	of	fractions	4,	6,	and	8-9.
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Figure C.6  Secondary purification and analysis of the second Exd preparation.  a) FPLC 
trace.  See text for details of purification.  b) SDS-PAGE gel stained with Coomassie blue 
shows	the	content	of	fractions	5-0	and	4-6.
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Appendix D
Solid-Phase Synthesis of Polyamides Using Marshall-Liener Resin
This work was done in collaboration with Rachel Wang and Mike Brochu (Dervan 
Group; Caltech).
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D.1 A Brief Review of  Solid-Phase Polyamide Synthesis
 The solid-phase synthesis of DNA-binding pyrrole-imidazole polyamides was first 
described	 in	 the	mid-990s	 by	 the	Dervan	 group.	  The commercially available Boc-β-
Ala-PAM	resin	 solid	 support	 allows	 rapid	 synthesis	of	polyamides	using	Boc-protected	
monomers	of	N-methylpyrrole	(pre-activated	Boc-Py-OBt),	N-methylimidazole	(Boc-Im-
OH), and γ-aminobutyric acid (Boc-γ-OH).  Dimers of N-methylimidazole	(Boc-Py-Im-
OH and Boc-γ-Im-OH) are prepared by solution-phase methods due to poor solid-phase 
imidazole coupling to pyrrole and γ-aminobutyric acids.  Nucleophilic cleavage of Boc-β-
Ala-PAM	resin	with	N,N-dimethylaminpropylamine (Dp) affords polyamides with -β-Dp 
tails	which	possesses	the	occasionally	undesirable	W	over	S	selectivity	(where	W	=	A	or	T	
and	S	=	G	or	C)	and	which	appears	to	often	be	a	negative	determinant	for	cell	uptake.3		The	
“β-less” Boc-Py-PAM resin has been reported to exhibit poor susceptibility to nucleophilic 
cleavage	in	the	presence	of	amines	such	as	Dp,4	although	cleavage	to	the	corresponding	
carboxylic	acid	is	possible	using	palladium.5	 	The	synthesis	of	polyamides	using	Kaiser	
oxime	 resin	allows	covalently	attachment	of	Py	monomers	directly	 to	 the	solid	support	
through	an	oxime	functional	group.		The	oxime	ester	shows	facile	cleavage	in	the	presence	
of a variety of nucleophiles to yield polyamides without a β-alanine spacer.6		Care	must	be	
taken	to	minimize	the	amount	of	TFA	during	BOC	deprotection	(0%	for	Py	and	50%	for	
Im	compared	to	80%	for	PAM).		Although	the	yield	and	purity	of	polyamides	derived	from	
oxime	 resin	 are	often	comparable	 to	 those	 from	PAM	resin,	 sometimes	 synthesis	using	
oxime	resin	can	be	problematic	and	low-yielding.
	 A	number	of	additional	methods	have	been	reported	for	the	solid-phase	synthesis	of	
polyamides in efforts to obtain higher yields at minimal cost while still enabling flexibility 
of synthesis.  Specifically, Fmoc-based solid-phase polyamide synthesis has also been 
developed	using	Wang	resin7	and	MBHA	resin8	and	both	produce	as	good	or	better	yields	
and	 purities	 as	 Boc-based	 chemistry.	 	The	 Sugiyama	 group	 frequently	 employs	 Fmoc-
based	synthesis,9	but	the	Boc-based	chemistry	is	still	frequently	used	by	the	Dervan	group.	
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Safety-catch	 resins	 have	 also	 been	 reported	 employing	 both	 Fmoc	 and	 Boc	 protection	
strategies	to	produce	comparable	yields	to	PAM	and	oxime	resins,0-	but	have	not	garnered	
widespread	 use.	 	 One	 report	 has	 suggested	 improvements	 for	 Boc-based	 polyamide	
synthesis	 using	 alternative	 coupling	 reagents	 (i.e.,	 HATU)	 and	 scavengers	 (phenol	 and	
water),	but	one	disadvantage	is	that	the	coupling	reagent	is	currently	more	expensive	than	
traditional	ones	(i.e.,	HBTU	and	DCC).		More	convergent	Boc-based	polyamide	synthesis	
using	dimers	and	trimers	for	coupling	have	also	been	reported	to	give	improved	yields,3	
but	 this	often	 requires	 the	 time-consuming	preparation	of	unique	oligomers	prior	 to	 the	
solid-phase	 synthesis	 of	 the	 target	 polyamide.	 	 Similarly,	 scattered	 reports	 of	 complete	
solution-phase	synthesis	have	shown	high	yields	(~	g)	for	polyamides	are	obtainable,4-5	
but	the	approach	is	not	as	rapid	as	solid-phase	methodology.		A	putative	liquid-solid	phase	
system	has	also	been	reported,	but	only	small	oligomers	have	been	synthesized	thus	far	
using	this	approach.6		This	appendix	describes	the	use	of	4-hydroxyphenylsulfanylmethyl	
polystyrene	 resin,	 originally	 reported	 by	Marshall	 and	 Liener	 in	 the	 970s	 for	 peptide	
synthesis,7	as	an	alternative	solid-phase	support	for	rapid	Boc-based	polyamide	synthesis.	
Similar to oxime resin, polyamides can be synthesized without a C-terminal β-alanine, but 
deprotection	with	higher	amounts	of	TFA	is	possible.
D.2 Experimental Protocols
Resin loading.		A	total	of	300	mg	4-hydroxyphenylsulfanylmethyl	polystyrene	resin	(i.e	
Marshall-Liener	resin,	NovaBiochem;.70	mmol/g,	~0.5	mmol	scale)	was	treated	with		
equivalents	of	Boc-Py-OBt	in	5	mL	DMF	and	3	equivalents	of	DIEA	for	48	hours	at	RT.	
Successful	loading	has	been	accomplished	in	as	short	as	4	hours.
Coupling.  Couplings were performed as described previously for Boc-β-Ala-PAM 
resin.
Deprotection.	 	All	 deprotection	 reactions	were	 performed	with	 50%	TFA/DCM	 for	 5	
min.
5
Figure D.1 Solid phase synthetic scheme for ImImPyPy-γ-ImPyPyPy-β-(+)-NH	 from	
commercially	available	4-hydroxyphenylsulfanylmethyl	polystyrene	resin,	i.e.,	Marshall-
Liener	resin:	i)		equivalents	Boc-Py-OBt,	3	equivalents	DIEA,	DMF,	4	h	ii)	50%	TFA/
DCM,	30	min	 iii)	 	 equivalents	Boc-Py-OBt,	 3	 equivalents	DIEA,	DMF,	 	 h,	 iv)	 50%	
TFA/DCM,	30	min,	v)		equivalents	Boc-Py-OBt,	3	equivalents	DIEA,	DMF,		h	vi)	50%	
TFA/DCM,	30	min,	vii) 2 equivalents Boc-γ-Im-OH, 1.9 equivalents HBTU, 3 equivalents 
DIEA,	DMF,		h,	viii)	50%	TFA/DCM,	30	min,	ix)		equivalents	Boc-Py-OBt,	3	equivalents	
DIEA,	DMF,		h,	x)	50%	TFA/DCM,	30	min,	xi)		equivalents	Boc-Py-OBt,	3	equivalents	
DIEA,	DMF,		h,	xii)	50%	TFA/DCM	30	min,		xiii)		equivalents	ImIm-OH,	.9	equivalents	
HBTU,	3	equivalents	DIEA,	DMF,		h,	xiv) 3,3′-diamino-N-methyl-dipropylamine, 50 °C, 
4	h.
5
Washing.		Following	each	deprotection	the	resin	was	drained	and	rinsed	x	DCM,	x	4:	
DMF:DIEA,	and	x	DMF.		Following	each	coupling	the	resin	was	drained	and	rinsed	x	
DMF	and	x	DCM.
Analytical cleavages.	 	To	monitor	the	progress	of	synthesis	a	small	sample	of	the	resin	
was	treated	with	a	small	volume	of	N,N-dimethylaminopropylamine for 15 min at 95 °C, 
filtered, diluted in 0.1% TFA in HO,	and	analyzed	by	HPLC.
Preparative cleavage.	 	 Similar	 to	 a	 couple	 relatively	 recent	 reports,8-9	 cleavage	 from	
Marshall-Liener	resin	did	not	require	sulfur	oxidation	with	hydrogen	peroxide	as	originally	
suggested.7
ImImPyPy-γ-ImPyPyPy-(+)-NH2 (1).	 	 05	mg	of	 resin	 containing	 the	 polyamide	was	
treated with 1 mL of neat 3,3′-diamino-N-methyl-dipropylamine and incubated at 50 °C 
for 16.5 hours.  The resin filtered and the filtrate was diluted with 0.1% TFA in HO	and	
acetonitrile and purified 2x by preparative HPLC.  Fractions with product identified by 
MALDI-TOF MS were flash frozen and lyophilized to yield a solid (11.0 μmol, 14.6% 
yield,	80-90%	pure).		(MALDI-TOF	MS)	[M+H]+	calcd	for	C56H7NO9
+	95.6,	observed	
95.7.
ImImPy(propylamine)Py-γ-ImPyPyPy-(+)-NHBoc (2).	 	 50	 mg	 of	 resin	 containing	 the	
polyamide	was	treated	with	300	mg	of	N-Boc-3,3′-diamino-N-methyl-dipropylamine	in	500	
μL DMF at 50 °C for 24 hours.  The resin was filtered and purified as described for above 
(2.3 μmol, 8.5% yield, ~90% pure).  (MALDI-TOF MS) [M+H]+	calcd	for	C63H84N3O
+	
338.7,	observed	338.7.
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Appendix E
Dimerizer-Exd-DNA Crystallization Trials
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E.1 Experimental Details
	 Crystallization	 of	 a	 polyamide-peptide/Exd/DNA	 complex	 was	 inspired	 by	 the	
three	 related	HOX/PBC/DNA	 ternary	complex	crystal	 structures	 (Figure	E.).-3	 	 Initial	
crystallization	 experiments	 were	 attempted	 using	 the	 originally	 reported	 conjugate	 1 
(HPLC purified,  >99% pure) (Figure E.2).4  Crude	DNA	inspired	from	the	Exd/Ubx/DNA	
structure was obtained from Integrated DNA Technologies and purified by non-denaturing 
PAGE	utilizing	UV	shadowing	and	band	extraction.		DNA	was	eluted	from	the	gel	with	M	
NaCl and filtered.  DNA was precipitated with iPrOH (1x) and 75% EtOH in HO	(x)	and	
lyophilized before being dissolved in 18 MΩ water.  DNA purity was assessed by analytical 
HPLC using a Clarity oligo-RP column (150 mm × 4.60 mm, 5 μm, Phenomenex, A buffer 
=	 0.05	M	TEAA	 (pH	 7,	 Fluka),	 B	 buffer	 =	 acetonitrile).	 	 DNA	was	 annealed	 prior	 to	
addition	of	conjugate	1 or Exd by heating to 95 °C followed by slowly cooling to RT (~20 
°C).  Exd expressed by Peter Snow (see section C.1) was concentrated to ~19.4 mg/mL 
(~2.04 mM) at 4 °C using a Microcon YM-3 (MWCO of 3 kDa) and diluted down to ~10 
mg/mL	in	crystallization	buffer	(0	mM	HEPES,		mM	EDTA,		mM	DTT,	pH	8.0)	similar	
to	a	previously	reported	procedure	for	Pbx.		A	total	of	60	nmol	of	each	component	was	
added in the following order: 24 μL 2.5 mM dsDNA, 46 μL HO (18 MΩ), 50 μL 1.2 mM 
conjugate	1 (pre-sonicated to ensure homogeneity), and 60 μL Exd, which was incubated 
for ~3 hours at 20 °C.  Crystallization was performed using the hanging drop method, i.e., 
:	mixture	 of	 precipitant	 to	 complex	 solution.	 	 Crystallization	 screens	 from	Hampton	
(Natrix	and	Crystal	Screen	Cryo)	and	Emerald	Biosystems	(Cryo	I/II)	and	follow-up	grid	
screens	(precipitate	concentration	in	%	increments	and	pH	in	0.	unit	increments)	yielded	
several	 crystals	 (Figure	E.3).	 	All	 crystals	 diffracted	poorly	 (best	 resolution	~6-8	Å)	 at	
room	temperature	and	many	cryoprotectant	solutions	destroyed	crystals	(30%	PEG	400,	
PFO-X5,	5%	glycerol,	5%	ethylene	glycol,	5%	isopropanol,	5%	(R,3R)-(+)-,3-
butanediol,	5%	DMSO,	.4	M	LiCl,	and	0.68	M	Mg(OAc)).		Initial	screens	with	poorly	
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formed	crystals	showed	that	some	appeared	to	tolerate	carbohydrate-based	cryoprotectants	
better (D-(+)-raffinose, D-(+)-trehelose, and D-(+)-glucose).
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Figure E.1		Summary	of	HOX/PBC/DNA	ternary	complex	crystal	structures.
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Figure E.2		Design	of	polyamide-peptide/Exd/DNA	complex	crystallization	experiments.	
A	model	of	the	presumed	complex	is	shown	above.	The	sequence	of	the	DNA	duplex	and	
the	structure	of	the	polyamide-peptide	conjugate	1	are	shown	below.
Figure E.3		Pictures	of	select	crystals	and	the	conditions	used	for	crystallization.
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Appendix F
Supplemental Figures
The figures in this section were taken in part from a manuscript coauthored with Peter B. 
Dervan (Caltech).
(Stafford,	R.	L,	Dervan,	P.	B.	“The	Reach	of	Linear	Protein-DNA	Dimerizers”	submitted 
to J. Am. Chem. Soc. 2007)	
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Figure F.1  Representative	gel	shift	results	for	Exd	in	the	presence	of	linear	protein-DNA	
dimerizers	with	differently	sized	linkers	between	the	two	proximally	oriented	DNA	sites	
with control compounds.		(a)	Schematic	of	the	positions	of	the	Exd	and	polyamide	DNA-
binding	sites	 showing	 the	A,T	spacer	 region	which	was	varied.	 	 (b)	Structure	of	parent	
polyamide ImImPyPy-γ-PyPyPyPy-β-Dp (15).	 	 (c)	 	 Gel	 shift	 experiments	 show	 that	 1	
forms	a	stable	complex	with	Exd	and	DNA	with	site	spacings	between	-6	bps,	whereas	
2	only	forms	stable	complexes	from	4-5	bps.	 	It	 is	also	shown	that	Exd	by	itself,	 in	the	
presence	of	the	parent	polyamide	15,	or	double-AA	mutants	3	and	4,	does	not	yield	a	stable	
complex	with	DNA	at	these	sites.		A	concentration	of	50	nM	of	the	indicated	compound	
was	added	to	all	lanes	and	Exd	was	titrated	from	0	pM	to	00	nM.
60
Figure F.2  Representative	gel	shift	results	for	Exd	in	the	presence	of	linear	protein-DNA	
dimerizers	with	differently	sized	linkers	between	the	two	distally	oriented	DNA	sites	with 
control compounds.		(a)	Schematic	of	the	positions	of	the	Exd	and	polyamide	DNA-binding	
sites	showing	the	A,T	spacer	region	which	was	varied.		(b)		Gel	shift	experiments	show	
that	1	forms	a	stable	complex	with	Exd	and	DNA	when	there	is	a		bp	overlap,	i.e.,	a	site	
spacing	of	-,	between	the	two	sites,	whereas	2	does	not	form	a	complex	with	Exd	at	any	
of	 these	 sites.	 	 It	 is	 also	 shown	 that	Exd	by	 itself,	 in	 the	presence	of	parent	polyamide	
15,	 or	 double-AA	mutant	3,	 does	not	yield	 a	 stable	 complex	with	DNA	at	 this	 site.	 	A	
concentration	of	50	nM	of	the	indicated	compound	was	added	to	all	lanes	and	Exd	was	
titrated	from	0	pM	to	00	nM.
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Figure F.3  Representative	gel	shift	results	for	Exd	in	the	presence	of	WM	dipeptide	linear	
protein-DNA	dimerizers	with	differently	sized	spacers	between	 the	 two	DNA	sites.	 	 (a)	
Schematic	 of	 the	 positions	 of	 the	 Exd	 and	 polyamide	DNA-binding	 sites	 showing	 the	
poly-AT	spacer	 region	which	was	varied	 in	 the	proximal	orientation.	 	 (b)	Schematic	of	
the	positions	of	the	Exd	and	polyamide	DNA-binding	sites	showing	the	A,T	spacer	region	
which	was	varied	in	the	distal	orientation.			(c)		Gel	shift	experiments	show	that	none	of	the	
site	spacings	lead	to	stable	complex	formation	for	compounds	5-8.		A	weak	complex	with	
compound	6 is observed at a spacing of 3 bp in the proximal orientation (Θapp	=	0.3	±	0.).	
A	concentration	of	50	nM	of	the	indicated	compound	was	added	to	all	lanes	and	Exd	was	
titrated	from	0	pM	to	00	nM.
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Figure F.4  Representative	gel	shift	 results	 for	Exd	 in	 the	presence	of	WMK	tripeptide	
linear	protein-DNA	dimerizers	with	differently	sized	spacers	between	the	two	proximally	
oriented	DNA	sites.		(a)	Schematic	of	the	positions	of	the	Exd	and	polyamide	DNA-binding	
sites	showing	the	A,T	spacer	region	which	was	varied	in	the	proximal	orientation.		(b)		Gel	
shift	 experiments	 show	 that	none	of	 the	 site	 spacings	 lead	 to	 stable	complex	 formation	
for	compounds	11	or	12.		(c)		Gel	shift	experiments	show	that	acetylated	WMK	tripeptide	
conjugates	13	and	14	do	not	lead	to	a	stable	complex	at	the	proximal	6	bp	spacing	site.		A	
concentration	of	50	nM	of	the	indicated	compound	was	added	to	all	lanes	and	Exd	was	
titrated	from	0	pM	to	00	nM.
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Figure F.5  The dependence of binding affinity (Ka) and the apparent fraction of DNA 
shifted with respect to the site spacing is shown.  (a)  The binding affinity of Exd does not 
change	by	more	than	3-fold	as	the	site	spacing	is	changed	in	the	presence	of	compounds	
1 and	2 when	a	complex	is	observed.		(b)		The	amount	of	complex	formed	also	does	not	
change	substantially	as	the	site	spacing	is	changed.
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Figure F.6  List	of	the	proximal	series	of	DNA	duplexes	used	in	gel	shift	experiments.
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Figure F.7  List	of	the	distal	series	of	DNA	duplexes	used	in	gel	shift	experiments.
